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2Abstract
The observation that M IP-la can inhibit the proliferation of transiently engrafting 
haemopoietic stem cells was first reported more than ten years ago. However, very little 
has since emerged about the molecular mechanism underlying stem cell inhibition. The 
work presented in this thesis therefore aimed at shedding some more light on the molecular 
mechanism and on how the structural properties of M IP-la relate to its function as a stem 
cell inhibitor.
Two properties of M IP-la, which it shares with most other chemokines, were first of all 
considered, its ability to self-aggregate and its interaction with proteoglycans. It has already 
been demonstrated that the aggregation of murine M IP-la is influenced by the pH and the 
ionic and hydrophobic strength of the buffer. In addition, three acidic residues in the 
carboxy terminal region of murine M IP-la have been previously shown to be involved in 
self-association as their neutralisation generates aggregation-incompetent mutants. Since 
the aggregation of human M IP-la has previously been found to be concentration- 
dependent, similar experiments were carried out for murine M IP-la which established that 
its self-association is also controlled in a comparable way which allowed the isolation of 
differentially aggregated murine M IP-la by progressive dilution. However, the forces that 
stabilise the oligomers appear to be stronger in human M IP-la as compared to murine 
M IP-la. In the recent determination of the crystal structure of murine M IP-la, two 
calcium ions were found in association with the tetramer that were proposed to mediate the 
formation of higher order aggregates. However, experiments carried out as part of this 
thesis demonstrate that this is not the case since the removal of these ions by the addition 
of EDTA and EGTA has no influence on the aggregation process.
Secondly, investigations were made into the way murine M IP-la interacts with the 
glycosaminoglycan heparin. More specifically, experiments were aimed at establishing 
whether there is a link between the aggregation state of M IP-la and its affinity for heparin 
since it is known for some chemokines, such as PF4, that the individual heparin binding 
sites in the monomers display positive cooperativity upon aggregation, resulting in a higher 
affinity of the tetramer for heparin. This may also have implications for a possible 
interaction of M IP-la with proteoglycans in the bone marrow microenvironment. In a first 
approach, three aggregation-incompetent murine M IP-la mutants, a monomer, dimer and a
3tetramer, were analysed for their binding to a heparin matrix. Surprisingly, the tetramer 
exhibited the lowest affinity for heparin, followed by the dimer and then the monomer with 
the highest affinity. One possible interpretation of this observation is that the heparin 
binding site becomes progressively occluded upon aggregation, thereby decreasing heparin 
binding in M IP-la oligomers. Alternatively, the neutralisation of the negative charges 
during the generation of these aggregation mutants may have altered the strength with 
which they bind to heparin since glycosaminoglycan - protein interactions are 
predominantly determined by electrostatic forces. In order to resolve this question, 
differentially aggregated murine M IP-la was prepared by progressive dilution (see above) 
and the different oligomers tested for their heparin binding affinity. No difference was 
observed in the strength with which the different aggregates bound to immobilised heparin 
which was also confirmed with stably cross-linked murine M IP-la oligomers. This 
suggests, that the aggregation state of murine M IP-la has no impact on its affinity for 
heparin which is instead controlled by its overall charge.
Attention was then turned to the interaction of murine M IP-la with the receptor on 
haemopoietic stem cells through which it mediates its inhibitory effect, as demonstrated in 
an in vitro assay, known as the CFU-A assay. It was first of all established that this 
inhibitory receptor is none of the four known murine M IP-la receptors (CCR1, CCR3, 
CCR5 and D6) for the following reasons; (1) none of the other chemokines tested, which 
included other ligands for the four M IP-la receptors as well as for all of the other known 
CC chemokine receptors, displayed any activity in the CFU-A assay, (2) the four known 
human M IP-la variants, which show differential binding to murine CCR1, CCR5 and D6, 
have indistinguishable potencies as stem cell inhibitors, and (3) stem cells from CCRl'7', 
CCR37', CCR57" and D67' mice were still inhibited in their proliferation by M IP-la, even 
when a chemokine analogue, which has the capacity to displace M IP-la from all of its four 
receptors, was included in the assays. All of these data suggest that M IP-la’s inhibitory 
signal is conveyed by a novel, as yet uncharacterised receptor.
As the crystal structure of murine M IP-la has recently been solved, attempts were made at 
identifying a region within M IP-la that is responsible for its inhibitory activity. This was 
achieved by creating chimaeras in which domains of murine M IP-la were exchanged with 
equivalent domains in the highly related CC chemokine RANTES. The chimaeras were 
generated by Overlap PCR, expressed in the Baculovirus System, purified in a number of 
chromatography steps and analysed for proper folding in calcium flux assays. They were
then each analysed for stem cell inhibition in the CFU-A assay. The results demonstrate 
that the main determinants for haemopoietic stem cell inhibition reside within the main 
body of murine M IP-la, between the second and the fourth cysteine residue. Further 
mutagenesis studies are currently underway with the aim of narrowing down this region 
even further to a possible inhibitory motif on the basis of which an inhibitory peptide may 
be designed.
In summary, the structure - function studies presented in this thesis have established that 
the aggregation of murine M IP-la is concentration-dependent and that the presence of 
calcium ions is not essential for that process to take place. It was also demonstrated that 
aggregation does not enhance M IP-la‘s affinity for heparin. Previous mutagenesis studies 
have shown that aggregation and heparin binding are not required for the direct inhibition 
of haemopoietic stem cells. However, they may nevertheless be relevant for the production, 
secretion and immobilisation of M IP-la in the context of the bone marrow 
microenvironment. Data is also presented that suggests that M IP-la mediates its 
suppressive effect via a novel receptor. Studies with MIP-la/RANTES chimaeras localise 
the inhibitory domain to the region between the second and fourth cysteine residue of 
murine M IP-la. This information may be crucial in the search for the inhibitory receptor 
which is likely to shed light on the regulation of haemopoietic stem cells and may possibly 
offer an explanation for the breakdown of this control in leukaemia.
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1.1. The Haemopoietic System
The haemopoietic system is characterised by a high turnover of mature blood cells from as 
many as eight different lineages (see Fig. 1.1) which are constantly, and throughout the 
entire life of the organism, replenished from a pool of multipotential stem cells that resides 
in the bone marrow. This complex system has a hierarchical structure as reflected in the 
fact that this small number of stem cells is sufficient to give rise to the vast quantity of 
circulating blood cells via a process of expansion and differentiation that involves a large, 
intermediate population of progenitors that become progressively more restricted in their 
differentiation and proliferation potential, a process that is also known as maturation. The 
following pages provide a brief overview of what is currently known about the origin and 
properties of haemopoietic stem cells and their regulation by stimulators, inhibitors, 
transcription factors and their environment.
1. 1. 1. The Stem Cell Compartment
Probably the most widely accepted definition of stem cells describes them as a rare (~1 in 
105 total bone marrow cells) and largely quiescent population of cells capable of 
proliferation, self-renewal, production of a large number of differentiated, functional 
progeny, regenerating the tissue after injury and of being flexible in the use of these options 
(Potten and Loeffler, 1990). In the case of haemopoietic stem cells, the best test for 
whether a cell fulfils these criteria is provided by the transplantation assay in which mice 
that have received a lethal dose of radiation that destroys their haemopoietic system, are 
rescued by a transplant of stem cells that will repopulate all the different blood lineages.
However, from such studies it has become clear that haemopoietic stem cells do not just 
comprise a single population of cells, but should rather be considered as a heterogeneous 
compartment consisting of stem cells with varying degrees of differentiation and self­
renewal capacities. It is nevertheless possible to subdivide the compartment into two types 
of stem cells according to the contribution they make during the rescue of an irradiated 
host. Two phases of repopulation following the transplant of bone marrow cells into 
irradiated animals have been observed which can be attributed to two different subsets of 
stem cells present in the transplanted bone marrow (Jones et al., 1990).
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Figure 1.1: The Haemopoietic System
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The first phase is accomplished by rapidly proliferating cells that represent the more mature 
members of the stem cell compartment which are unable to mediate long term repopulation 
of the haemopoietic system of the host, but which afford transient protection from the 
immediate and acute effects of radiation. These cells are therefore also known as short term 
repopulating (STR) cells or radioprotective cells.
The second phase of repopulation is more delayed since it involves cells that proliferate 
more slowly and that are thought to be dependent on the STR cells to establish a suitable 
environment into which these cells of the second wave can seed themselves. It is these cells 
that eventually mediate long term replenishment of the entire haemopoietic system of the 
host and accordingly are termed long term repopulating (LTR) cells. They are also referred 
to as competitive repopulating units (CRUs) on the basis of an assay in which genetically 
distinguishable bone marrow cells are injected together in order to compete for the 
repopulation of the host (Szilvassy et al., 1990).
For obvious reasons, such repopulation assays cannot be performed in humans. Therefore, 
in order to be able to test for human cells with repopulating activities, human haemopoietic 
stem cells are injected into irradiated immunocompromised non-obese diabetic/severe 
combined immunodeficient (NOD/SCID) mice where human haemopoietic cells can be 
found to engraft and thus form a chimaeric human/murine haemopoietic system 
(Larochelle et al., 1996). All of these studies have established that the presence of both of 
these cell types (LTR+STR) is required to successfully rescue mice from the effects of 
lethal irradiation. Yet, even within these two subgroups, the stem cell populations are not 
homogeneous as has been demonstrated by a number of in vivo and in vitro assays. These 
assays (Graham and Wright, 1997) have traditionally been used to describe different types 
of haemopoietic stem cells and also more mature progenitor cells on the basis of their 
proliferative behaviour in response to different stimuli and the type of progeny they 
produce. In many cases it is still unclear how the different cell types detected in these 
assays relate to each other, especially since only slight variations in the assay conditions 
can markedly influence the outcome. Most of these assays involve the proliferation of 
stem/progenitor cells in either semisolid medium (agar or methylcellulose) where the 
progeny of the cells can be detected as colonies or on preformed supportive cell layers. The 
most common assays will be described in more detail below.
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1.1.1.1. The CFU-S Assay
This assay, which was one of the first stem cell assays described (Till and McCulloch, 
1961), assesses stem cell proliferation in vivo and is based on the observation that within 
two weeks following transplantation of bone marrow into lethally irradiated mice, 
clonogenic cells (=CFU-S cells) seed into the spleen where they form readily visible 
colonies that contain differentiating and differentiated haemopoietic cells. Furthermore, 
evidence of self-renewal of the CFU-S cells within colonies is evident in their ability to 
form secondary colonies when retransplanted. There are different types of CFU-S colonies 
which appear at different time points. The colonies that become visible at around day 8 are 
derived from more actively proliferating and therefore more mature and more committed 
erythroid progenitor cells, whereas the colonies visible at day 12 are derived from more 
immature and more multilineage cells. However, both types belong to the STR stem cell 
class which is why LTR cells are also sometimes called pre-CFU-S cells.
1.1.1.2. The CFU-A Assay
This is an in vitro clonogenic assay that detects the progeny of a cell thought to be 
equivalent to the CFU-S day 12 cell (Pragnell et al., 1988). It involves the plating of total 
murine bone marrow in the presence of stem cell factor (SCF), macrophage-colony 
stimulating factor (M-CSF) and granulocyte/macrophage (GM)-CSF in semisolid medium 
and will be described in more detail in the experimental section of this thesis as it is one of 
the major techniques performed as part of this work. A human equivalent to the murine 
CFU-A assay has also been developed (Holyoake et al., 1993).
1.1.1.3. Other Clonogenic Assays
Other in vitro colony-forming assays include an assay that detects so-called blast colony- 
forming cells (Bl-CFC) in mice (Nakahata and Ogawa, 1982) and in humans (Rowley et 
al., 1987) as cells giving rise to colonies containing mainly undifferentiated cells. The 
proliferating cells are similar to the more immature CFU-S cells and may even include 
some pre-CFU-S cells. An assay that detects a slightly more mature cell, the so-called high 
proliferative potential colony-forming cell (HPP-CFC) was developed for mouse and 
human cells (McNiece et al., 1989), and the colonies contain macrophages and 
granulocytes, erythrocytes and megakaryocytes. By varying the combinations of growth 
factors included in this assay, three different subclasses of HPP-CFCs can be detected with
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varying degrees of maturity and with the most immature, HPP-CFC-1, being more or less 
equivalent to the cell detected in the CFU-A and CFU-S dayl2 assay (and possibly even 
slightly overlapping with the Bl-CFC). A cell overlapping with the slightly more mature 
members of the CFU-S compartment can be detected in vitro in the mixed colony-forming 
cell (Mix-CFC) assay in the mouse (Johnson and Metcalf, 1977) or in the CFU-GEMM 
assay in humans (Fauser and Messner, 1979) where the progeny of that cell can be 
recognised as colonies containing cells of the granulocytic, erythroid, monocytic and 
megakaryocytic lineages.
While all of the assays mentioned above detect various members of the stem cell 
compartment, clonogenic assays have also been developed for more mature progenitors 
which are named according to the type of progenitor they detect. For example, an assay that 
promotes the proliferation and colony formation from a progenitor that gives rise to the 
granulocytic lineage, is called colony-forming unit-granulocyte (CFU-G) assay. The 
general rule is that the more growth factors included in these assays, the more immature the 
stem/progenitor cell detected. Thus, if only one growth factor is included, a fairly mature 
progenitor usually only capable of giving rise to one lineage will be detected, whereas 
combinations of several different growth factors are required to induce the proliferation of 
stem cells since these cells are characterised by being mainly quiescent and more refractory 
to the stimulation by single growth factors.
1.1.1.4. Stem Cell Cultures on Stromal Cells
It is almost impossible to detect and maintain LTR cells in vitro in any of the clonogenic 
assays described above. These immature cells require contact to stromal cells, a reduced 
model of the bone marrow microenvironment, in order to survive and proliferate in culture. 
The first such culture capable of maintaining LTR cells was developed in the 1970s 
(Dexter et al., 1977) and involved the in vitro culturing of whole murine bone marrow for
several months. During that time, an adherent layer of stromal cells formed onto which
haemopoietic stem and progenitor cells were able to seed, proliferate and differentiate for a 
prolonged period. These long term culture (LTC) systems were further developed by first 
establishing an adherent stromal layer that was subsequently irradiated in order to eradicate 
any seeded haemopoietic cells (Ploemacher and Brons, 1989). This preformed stromal 
layer could then be used to test the seeding efficiency of different types of stem cells which 
established that LTRs are more readily seeded onto these layers than STRs. This culture 
system was also adapted for a limiting dilution assay that allowed the description of stem
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cells that were termed cobblestone area-forming cells (CAFCs) on the basis of the 
morphological appearance of the colonies (Ploemacher et al., 1989). It was observed that 
stem cells with differing maturities appeared at different time points, with the more mature 
members (e.g. CFU-S dayl2) being detected earlier (day8) than the more immature stem 
cells (pre-CFU-S at day28). It seems to be a general rule of LTCs that the time of 
appearance correlates inversely with the degree of maturity of stem cells. LTRs detected in 
LTCs after 6-8 weeks are also often referred to as longterm culture-initiating cells (LTC- 
ICs) and were originally thought to be the most immature haemopoietic stem cell 
detectable in culture. However, since then, researchers have been able to extend the time of 
culture of LTCs even further, resulting in the detection of a possibly even earlier stem cell 
(Hao et al., 1996). Recently, another more complex variant of the LTC system has been 
developed (Punzel et al., 1999) in which stem cells can be tested for their ability to give 
rise to the myeloid as well as to the lymphoid lineage which is generally considered to be a 
characteristic of true haemopoietic stem cells. This system combines the ‘classical’ LTC-IC 
assay with an assay for lymphoid potential and allows cells that fulfil these criteria to be 
detected. This assay is referred to as the myeloid-lymphoid-initiating cell (ML-IC) assay.
1.1.1.5. Other Ways of Describing Stem Cells
Apart from their detection in the in vitro assays described above and the fact that they can 
regenerate the entire haemopoietic system and are largely protected from the effects of 
cytotoxic drugs due to their quiescence, researchers have been trying to find other and more 
direct ways of identifying haemopoietic stem cells. It is hoped that this may allow 
purification of this extremely rare population of cells for scientific as well as therapeutic 
purposes. One way of distinguishing early stem cells from other cells in the bone marrow is 
on the basis of their size (Jones et al., 1990). LTR stem cells have a small, lymphocyte-like 
appearance and can thus be separated from other, larger bone marrow cells by a technique 
called counterflow centrifugal elutriation, which sorts cells on the basis of size and density. 
This technique allowed, for the first time, the physical separation of STR cells from LTR 
cells (de Haan and Van Zant, 1999).
Another method of identifying multipotential haemopoietic stem cells capitalises on the 
observation that these cells stain poorly with the mitochondria-specific dye Rhodamine 123 
or the DNA-specific dye Hoechst 33342. This weak staining was initially believed to be 
due to the stem cell mitochondria being smaller and less active, and a more condensed 
chromatin organisation in quiescent stem cells, but was finally linked to the expression of a
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P-glycoprotein efflux pump of the ABC transporter type, members of which are involved in 
the drug resistance observed in certain tumours (Chaudhary and Roninson, 1991). An 
active pump of this type seems to be important for certain stem cell properties, since the 
overexpression of the ABC transporter MDR1 in bone marrow cells resulted in a 
myeloproliferative disorder (Bunting et al., 2000). However, the identity of the P- 
glycoprotein on haemopoietic stem cells that stain poorly for Hoechst 33342, is still 
unknown. FACS analysis of stem cells stained with Hoechst 33342 has identified a group 
of stem cells now termed side population (SP) cells (Goodell et al., 1996) which have LTR 
character. Populations of cells that exhibit a similar staining pattern have also been 
identified amongst other somatic stem cells, such as muscle cells (see below).
By far the most commonly employed method for identifying and purifying stem cells is 
based on the expression of relatively specific surface molecules (Spangrude et al., 1988). 
Probably the best known stem cell marker is the glycoprotein CD34, the exact function of 
which still remains unclear, but which has traditionally been one of the most useful ways of 
enriching for haemopoietic stem cells. However, in recent years, doubts have begun to 
emerge as to how useful this surface molecule is as a marker of mulitpotential stem cells. 
One of the first reports to this effect (Osawa et al., 1996) demonstrated that a single cell 
with a CD34' phenotype was able to repopulate the entire haemopoietic system of an 
irradiated mouse. The authors of this report proposed that CD34 marks STR cells, while 
LTR cells do not express this protein. A similar conclusion was drawn from another study 
in which STR cells were described as being positive for CD34 expression and negative for 
CD38, a marker normally thought to be present on mature cells, while LTR cells were 
found to have the opposite phenotype, CD34 CD38+ (Zhao et al., 2000). This dispute over 
the usefulness of CD34 as a stem cell marker received further clarification by work 
showing that CD34 expression on haemopoietic stem cells is reversible and reflects the 
activation state of the cell rather than its developmental state (Sato et al., 1999). These 
authors demonstrated that under normal steady-state conditions, most of the cells that 
confer long term reconstitution in an irradiated recipient are CD34', but that expression of 
this surface molecule in these cells was rapidly induced after insult to the haemopoietic 
system or if these cells were numerically expanded in vitro. Both of these situations led to 
an activation of LTR cells which, as a result, converted to a CD34+ state. In agreement with 
this observation, most of the stimulated CD34+ LTR cells when transplanted into an 
irradiated recipient, reverted to a CD34' phenotype once the newly replenished 
haemopoietic system had reached steady-state conditions.
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The tyrosine kinase receptor c-kit has also traditionally been regarded as a stem cell marker 
and has been used to enrich for haemopoietic stem cells. Its importance in haemopoiesis is 
stressed by the fact that mice which have a complete disruption of the gene coding for c- 
kit, display a severe defect in haemopoiesis early on in development (Russell, 1979). While 
the c-kit+ haemopoietic stem cell fraction seems to encompass cells with STR as well as 
LTR abilities, evidence has emerged recently to suggest that these cells are recruited from 
an even more immature population of c-kit' haemopoietic stem cells, that do not proliferate 
in response to multiple growth factors and do not have radioprotective properties, but that 
will contribute to the longterm reconstitution of the haemopoietic system when injected in 
the presence of radioprotective cells, albeit with delayed reconstitution kinetics (Ortiz et 
al., 1999). Thus, it seems that reconstitutive haemopoiesis is maintained by c-kit+ 
multipotential stem cells that are recruited from a more immature quiescent c-kit' stem cell 
population which represents a critical developmental stage in definitive haemopoiesis.
Other haemopoietic stem cell purification protocols include Sca-1 as a stem cell marker 
and select against the expression of Thy-1 and lineage markers expressed on differentiated 
blood cells (Spangrude et al., 1988). Recently, other haemopoietic stem cell markers have 
been reported such as aldehyde dehydrogenase (Storms et al., 1999), AA4 (Petrenko et al., 
1999), the integrin Gfllb-IIIa for haemopoietic progenitors (Ody et al., 1999), CD27 for 
STR cells (Wiesmann et al., 2000) and the receptor tyrosine kinase Tie-2 for LTR cells 
(Hsu et al., 2000) which may well become part of future haemopoietic stem cell 
purification protocols.
1.1.2. The Regulation of Haemopoietic Stem Cells
The fact that haemopoietic stem cells, which are normally in a quiescent state, can be 
rapidly induced to enter the cell cycle following cytotoxic drug treatment and can 
subsequently return to a quiescent state once steady state conditions have been 
reestablished, suggests that the proliferation of these cells is under the control of 
stimulatory as well as inhibitory factors. A number of molecules have been identified as 
having positive or negative effects on the proliferation of different members of the stem 
cell compartment and some of these are described below.
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1.1.2.1. Inhibitors of Proliferation
The search for inhibitors of early haemopoietic stem cells was not only driven by the hope 
that these factors would shed light on the processes regulating haemopoiesis under 
physiological as well as pathological conditions, but also that they may prove to be useful 
clinical agents. For example, current chemotherapy protocols employ doses of cytotoxic 
drugs that are limited by the detrimental effects these agents have on normal cells, 
especially cells of the haemopoietic stem cell compartment. Therefore, protection of these 
cells by factors that will inhibit their cell cycle, would not only lead to reduced damage to 
the haemopoietic system and a faster recovery after chemotherapy, but would also allow 
administration of higher drug doses with a higher chance of complete removal of cancer 
cells. Clinical trials aimed at testing the usefulness of these inhibitors during chemotherapy 
schemes have therefore been initiated for some of the factors described below.
A tetrapeptide with the sequence NAc-Ser-Asp-Lys-Pro-OH (AcSDKP) was purified and 
shown to inhibit the proliferation of CFU-S dayl2 and earlier members of the stem cell 
compartment (Bonnet et al., 1995; Lenfant et al., 1989) as well as erythroid and 
granulocytic progenitors in the LTC system (Cashman et al., 1994). It has been proposed 
that AcSDKP is derived from the amino terminus of Thymosin-|34 by proteolytic 
processing of this precursor. Interestingly, Thymosin-|34 has also been demonstrated to 
possess stem cell inhibitory activites, which however map to the carboxy terminus of this 
protein (Bonnet et al., 1996), suggesting the AcSDKP sequence to be uninvolved. Several 
modes of action have been proposed for AcSDKP, including an interference of the peptide 
with the response of stem cells to growth stimulating factors (Robinson et al., 1993). 
However, other studies have indicated that AcSDKP requires the presence of accessory 
cells in the form of an adherent layer in order to be able to inhibit stem cell proliferation 
(Cashman et al., 1994). It was therefore suggested that it may carry out its function 
indirectly by inducing the release of an inhibitory factor from these accessory cells, with 
circumstantial evidence pointing to the chemokine M IP-la as this factor.
The pentapeptide is an inhibitory peptide with the sequence pyroGlu-Glu-Asp-Cys-Lys 
(pEEDCK) produced by mature granulocytes and found as a normal constituent of the bone 
marrow milieu (Paukovits et al., 1998). It reversibly inhibits the proliferation of the more 
mature progenitors, CFU-GM, as well as that of early stem cells, CFU-S and pre-CFU-S, in 
vitro and in vivo and is thus able to protect these stem cells from the effects of cytotoxic 
drugs (Paukovits et al., 1990; Paukovits et al., 1993). This peptide may be an important
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stem cell regulator in vivo since the addition of anti-pEEDCK antiserum to longterm bone 
marrow cultures or the injection of antiserum into mice significantly increases the numbers 
of CFU-GM in the bone marrow cultures and in the femora of the injected mice (Paukovits 
et al., 1999). Interestingly, the inhibitory activity of the pentapeptide is lost when this 
peptide forms dimers via a redox mechanism, thought to be mediated by activated 
granulocytes (Paukovits et al., 1998), which converts it into a stem cell stimulator 
(Paukovits and Paukovits, 1995). The mechanism by which pEEDCK exerts its inhibitory 
activity is unknown. It was, however, recently suggested that it interferes with the action of 
growth factors such as IL-11 by binding to them directly (Paukovits et al., 1999).
Transforming Growth Factor (3 (TGF(3) is a protein involved in many different 
developmental processes, including haemopoiesis (Fortunel et al., 2000). There are three 
highly homologous isoforms in mammals, TGFpi, -|32 and -p3, all three of which have 
been shown to be potentially involved in the regulation of haemopoiesis. The effects of 
these proteins on haemopoietic stem cells in vitro was studied by adding them directly to 
clonogenic assays. This established that all three isoforms inhibit the proliferation of the 
very early members of the stem cell compartment, such as LTC-IC and HPP-CFC, with 
TGF|32 displaying the lowest efficiency. In addition, both TGFpi and TGF|32 stimulate the 
proliferation of late progenitors, an activity not shared by TGF|33 (Jacobsen et al., 1991).
The inhibitory effects of TGFj3 on early stem cells were also observed in long term bone 
marrow cultures, and antibodies against this protein were capable of prolonging or 
reactivating the proliferation of LTC-ICs in these cultures, indicating that TGFp is actually 
produced and functions as an endogenous inhibitory factor (Eaves et al., 1991). The role of 
TGFp as a regulator of haemopoietic stem cells was also confirmed in vivo. It was shown 
to protect haemopoietic stem/progenitor cells from the cytotoxic drug treatment in a 
reversible fashion (Grzegorzewski et al., 1994), and the local administration of TGFpi into 
the femur of mice, revealed a preferential growth-inhibitory effect of this factor on the 
earlier members of the stem cell compartment (Goey et al., 1989).
Knockout mice for all three TGFp isoforms are also available, but difficult to interpret 
from an haemopoietic viewpoint because of the disruption of many other vital 
developmental processes that make all three knockouts lethal. However, some 
haemopoietic defects, such as reduced erythroid cell numbers in the yolk sac, were 
observed in TGFpi knockout mice (Dickson et al., 1995). Further evidence for a role of
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these proteins in the regulation of haemopoietic processes is that abnormalities in TGFp 
expression or in any other components of the TGFp signalling cascade can contribute to 
defects such as neutropenia and leukaemia (Fortunel et al., 2000). There seem to be 
several levels at which TGFp may exert its effects (Fortunel et al., 2000). It has been 
demonstrated to modulate the expression of several growth factor receptors, including c-kit 
(Heinrich et al., 1995), and was also proposed to induce apoptosis. However, several in 
vitro and in vivo studies have clearly shown that the inhibition of stem cell proliferation 
induced by TGFp is a reversible process (Batard et al., 2000; Goey et al., 1989).
Macrophage Inflammatory Protein-la (MIP-la), described in more detail in the final 
section of this introduction, was the first chemokine to be shown to have an effect on the 
proliferation of haemopoietic stem and progenitor cells (Graham et al., 1990), that was 
distinct from its well-known function as a pro-inflammatory cytokine. Since then, several 
other chemokines have also been shown to regulate stem cell proliferation (see later section 
on Chemokines in Haemopoiesis, section 1.2.4.). Most of them, including M IP-la, have a 
bidirectional effect similar to that observed with TGF-P, in that they inhibit the 
proliferation of earlier members of the stem cell compartment, while stimulating the 
proliferation of later progenitors. It remains to be shown what the relationship (if any) is 
between these effects on haemopoietic stem cells and the role of chemokines in the 
regulation and activation of mature leukocytes during inflammatory responses.
Other inhibitors of haemopoietic stem cells exist that have not been studied in as much 
detail as the ones described above. These include all-trans retinoic acid which again 
seems to be a bidirectional inhibitor that stimulates late committed CFU-GM and early 
myeloid progenitors (CFU-Blast), but inhibits the very early CAFCs, possibly through 
increasing soluble forms of adhesion molecules (Sammons et al., 2000). Interferon-y 
(IFNy) and Tumour Necrosis Factor-a (TNFa) have also both been reported as 
bidirectional inhibitors, with IFNy being a selective inhibitor of very early haemopoietic 
stem cells (Snoeck et al., 1994). The fact that TNFa regulates haemopoietic processes at 
the stem cell level was mainly deduced from studying the phenotype of mice deficient for 
the p55 subunit of the TNFa receptor (Rebel et al., 1999; Zhang et al., 1995). These mice 
had increased marrow and peripheral blood cellularity of the myeloid compartment, 
accompanied by a decrease in the actual numbers as well as the self-renewal ability of 
haemopoietic stem cells.
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Thus, several inhibitors of haemopoietic stem cell proliferation have been identified, 
however, their importance for steady state haemopoiesis and how their actions relate to 
each other in vivo is still unclear. For example, although it has been demonstrated that 
M IP-la and TGFp have overlapping target cells and that the expression of TGFp is 
upregulated by M IP-la (Maltman et al., 1996), an inhibitor of TGFp does not abrogate 
MIP-la-induced stem cell inhibition, thus demonstrating that M IP-la works independently 
of TGFp. It is also doubtful whether any of these inhibitors will have a clinical value. As 
will be described in a later section, phase I and phase II clinical trials that were carried out 
to assess M IP-la as a potential haemopoietic stem cell protective agent during 
chemotherapy, did not produce the expected results. And although TGFp is a very 
powerful stem cell inhibitor, its crucial role in a number of other developmental processes 
and its related toxicity prevent any possible clinical applications of this protein.
1.1.2.2. Stimulators of Proliferation
An extensive repertoire of haemopoietic growth factors, including SCF, Interleukin (IL)-1, 
-3, -4, -6 , -11, -12, G-CSF and GM-CSF, has been identified over the years that influence 
the survival, proliferation and differentiation of haemopoietic cells (Graham and Wright, 
1997; Ogawa, 1993). These can be roughly categorised into three groups: (1) late-acting 
lineage-specific, (2) intermediate acting nonlineage specific and (3) factors affecting the 
kinetics of cell cycle dormant immature stem cells.
In the regulation of immature cell proliferation, most of these growth factors will only act 
in synergy which often makes it difficult to exactly define the effects of a single growth 
factor. For example, SCF, IL-3 and GM-CSF will individually maintain the viability of 
early haemopoietic stem cells, but require the presence of synergising factors such as IL- 6  
or IL-11 to induce those cells to proliferate (Graham and Wright, 1997; Kollet et al., 1999). 
SCF and flt3 ligand (FL) is another pair of growth factors that can synergise with each 
other as well as a whole range of other growth factors to support the proliferation and 
differentiation of a number of different components of the stem cell compartment (Borge et 
al., 1999; Graham and Wright, 1997). There is a great deal of interest in potential 
stimulators of stem cell proliferation from a clinical point of view, and some of the factors 
mentioned above are routinely included in protocols for the in vitro or ex vivo expansion of 
stem cells for transplantation. However, the answers to several important questions remain 
to be determined. For example, it is not yet known whether the expansion of stem cells 
observed in the presence of some of these factors is a true process of self-renewal, or
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whether it is always accompanied by a certain degree of differentiation or phenotypical 
alteration. It is known that haemopoietic stem cells cannot divide indefinitely, but have a 
finite life span, and that serial transplantation will compromise and eventually exhaust the 
stem cell pool.
Related to this debate is the question of how adult stem cells divide at a single cell level, 
whether they can undergo symmetric as well as asymmetric divisions and how this may be 
controlled. In theory, a stem cell should have the following options: (1) it could give rise to 
two identical, undifferentiated daughter stem cells in a true self-renewal and expansion 
process, (2 ) it could give rise to two identical daughter cells that have undergone 
differentiation during the process (i.e. proliferation coupled to differentiation) or (3) it 
could give rise to two cells that can behave differently, with one of them staying dormant 
while the other one continues to proliferate and differentiate. While the existence of 
symmetric stem cell divisions can be inferred from the fact that a single pluripotent 
haemopoietic stem cell can repopulate the haemopoietic system in transplantation assays, 
asymmetric divisions have recently been detected at a single cell level (Ema et al., 2000; 
Huang et al., 1999). In one of these reports (Huang et al., 1999), the fluorescent dye 
PKH26 which incorporates into membranes was used to trace stem cell divisions since the 
decrease in fluorescence that occurs when the dye becomes equally distributed among the 
membranes of the progeny of a cell, is directly proportional to the number of cell divisions. 
The observation of single PKH26-stained CD34+CD38' cells by a time-lapse camera 
system revealed that in addition to multiple, synchronous and symmetric divisions, single 
cells also gave rise to a daughter cell that remained quiescent for up to eight days, whereas 
the other daughter cell proliferated exponentially. Further experiments described in this 
report also suggest that although lineage commitment and cell proliferation can be skewed 
by extrinsic signals, symmetry of early divisions is probably under the control of intrinsic 
factors.
Related to this is yet another important question which is whether differentiation of stem 
cells is an instructive, permissive or even stochastic process, with experimental evidence 
supporting a role of growth factors in instructing as well as permitting the differentiation 
process. For example, in a recent report, the reprogramming of lymphoid progenitors to 
progenitors that give rise to cells of the myeloid lineage in response to IL-2, was achieved 
by the enforced expression of the receptor for IL-2 (Kondo et al., 2000). On the other hand, 
while the growth factors IL-7 and M-CSF have also been associated with differentiation 
along specific lineages, it has recently been demonstrated that defects observed in mice that
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are deficient in the genes of either of these proteins, can be reversed by overexpressing Bcl- 
2, a blocker of apoptosis (Akashi et al., 1997; Lagasse and Weissman, 1997; Maraskovsky 
et al., 1997). This implies that these two factors, rather than being instructive to the 
differentiation process, act as ‘survival’ or ‘happiness’ factors that prevent the cells from 
undergoing apoptosis and allow them to undergo differentiation spontaneously or in 
response to intrinsic factors.
These intrinsic factors are most likely to be transcription factors as a great number of them 
have now been associated with the differentiation along specific blood cell lineages 
(Amatruda and Zon, 1999; Blobel, 2000; Enver and Greaves, 1998). However, despite the 
fact that the knockouts of certain transcription factors in mice result in a phenotype that 
implicates this factor in determining the fate of uncommitted progenitors, a picture has now 
emerged that resembles that of growth factors, in that a combination of transcription factors 
will determine cell fate rather than individual factors on their own. It was even observed 
that prior to differentiation, components of competing or alternative lineage pathways are 
simultaneously active at the level of chromatin accessibility and gene expression in varying 
patterns or combinations reflecting considerable intrinsic heterogeneity and developmental 
plasticity (Enver and Greaves, 1998; Papayannopoulou et al., 2000). A multipotential stem 
cell therefore seems simultaneously to have several options open to it, and the decision 
towards a specific lineage is likely to involve several steps of activation where a certain 
threshold has to be overcome at every single step that then results in the shutdown of 
alternative pathways and the increased accessibility of components that drive 
differentiation further along the chosen path. It is therefore the relative balance of positive 
and negative regulators that will determine the outcome.
1.1.3. The Bone Marrow Microenvironment
As mentioned above, combinations of soluble cytokines and growth factors can never 
mimic the environment that the haemopoietic stem cell finds itself in within the bone 
marrow which explains why only long term bone marrow cultures can detect the earliest 
stem cells which can not be scored in any other in vitro clonogenic assay. In the bone 
marrow, haemopoietic stem cells are in close contact with stromal cells and other 
components of the marrow extracellular matrix and thus form defined niches or ‘hematons’ 
(Blazsek et al., 2000) that act as protective and regulatory microenvironments 
(Greenberger, 1991; Whetton and Graham, 1999). Stroma in several other tissues have a 
similar composition and include macrophages, fibroblasts, osteoblasts, adipocytes,
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epithelial cells and endothelial cells, yet only the haemopoietic microenvironment can 
support haemopoiesis which is likely to be due to the expression of specific growth factors 
and adhesion molecules.
There are several components in the microenvironment that contribute to stem cell 
maintenance and regulation. Stromal cells have been shown to secrete a number of 
important haemopoietic mediators such as IL-1, -6 , -11, several CSFs, SCF, FL, TNFa and 
TGFp (Sensebe et al., 1997). Some of these factors may also be presented on the surface of 
these cells in a membrane-bound form. Equally important is the interaction between 
haemopoietic stem cells and stromal cells via adhesion molecules both for the retention of 
stem cells in the bone marrow as well as for the migration and homing to the bone marrow 
during development and after transplantation. For example, knockout studies have revealed 
that p i integrins mediate the adhesion of haemopoietic stem cells to vascular endothelial 
cells, and that in their absence seeding of the bone marrow during development and after 
stem cell transplantation by haemopoietic stem cells does not occur (Potocnik et al., 2000). 
These adhesion molecules may also have a role in regulating the proliferation and 
differentiation of haemopoietic stem cells. For example, PSGL-1 binds to P-selectins on 
stem cells and mediates the suppression of stem cell proliferation (Levesque et al., 1999), 
and CD9, which interacts with p i integrins on haemopoietic stem cells, has been 
implicated in regulating their differentiation (Aoyama et al., 1999). Other adhesion 
molecules thought to be involved in stem cell regulation in the microenvironment are a4 
integrins (Arroyo et al., 1999) and laminins (Gu et al., 1999).
Gap junctions, and especially connexin 43 within these junctions, have also been shown to 
be a crucial component of a functional haemopoietic stem cell niche (Cancelas et al., 2000; 
Montecino-Rodriguez et al., 2000), with the loss of even one allele of connexin 43 
affecting blood cell development.
A lot of evidence has also been accumulated to support the role of glycosaminoglycans in 
regulating haemopoietic stem cell function in the hematon. Not only were specific 
glycosaminoglycans found to bind to haemopoietic stem cells and influence the growth and 
differentiation characteristics of cultured CD34+ cells (Madihally et al., 1999), but even the 
sulphation pattern and content in the glycosaminoglycan heparan sulphate (for a more 
detailed description of glycosaminoglycans, see section on chemokine-proteoglycan 
interactions, section 1.2.5.4.) determined whether it supported haemopoietic stem cell 
maintenance (Gupta et al., 1998) or differentiation along the erythroid lineage (Drzeniek et
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al., 1999). In addition, sulphated polysaccharides were shown to be able to mobilise 
haemopoietic stem and progenitor cells, possibly through the disruption of 
glycosaminoglycan-mediated stem - stromal cell interaction or through the release of 
chemokines and cytokines that are often found in association with glycosaminoglycans 
(Sweeney et al., 2000).
Thus, haemopoietic stem cell regulation is a very complex process that involves a wide 
range of different components. In this complicated network, the relative contribution made 
by each one of these individual components is only just starting to emerge and the 
interaction between all of these regulatory molecules is still largely unknown. The fact that 
the environment of a cell is the primary determinant for its fate, is stressed even further in 
the following section.
1.1.4. Stem Cell Plasticity
Each type of tissue is likely to contain a population of stem cells that give rise to the 
different mature cells characteristically found in that particular tissue type. In some cases, 
where there is a high turnover or loss of mature cells, as for example in the haemopoietic 
system, the small intestine and the epidermis, this replenishment is a continuous process, 
while in other cases, for example in the central nervous system, liver and muscle, 
generation of new mature cells from a pool of proliferating and differentiating stem cells 
occurs more slowly and in response to injury. Until recently, it was believed that each 
tissue contained its own specific stem cell type and that these different types of somatic 
stem cells were restricted in their differentiation potential to the type of mature cells 
normally found in that tissue. However, this view of tissue-restricted stem cells has now 
been challenged by reports that suggest that somatic tissue-derived stem cells may have a 
remarkable degree of plasticity.
In the first of these reports (Ferrari et al., 1998), the process of muscle regeneration was 
closely examined since it was noticed that the pool of resident satellite cells, that are 
considered to be muscle stem cells and thought to give rise to committed myogenic 
precursors, is too small to account for the extensive repair observed after muscle damage, 
thus implying migration or recruitment of undifferentiated precursors from other sources. 
And indeed, it was demonstrated that cells from genetically marked whole bone marrow 
when injected into regenerating muscle, were able to contribute to the formation of new 
muscle fibres. Further support for the capability of haemopoietic stem cells to give rise to
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muscle cells was provided by another report (Gussoni et al., 1999) in which it was shown 
that whole bone marrow or purified haemopoietic stem cells (SP cells, see above) cannot 
only reconstitute the haemopoietic system in lethally irradiated mdx mice, which serve as a 
model for the human disease Duchenne Muscular Dystrophy, but also partially restore 
dystrophin expression in the affected muscle. The authors were also able to identify cells 
within muscle that have a high degree of dye efflux and thus possess a similar SP cell 
phenotype. Furthermore, these muscle SP cells, when injected again into lethally irradiated 
mdx mice, not only gave rise to dystrophin-expressing muscle cells, but also reconstituted 
the haemopoietic system in these mice, albeit with lower efficiency than bone marrow- 
derived SP cells.
Thus, reprogramming of somatic stem cells can be observed in both directions, with the SP 
phenotype possibly serving as a general marker for cells with stem cell characteristics. In 
yet another report (Jackson et al., 1999), cells from disaggregated muscle tissue were 
cultured in vitro in a system not normally employed in a haemopoietic context. The 
haemopoietic differentiation potential of these cells was then tested in a competitive 
repopulation assay where they were injected in combination with bone marrow cells into 
lethally irradiated mice and shown to repopulate all blood lineages with a ten fold higher 
efficiency than bone marrow cells.
This observed plasticity is not just reserved for muscle and blood stem cells. Clonal or 
primary neural stem cells from either embryonic or adult murine forebrain were able to 
rescue the haemopoietic system of sublethally irradiated mice and contribute to all blood 
lineages, as demonstrated by a number of in vitro clonogenic haemopoietic assays 
(Bjornson et al., 1999). Sublethal, as opposed to lethal, irradiation was required because it 
was assumed that neural stem cells would need more time to adopt a haemopoietic stem 
cell phenotype. This assumption was supported by the fact that neural stem cells before 
transplantation do not produce colonies in in vitro haemopoietic colony forming assays and 
also show a delayed (by three weeks) repopulation of the immune system with weaker 
engraftment as compared to haemopoietic stem cells.
Finally, bone marrow stem cells were also demonstrated to participate in the production of 
hepatocytes, following liver injury (Petersen et al., 1999). Thus, the evidence described 
above suggests that haemopoietic stem cells are not restricted in their differentiation 
potential to the production of haemopoietic cells, but can also give rise to mature cells 
found in the muscle and in the liver. Furthermore, stem cells from other tissues, such as
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brain and muscle, also seem to be endowed with a similar degree of plasticity and may be 
identified on the basis of high dye efflux.
Haemopoietic stem cells not only display plasticity in the type of tissue they produce, but 
also in their developmental potential. When mouse adult haemopoietic stem cells (lin‘ c- 
kit+ Sca-1+) were injected into mouse blastocysts, they not only contributed to all blood 
lineages at different developmental stages in the developing embryo, but the erythroid 
progeny of the stem cells starts re-expressing embryonic- and foetal-type globin (Geiger et 
al., 1998). Similarly, the transplantation of embryonic or foetal progenitor cells into adult 
recipients causes an almost complete switch in their globin transcription to the adult type. 
Thus, haemopoietic stem and progenitor cells have a more extensive repertoire of 
developmental programmes open to them than originally assumed, and the final decision 
on which direction to take is predominantly made by the microenvironment the cell finds 
itself in.
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1.2. Chemokines
Chemokines are members of a large family of chemotactic cytokines which were originally 
described as a subfamily of proinflammatory cytokines with a characteristic four cysteine 
motif that regulate the migration of leukocytes during inflammation. Recent years, 
however, have not only seen a dramatic expansion in the number of chemokines identified, 
concomitant with the characterisation of new subgroups, but it has also become clear that 
chemokines have a number of additional functions both within and outside the immune 
system.
As mentioned above, the majority of chemokines contain four conserved cysteine residues, 
the exact distribution of which forms the basis of their subdivision into chemokine 
families. Table 1.1 gives a complete list of all currently identified chemokines, their 
alternative names, the receptors they bind to and, in the case of CXC chemokines, the 
presence or absence of a three amino acid motif (ELR - see also section 1.2.5.3.). The two 
largest groups are the a  or CXC chemokines, so called because of the presence of one 
intervening amino acid between the first two conserved cysteine residues, and the (3 or CC 
chemokines in which the first two cysteine residues are directly adjacent to each other. This 
subdivision is also reflected in the chromosomal location of these proteins, with most of 
the CXC chemokines forming a cluster on mouse chromosome 5 (human chromosome 4) 
and the CC chemokines forming a cluster on mouse chromosome 11 (human chromosome 
17). Additional miniclusters are found both within and outside these two major clusters 
which represent further functional subdivisions within these groups. It has been suggested 
that most, if not all, chemokines arose from gene duplication of a single ancestral gene and 
that this diversification in chromosomal location likely reflects functional specialisation 
that has developed during the evolution of this superfamily (Zlotnik and Yoshie, 2000). 
These two major chemokine groups can be subdivided even further on the basis of 
functional differences, e.g. specific target cells, constitutive versus induced expression, 
angiogenic versus angiostatic properties, as well as on the basis of structural differences, 
e.g. presence or absence of specific sequence motifs, as will be discussed in the following 
sections.
Table 1.1: The Chemokine Family
C C  C h e m o k i n e s
S y s t e m a t i c  N a m e C o m m o n  N a m e s R e c e p t o r ( s )
CCL1 1-309, TCA3 CCR8
CCL2 MCP-1, MCAF, JE (mouse) CCR2, D6
CCL3 M IP-la, SCI, LD78a/LD78(3 (2 isoforms in humans) CCR1, CCR3 (mouse), 
CCR5, D6
CCL4 MIP-ip, Act-2 CCR5, D6
CCL5 RANTES CCR1, CCR3, CCR5, D6
CCL6 CIO (no human homologue known) Unknown
CCL7 MCP-3 CCR1, CCR2, CCR3, D6
CCL8 MCP-2 CCR1, CCR2, CCR3, 
CCR5, D6
CCL9/CCL10 MRP-2, CCF18, MlP-ly, (no human homologue) Unknown
CCL11 Eotaxin CCR3
CCL12 MCP-5 (no human homologue known) CCR2, D6
CCL13 MCP-4, CkpiO, NCC-1 (no mouse homologue known) CCR1, CCR2, CCR3, D6
CCL14 HCC-1, HCC-3, NCC-2, Ck|31, MCIF (no mouse h.) CCR1 (D6)
CCL15 HCC-2, NCC-3, MIP-5, MIP-16, Lkn-1 (no mouse h.) CCR1, CCR3
CCL16 NCC-4, LEC, HCC-4, LCC-1, Ck|312 CCR1
CCL17 TARC, ABCD-2 CCR4
CCL18 DCCK1, PARC, MIP-4, Ck|37 (no mouse homologue) Unknown
CCL19 ELC, MIP-3|3, exodus-3, C k p ll CCR7, CCR11
CCL20 LARC, MIP-3a, exodus-1, Ck|34 CCR6
CCL21 SLC, 6Ckine, exodus-2, TCA4, Ck(39 CCR7, CCR11
CCL22 MDC, ABCD-1 CCR4
CCL23 MPIF-1, MIP-3, Ckp8 (no mouse homologue) CCR1
CCL24 MPIF-2, eotaxin-2, Ck|36 CCR3
CCL25 TECK, Ckpi5 CCR9, CCR11
CCL26 eotaxin-3, MIP-4a (no mouse homologue) CCR3
CCL27 ESkine, CTAK, skinkine CCR10
CCL28 MEC CCR10
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C X C  C h e m o k i n e s  
S y s t e m a t i c  N a m e
CXCL1 (ELR+) 
CXCL2 (ELR+) 
CXCL3 (ELR+) 
CXCL4 (ELR-) 
CXCL5 (ELR+) 
CXCL6 (ELR+) 
CXCL7 (ELR+) 
CXCL8 (ELR+) 
CXCL9 (ELR-) 
CXCL10 (ELR-) 
CXCL11 (ELR-) 
CXCL12 (ELR-) 
CXCL13 (ELR-) 
CXCL14 (ELR-) 
CXCL15 (ELR+) 
CXCL16 (ELR-)
C  C h e m o k i n e s  
S y s t e m a t i c  N a m e
XCL1/XCL2
C X 3C  C h e m o k i n e s  
S y s t e m a t i c  N a m e
CX3CL1
C o m m o n  N a m e s
GROa, MGSA-a, NAP-3. MIP-2 
GROp, MGSA-p, MIP-2a 
GROy, MGSA-y, MIP-2P 
PF4
ENA-78, LIX 
GCP-2, CKA-3
PBP, CTAPIII, p-TG, NAP-2, LA-PF4 (no mouse h.) 
IL-8, NAP-1, GCP-1 (no mouse homologue known) 
Mig 
IP10
I-TAC, IP9 (no mouse homologue known)
SDF-1, SDF-la/SDF-ip (2 human isoforms)
BLC, BCA-1 
BRAK, bolekine 
WECHE, lungkine 
CXCL16
R e c e p t o r ( s )
CXCR2
CXCR2
CXCR2
Unknown
CXCR2
CXCR1, CXCR2 
CXCR2
CXCR1, CXCR2
CXCR3
CXCR3
CXCR3
CXCR4
CXCR5
Unknown
Unknown
CXCR6
C o m m o n  N a m e s  R e c e p t o r
Lymphotactin, SCM -la/SCM -ip (2 human isoforms) XCR1
C o m m o n  N a m e s  R e c e p t o r
Fractalkine, neurotactin CX3CR1
39
In addition to CC and CXC chemokines, two further subfamilies have recently been 
described with, so far, only one member identified per group. Lymphotactin is the sole 
member of the y or C chemokine subfamily and contains only two instead of the usual four 
cysteine residues. Fractalkine, also known as Neurotactin, the only representative of the 6  
or CX3 C chemokines, has its first two cysteine residues separated by three amino acids and 
also has the unusual feature of possessing a transmembrane domain and potentially existing 
in a soluble as well as a membrane-anchored form (Bazan et al., 1997; Pan et al., 1997). 
Only one other chemokine, CXCL16, with a similar transmembane domain is known to 
date (Matloubian et al., 2000).
The numerous functions of chemokines are mediated through seven-transmembrane G 
protein-coupled receptors (GPCRs), most of which employ the Pertussis Toxin-sensitive Gj 
class of heterotrimeric G proteins (Kuang et al., 1996). Binding of a chemokine to its 
specific receptor induces dissociation of receptor-G protein complexes and, in turn, 
dissociation of a  from j3y G protein subunits. |3y then signals to downstream effectors, 
notably phospholipase C |32 which is expressed selectively in haemopoietic cells. This 
enzyme catalyses the hydrolysis of plasma membrane phospholipids to diacylglycerol, 
which activates protein kinase C, and inositol triphosphate, which induces release of Ca2+ 
from intracellular stores. A common assay for the functional interaction of chemokines 
with their receptors measures the rise in intracellular Ca2+ in chemokine receptor- 
transfected cell lines which have been loaded with a calcium-sensitive dye (as described in 
more detail in the Materials and Methods section of this thesis). Other signalling pathways 
such as the MAP Kinase pathway have also been shown to be activated in response to 
chemokine signalling (for a review of chemoattractant signalling see Bokoch, 1995).
Eleven receptors for the CC chemokines (CCR1-11) and six for the CXC chemokines 
(CXCR1-6) have been identified to date and one each for the C (XCR1) and CX3 C 
(CX3 CRI) chemokine family. Within the CC and CXC family of chemokines and 
receptors, a great deal of promiscuity exists which is reflected in the fact that several 
chemokines can bind to more than one receptor and several receptors can bind more than 
one chemokine. For example, murine M IP-la has been found to bind to as many as four 
receptors, CCR1, CCR3, CCR5 and D6  (Nibbs et al., 1997) and the promiscuous 
chemokine receptor D6  has been found to bind at least nine CC chemokines (Nibbs et al.,
1997). Furthermore, there is one chemokine receptor that can bind chemokines of the CC 
as well as of the CXC family (Horuk et al., 1994), while all other cellular chemokine 
receptors known so far are restricted to their own subfamily of chemokines. The reason for
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this apparent redundancy is not entirely clear, however, in a recent review (Mantovani,
1999), Mantovani suggests that such promiscuity provides the immune system with a high 
degree of robustness. This concept seems to be further supported by the observation that 
chemokines are also redundant in their action on target cells and that certain cells 
concomitantly produce several chemokines with an overlapping spectrum of action. 
Furthermore, several knockout mice have been generated which are deficient for certain 
chemokines and their receptors. In most cases, these mice lacked an overt phenotype, 
although they do display occasional deficiency in response to certain pathological 
situations. There is, however, one chemokine, SDF-1, for which there is an absolute 
requirement since it is known to play important roles in development (see below).
1.2.1. Chemokines and Leukocyte Trafficking
It has become clear in recent years that chemokines and their receptors are involved in the 
control of the migration of leukocytes both during the development of these cells and their 
subsequent trafficking in immune surveillance as well as during a humoral immune 
response (for reviews on this subject, see Cyster, 1999; Kim and Broxmeyer, 1999; 
Melchers et al., 1999; Sozzani et al., 1999). This resulted in the categorisation of these 
proteins into “constitutive” chemokines and “induced/inflammatory” chemokines. ELC, 
SLC, BCA-1, SDF-1, TECK and MDC are examples of the former class of chemokines 
which are constitutively expressed at defined locations in the primary and secondary 
lymphoid organs and which regulate the basal trafficking of cells that express the 
corresponding receptors to these sites. Examples of inflammatory chemokines are M IP-la, 
RANTES, MIP-lj3 and the monocyte chemoattractant proteins (MCPs), whose expression 
is induced during the course of an immune response and which serve to attract leukocytes 
to the sites of infection.
Progenitors of lymphocytes initiate T lymphopoiesis mainly in the thymus and B 
lymphopoiesis in the bone marrow. Within these primary lymphoid organs, the progenitors 
colonise specific niches for proliferation and development into mature naive lymphocytes. 
Knockout mice that are deficient either in SDF-1 or its receptor CXCR4 show amongst 
other defects a complete absence of B lymphopoiesis. This, however, does not represent an 
actual developmental block, but rather an inability to home to the specific niches in the 
bone marrow in which B lymphopoiesis occurs since B cell progenitors are found in the 
peripheral blood of these mice (Nagasawa et al., 1996; Tachibana et al., 1998; Zou et al., 
1998). It has recently been shown that these early B cell progenitors also respond to TECK
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(Bowman et al., 2000), a chemokine which until then had only been implicated in T cell 
development in the thymus and homing of gut-specific T lymphocytes to the intestine 
(Kunkel et al., 2000; Zabel et al., 1999).
Concomitant with the exit of B lymphocytes from the bone marrow, they display an 
upregulation in their responsiveness towards BCA-1 (Bowman et al., 2000), which together 
with its receptor CXCR5 is essential for the homing of B cells to B cell rich areas in the 
spleen and in Peyer’s Patches (Gunn et al., 1998). This homing has been formally 
demonstrated in CXCR5 null mice which displayed an absence of germinal centres in these 
tissues (Forster et al., 1996). CXCR5 is also found to be upregulated in antigen-activated 
CD4+ T cells which can then migrate to B cell areas in order to mount T cell-dependent 
antibody responses (Ansel et al., 1999).
Another chemokine receptor that is very important for the homing of lymphocytes and 
dendritic cells (DCs) to lymphoid organs is CCR7, knockout mice for which were recently 
generated (Forster et al., 1999). It had previously been shown that immature DCs, i.e. cells 
that had not encountered antigen, express receptors for proinflammatory chemokines, such 
as CCR5, which allows them to be attracted to sites of infection. Following activation 
through contact with antigen, DCs downregulate CCR5 expression and at the same time 
start expressing CCR7, the receptor for SLC and ELC, which allows them to migrate to 
lymphoid tissues where they become antigen presenting cells and serve to activate 
lymphocytes (Iwasaki and Kelsall, 2000). SLC is expressed in the endothelium of 
lymphoid organs and mediates the homing of T lymphocytes and DCs to these tissues. 
There has been some controversy over whether SLC also induces B lymphocyte homing 
since data by Warnock (Warnock et al., 2000) seems to suggest that B lymphocytes utilise 
a different entry mechanism. B lymphocytes do, however, respond to SLC, and results from 
the CCR7 knockout studies indicate that, despite the possibility that B cells enter the 
lymphoid organs via a different route, their expression of CCR7 may keep them for a 
defined period of time in close contact with T cells in the T cell rich areas in order to allow 
effective B cell-T cell interactions to take place. There is also evidence for an increase in 
responsiveness of B cells to SCL and ECL after activation which induces them to move 
towards T cell rich areas. At the same time, they secrete MIP-ip, M IP-la and MDC which 
attract activated T cells (Cyster, 1999).
On the basis of the findings mentioned above, different subsets of leukocytes can now be 
distinguished according to the chemokine receptor repertoire expressed on their surfaces
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and, consequently, the chemokines they respond to. This does not only depend on their 
developmental stage, but also on their tissue specificity and the subtype of these cells. For 
example, Sallusto (Sallusto et al., 1999) report the existence of two different subsets of 
memory T cells which apparently circulate around the body by different pathways and 
mediate the memory response in different ways. One subset does not express CCR7 and is 
regarded as an “effector” memory T cell that does not migrate through the secondary 
lymphoid organs but instead surveys the peripheral tissues for its specific antigen. The 
other subset is termed “central” memory T cell and is characterised by the expression of 
CCR7. It can, however, rapidly convert to an “effector” subtype once it encounters its 
specific antigen in secondary lymphoid tissues upon which it loses CCR7 expression and 
migrates to the site of infection. Chemokine-mediated tissue specificity of lymphocytes 
was recently demonstrated by work by Campbell et al 1999 (Campbell et al., 1999) who 
showed that CCR4 mediates the adhesion of skin-specific memory T cells.
The mechanism by which circulating leukocytes leave the blood and migrate into tissue in 
response to a chemokine gradient is a multi-step process. It involves in the first instance 
selectin-mediated rolling of leukocytes along vessel walls and, subsequently, following 
chemokine-mediated activation, firm adhesion through integrins present on the endothelial 
cells as well as on the leukocytes themselves. The arrested cells will then leave the blood 
flow and migrate through the endothelial cell layer along the chemokine gradient in a 
process called diapedesis.
In order to be able to maintain a stable chemokine gradient on the luminal surface of 
endothelial cells that is not washed away by the blood flow, chemokines have to be 
tethered in a way that allows them to be presented to passing leukocytes. One way this 
could be achieved is by binding of chemokines to proteoglycans present on cell surfaces 
and in the extracellular matrix. Most if not all chemokines have the capacity to interact 
with sulphated proteoglycans such as heparin and heparan sulphate via a number of basic 
residues usually arranged in clusters (discussed in more detail in a later section). A recent 
report by Pelletier (Pelletier et al., 2000) also seems to implicate the adhesion protein 
fibronectin in the tethering of chemokines to vessel walls and in their presentation to 
chemokine receptors on passing leukocytes. They found that SD F-la bound to fibronectin 
with a relatively high Kd of 20 nM and that the presented chemokine was more efficient in 
stimulating directed migration of responsive cells which also showed a clustering of 
CXCR4 at their leading edge. In fact, the authors go so far to suggest that continuous 
directed movement of leukocytes does not actually require the presence of a chemokine
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gradient. Instead, they propose that the initial encounter of tethered chemokine at a certain 
threshold concentration is sufficient to induce the polarisation of these cells and that they 
then simply continue migrating in the direction in which they first polarised.
A mechanism has recently been proposed by which chemokines that are produced within 
the tissue at the site of an infection reach the other side of the endothelial cell layer where 
they may form a gradient. Until then it was thought to be accomplished by chemokine 
diffusion through the intercellular gaps. However, work by Middleton (Middleton et al.,
1997) demonstrated that IL-8 , when injected intradermally, binds to the abluminal surface 
of the endothelial cell layer of postcapillary vessel walls, undergoes internalisation and 
incorporation into calveolin-containing vesicles, is transcytosed across the endothelial cell 
layer and is eventually found on the apical side of these cells. This process of receptor- 
mediated transcytosis has been proposed to involve the promiscuous chemokine receptor 
DARC (Duffy antigen receptor for chemokines) which binds to CC as well as CXC 
chemokines. Knockout mice for this receptor have very recently been generated (Dawson 
et al., 2 0 0 0 ) which have a normal phenotype under non-pathological conditions, but show 
an exaggerated inflammatory response to a challenge with bacterial lipopolysaccharide 
which suggests that DARC modulates the intensity of inflammatory reactions and thus acts 
as a regulatory sink for chemokines.
1.2.2. Subversion and Exploitation of the Chemokine System by 
Pathogens
It is now clear that chemokines are essential for mounting an effective immune response 
which is why they are a common target for exploitation by pathogens that attempt to evade 
the immune system (for reviews on this subject see Lalani et al., 2000; Murphy, 2000; 
Pease and Murphy, 1998). Pathogens have evolved a number of diverse strategies for 
corrupting the chemokine system. One way of exploiting the system has been achieved by 
the Human Immunodeficiency Virus (HIV)-l and the parasite Plasmodium vivax which 
causes Malaria. These two pathogens use chemokine receptors for entry into host cells; in 
the case of the Malaria parasite it is DARC (Horuk et al., 1993) whereas HIV-1 employs a 
number of CC and CXC chemokine receptors (CXCR4, CCR2b, CCR3, CCR5, CCR8  and 
CX3 CRI - depending on the strain) in combination with the T helper cell marker CD4 
(Clapham and Weiss, 1997). It was also demonstrated that activated CD8 + T lymphocytes 
from HIV-infected individuals secrete a soluble activity that suppresses HIV infection and 
which was shown to contain a number of chemokines, including RANTES, M IP-la, MIP-
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ip  (Cocchi et al., 1995), and MDC (Pal et al., 1997) which compete directly with the virus 
for chemokine receptors. Also, individuals who are homozygous for a CCR5 deletion are 
largely protected from HIV infection (Doranz et a l, 1996).
HIV also encodes in its genome the glycoprotein gpl20 which is a chemokine mimic that 
mediates neuronal apoptosis via CXCR4 (Hesselgesser et al., 1998) and the Tat protein 
which is a CC chemokine mimic that acts as an agonist (for CCR2 and CCR3) (Albini et 
al., 1998). Chemokine homologues are found in a number of other viruses where they 
serve different functions. The genome of Kaposi’s sarcoma-associated herpesvirus 
(KSHV), for example, encodes three CC chemokine homologues vMIP-I, vMIP-II and 
vMIP-III which carry out a wide range of different functions. All three of them have been 
demonstrated to possess angiogenic properties (Dittmer and Kedes, 1998; Stine et al., 
2 0 0 0 ), which may be important for the blood supply of the lesions produced by this virus. 
In addition, vMIP-II has also been shown to display antagonistic effects on CCR1, CCR2, 
CCR3, CCR5 and CXCR4 (Kledal et al., 1997; Murphy, 2000), while all three of them 
display chemoattractant properties towards Th2 cells either through CCR8  (vMIP-I, vMIP- 
II) or through CCR4 (vMIP-III) both of which are expressed on Th2 cells. The reason for 
this chemoattractant effect is not entirely clear, but may serve to change the balance of the 
immune response away from a virally-targeted ThI towards a Tr2 response. KSHV, like a 
number of other viruses, also encodes a chemokine receptor homologue which is 
constitutively active, but which retains chemokine binding properties (Gershengorn et al., 
1998), and which also acts as an angiogenic factor (Bais et al., 1998). Another chemokine 
receptor homologue is encoded in the ORF U28 of the human cytomegalovirus. Its function 
seems to be the sequestration and internalisation of chemokines (Bodaghi et al., 1998).
Another way of manipulating the chemokine system was discovered in a number of 
poxviruses which encode in their genomes proteins that do not exhibit homology to any 
known host proteins but which are potent chemokine binding proteins and thus serve as 
broad spectrum chemokine scavengers. Interestingly, the genome of the Myxoma virus 
contains a gene that codes for a hybrid protein (M-T7) that binds chemokines with its 
carboxy terminus and has homology to the IFNy receptor and therefore IFNy binding 
properties in a different domain. Because M-T7 only binds to the rabbit form of IFNy, but 
can bind to chemokines from different species, its clinical use as a selective chemokine 
blocking and therefore antinflammatory agent is currently being explored (Liu et al., 2000). 
This is a good example of how an understanding of the viral mechanisms used to perturb 
chemokine function might not only lead to the gain of insights about the normal function of
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the chemokine system, but might also lead to novel therapeutic applications for the 
treatment or prevention of a wide spectrum of inflammatory or viral diseases.
1.2.3. Chemokines and Disease
Although an inflammatory response is necessary for the resolution of a pathogenic event, 
the toxic nature of many products secreted by various cells implicated in these events can 
cause significant damage to tissues (Perry et al., 1995). Chemokines and their receptors are 
instrumental for various aspects of an inflammatory response and have therefore been 
implicated in numerous inflammatory disorders that are characterised by aberrant immune 
inflammatory responses, such as allergies and autoimmune diseases. In addition, tumours 
have been shown to exploit several functions of chemokines in order to promote the 
proliferation and spread of cancer cells. And recent findings in the study of neurological 
disorders seem to suggest that pathogenic actions of chemokines can sometimes arise from 
the inappropriate extensions of their normal physiological functions (see Asensio and 
Campbell, 1999 and below).
1.2.3.1. Allergy and Asthma
During recent years the prevalence of allergic diseases has increased rapidly in developed 
countries. There are basically two types of hypersensitivity reactions that result in allergic 
responses. The first type involves an immediate hypersensitive reaction that is initiated by 
antigen binding to IgE molecules, followed by a late phase reaction that is characterised by 
an accumulation of basophils, neutrophils, eosinophils and TH2 cells. This type of reaction 
is responsible for allergic diseases such as asthma. The second type is a delayed-type 
hypersensitivity reaction, such as found in contact allergic responses, and involves CD4+ T 
lymphocytes of the ThI class. Chemokines contribute to these responses through their 
ability to recruit and activate leukocyte populations, induce degranulation, and cause the 
release of inflammatory mediators from effector cells such as basophils, mast cells, 
neutrophils and eosinophils (Lukacs et al., 1999). The close and intriguing association of 
chemokine receptor expression with the TH1 or TH2 cell phenotypes, with CCR3, CCR4 
and CCR8  expressed by TH2 cells and CCR5 and CXCR3 found on TH1 cells (Zlotnik and 
Yoshie, 2000), suggests that chemokines may participate in these hypersensitivity 
responses by not only influencing the migratory patterns of these cells but also by induction 
of differentiation towards the TH1 or TH2 phenotypes (Homey and Zlotnik, 1999; Lloyd et 
al., 2000). In the research into the causes of asthma, attention has also been focused on
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chemokines that have the ability to attract eosinophils, as it is these cells that are thought to 
be primarily responsible for the induction of bronchial mucosal injury and are associated 
with bronchial obstruction during asthmatic responses (Folkard et al., 1997; Holgate et al.,
1997). It was found that the movement of these cells through the vessel wall into the lung 
interstitium, and subsequently into the airway, during the early stages of asthma is 
dependent upon RANTES and M IP-la, whereas eotaxin is necessary for the eosinophil 
accumulation during chronic stages of the response (Campbell et al., 1999; Campbell et al.,
1998). It is therefore eotaxin and its receptor CCR3 that have been the main focus in the 
search for therapeutic treatments for asthma (Sabroe et al., 2000). Indeed, an amino 
terminally altered form of Ckp7 has proved to be a very effective antagonist of CCR3 
(Nibbs et al., 2000).
1.2.3.2. Cancer
There are three ways in which chemokines can potentially influence the growth of tumours: 
by their angiogenic or angiostatic properties, by initiating tumour immunity or by 
regulating their metastasis (Oppenheim et al., 1997). CXC chemokines can be subdivided 
into two groups according to the presence or absence of a conserved three amino acid motif 
consisting of glutamic acid, leucine and arginine, ELR, which directly proceeds the first 
cysteine residue (see Table 1.1). These three amino acids are not only crucial for 
ligand/receptor interactions on neutrophils (Clark-Lewis et al., 1993; Hebert et al., 1991 
and see below), but were also demonstrated to confer angiogenic properties, while ELR' 
CXC chemokines were found to act as angiostatic factors (Strieter et al., 1995). As tumours 
progress, their demand for sufficient blood supply increases and, as a result, the growth of 
new blood vessels into the tumours is intitiated in a process termed angiogenesis which 
depends on the relative balance of angiostastic and angiogenic factors (Belperio et al., 
2000). Angiogenic chemokines such as GROa have been implicated in promoting the 
growth of tumours since they were found to be expressed in human melanomas and their 
depletion resulted in a marked reduction of tumour-derived angiogenesis and, as a 
consequence, tumour growth was inhibited (Luan et al., 1997). ELR' CXC chemokines, on 
the other hand, have the ability to suppress tumours due to their angiostatic properties. For 
example, IP 10 has been demonstrated to impair angiogenesis in Burkitt’s lymphoma cell 
lines to the extent that severe damage was caused in established tumour vasculature, 
resulting in tissue necrosis (Sgadari et al., 1996).
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Evidence exists that some chemokines are expressed inside tumours where they induce 
infiltration of leukocytes that can lead to a temporary tumour regression (Negus et al., 
1997; Rollins and Sunday, 1991; Zhang et al., 1997). In other cases, transfection of genes 
encoding chemokines, such as IP10, RANTES and 1-309, into tumour cells promoted the 
development of immunity in mice to tumours that overexpress these chemokines (Laning et 
al., 1994; Luster and Leder, 1993; Mule et al., 1996). Furthermore, mice injected with 
tumours expressing these chemokine genes reject the tumours and develop specific 
resistance to subsequent challenge with nontransfected parental tumour cells. There have 
been recent reports stating that not only CXC chemokines but also CC chemokines have 
direct effects on angiogenesis where MCP-1 was shown to be angiogenic (Salcedo et al.,
2000) whereas SLC displayed angiostatic qualities (Vicari et al., 2000). In the latter report, 
SLC also seemed to cause an infiltration of leukocytes that resulted in tumour regression.
There have been a few reports of chemokines being directly involved in the migration of 
tumour cells and potentially in their metastatic spread to specific organs (Oppenheim et 
al., 1997; Youngs et al., 1997). However, this has not been clearly demonstrated in an in 
vivo situation.
1.2.3.3. Neurological Disorders
There is increasing evidence that chemokines play a significant role in the central nervous 
system (CNS) under both pathological as well as physiological conditions (for recent 
reviews see Asensio and Campbell, 1999; Mennicken et al., 1999). For example, mice 
lacking the gene for either CXCR4 or its ligand SDF-1 display defects in neuronal 
patterning during development (Nagasawa et al., 1996; Tachibana et al., 1998; Zou et al.,
1998). In the adult brain, the specific localisation of certain chemokines, such as 
fractalkine, and the fact that chemokine receptors show some homology to neurotransmitter 
receptors suggests that chemokines and their receptors might have an important role in 
physiological cellular communication within the adult mammalian CNS (Asensio and 
Campbell, 1999). In addition, work by Araujo (Araujo and Cotman, 1993) and Robinson 
(Robinson et al., 1998) indicates that CXCR2 and its ligands may promote the growth and 
survival of neural cells.
As in the immune system, the expression of chemokines and their receptors in the CNS is 
upregulated by inflammatory mediators which then allows them to mediate leukocyte 
infiltration of the CNS. This is an important step in response to diverse challenges,
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including infection, trauma and stroke but, as in the immune system, can lead to 
inflammatory disorders when the normal regulation is disturbed. One such example is 
multiple sclerosis (MS) which is a human chronic inflammatory and demyelinating disease 
that induces subsequent neuronal death. Brain lesions of MS patients were found to be 
enriched in CCR5+ and CXCR3+ T cells (Balashov et al., 1999; Sorensen et al., 1999) and 
their corresponding ligands M IP-la and RANTES (for CCR5) and IP10 and Mig (for 
CXCR3). And studies on CCR2 mice have implicated this receptor and its ligands in 
Experimental Autoimmune Encephalomyelitis which serves as an animal model for MS 
(Fife et al., 2000). Other chemokine-associated neurological diseases include HIV 
dementia, Alzheimer’s disease and CNS tumours (Asensio and Campbell, 1999; 
Mennicken et al., 1999).
1.2.4. Chemokines in Haemopoiesis
Since the first discovery of a chemokine as an haemopoietic stem cell (HSC) inhibitor by 
Graham (Graham et al., 1990), a number of chemokines have now been shown to act as 
negative or positive regulators of different types of haemopoietic stem or progenitor cell 
proliferation. There exists, however, a certain degree of controversy since it is often 
difficult to compare and reconcile the results from different groups as different 
haemopoietic stem and progenitor assays and different conditions therein are employed to 
investigate the regulatory activities of chemokines within the HSC compartment. It is 
nevertheless likely that research into this area of chemokine activity will continue to 
expand, fuelled by the hope that some members of the chemokine family will prove to be 
valuable therapeutic agents in clinical applications, such as chemotherapy and HSC 
expansion (see below).
A number of functions have now been proposed for chemokines in the regulation of the 
haemopoietic system. As mentioned above, a large number of chemokines (more than 15 in 
the CC chemokine subfamily and at least 8  of the CXC chemokines) have now been 
demonstrated to reversibly suppress the proliferation of early progenitors as measured in a 
number of in vitro colony formation assays (Broxmeyer and Kim, 1999; Graham et al., 
1990; Hromas et al., 1997; Maekawa and Ishii, 2000; Patel et al., 1997; Youn et al., 1995; 
Youn et al., 1998) as well as in vivo (Cashman et al., 1999; Dunlop et al., 1992). Although 
some of these chemokines display overlapping activities, with CFU-GEMM and CFU-GM 
cells being common targets, a number of studies now seem to suggest that different 
chemokines may have differential inhibitory effects on diverse haemopoietic cell lineages.
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For example, in 1997 Patel et al (Patel et al., 1997) isolated two CC chemokines which 
were named myeloid progenitor inhibitory factors (MPIF) 1 and 2. As their names suggest, 
these two proteins exhibit suppressive activities on haemopoietic progenitors in addition to 
more characteristic chemotactic activities on mature leukocytes. However, while MPIF-1 
targets the proliferation of low proliferative potential colony-forming cells which represent 
committed progenitors that give rise to granulocyte and monocyte lineages, MPIF-2 
suppresses the colony formation by the high proliferative potential colony-forming cell, a 
multipotential haemopoietic progenitor. More recently, a CXC chemokine, termed 
WECHE, was isolated from an AGM (a mesodermally derived region containing the dorsal 
aorta, genital ridge/gonads and pro/mesonephros, where the first definitive haemopoietic 
stem cells arise) - derived endothelial cell line and shown to inhibit the formation of the 
erythroid lineage at a very early stage in haemopoietic development (Ohneda et al., 2000). 
The observation that chronic myeloid leukaemia progenitors are often refractory to 
inhibition by chemokines such as M IP-la and MCP-1 (Cashman et al., 1998; Eaves et al.,
1993) opened up the possibility of using these chemokines during chemotherapy as they 
were shown to protect normal progenitors from the effects of cytotoxic drugs by preventing 
them from entering the cell cycle, while leukaemic cells remained unprotected. However, 
such protective agents could be used for ameliorating the side effects of chemotherapy in 
any type of cancer (discussed in more detail in the section on M IP-la).
Not only negative but also positive regulation of the proliferation of haemopoietic stem and 
progenitor cells by chemokines has been observed (Broxmeyer and Kim, 1999; Maekawa 
and Ishii, 2000; VerFaillie, 1996). M IP-la, for example, despite being an inhibitor of early 
haemopoietic progenitors, can have an enhancing effect on more mature progenitors, i.e. 
progenitors that only require stimulation with a single growth factor for colony formation 
(Broxmeyer et al., 1990). Chemokines may also play a role in the mobilisation and release 
of progenitors from the bone marrow into the peripheral blood as was seen for M IP-la (see 
section on M IP-la) and IL- 8  (Laterveer et al., 1996). The process by which IL- 8  achieves 
progenitor mobilisation is thought to involve metalloproteinase gelatinase B (MMP-9), a 
protein imlicated in the degradation of extracellular matrix molecule, which is released 
from neutrophils following IL- 8  activation and may then induce stem cell mobilisation by 
cleaving matrix molecules to which stem cells are attached (Pruijt et al., 1999).
The mechanism by which chemokines suppress haemopoietic stem and progenitor cells is 
not well understood. In a number of cases, it is not even known whether they inhibit the 
proliferation of these early cells or just the differentiation into certain haemopoietic
lineages (Ohneda et al., 2000). It has also been suggested that analogous to their effect on 
mature leukocytes whose integrin-dependent adhesion to vascular endothelium is triggered 
by chemokines, these proteins may also increase the integrin-mediated adhesion of 
progenitors to stroma which can induce inhibition of proliferation (Hurley et al., 1995). 
The signalling events involved in suppression also still remain largely unknown. Work by 
(Aronica et al., 1995) on the human growth-factor-dependent haemopoietic cell line M07e 
which they showed to be inhibited in its proliferation by IP10 and M IP-la, seems to 
implicate Raf-1 kinase-dependent pathways in proliferation. In other attempts to elucidate 
the signalling events following chemokine binding and leading to suppression of 
proliferation, mice lacking the genes for certain chemokines, chemokine receptors and 
signalling molecules have been examined for defects in haemopoietic development. For 
example, mice in which the phosphotyrosine phosphatase SHP-1 which is predominantly 
expressed in haemopoietic cells, is inactive display a number of severe haemopoietic and 
immune defects. In addition, their myeloid progenitors seem to be resistant to chemokines 
that suppress proliferation, thus implicating this signalling molecule in chemokine-induced 
suppression (Kim et al., 1999). Reid (Reid et al., 1999) analysed mice in which the gene for 
the chemokine receptor CCR2 was deleted and found that the bone marrow-derived 
myeloid progenitors showed increased cycling rates compared to progenitors found in wild 
type mice. However, there was no increase in total cellularity within the haemopoietic 
system which was explained by these investigators by an increase in apoptosis observed in 
these bone marrow cells, thus implicating CCR2 not only in myelosuppression but also in 
increase of cell survival.
The most striking evidence for the involvement of chemokines in haemopoiesis is 
provided by mice lacking the CXC chemokine SDF-1 (Nagasawa et al., 1996) or its 
receptor CXCR4 (Tachibana et al., 1998; Zou et al., 1998). Apart from neuronal and 
vascularisation defects, these mice also have striking haemopoietic defects, including 
absence of B lymphopoiesis as well as bone marrow myelopoiesis. SDF-1 is constitutively 
expressed in bone marrow-derived stromal cells where it serves to attract haemopoietic 
stem cells to their bone marrow niches as they migrate from the foetal liver to the bone 
marrow during normal development. This explains why myelopoiesis occurs normally in 
the foetal liver, but progenitors subsequently fail to migrate to the bone marrow and are 
instead found in the peripheral blood. The importance of SDF-1 and its receptor CXCR4 in 
homing of CD34+ to the bone marrow microenvironment was supported by two recent 
publications by Peled (Peled et al., 1999; Peled et al., 2000) in which it was demonstrated 
that SDF-1 expressed on the bone marrow vascular endothelium stimulates integrin-
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mediated arrest of CD34+ cells that are also CXCR4+. Furthermore, it also mediates the 
trans-stromal migration of these cells and their subsequent movement through the 
extracellular matrix to their respective “niche”. This process is not only important for the 
movement of haemopoietic stem cells during development but also for the successful 
engraftment of donor haemopoietic stem cells into a recipient following transplantation. In 
addition to mediating stem cell homing, SDF-1 also regulates the proliferation of B cell 
progenitors.
Apart from SDF-1, a number of other chemokines have now been shown to induce 
chemotaxis in haemopoietic stem and progenitor cells, namely SLC and ELC which were 
demonstrated to chemoattract CFTJ-GM cells via their receptor CCR7 (Kim and 
Broxmeyer, 1999), and IP10 and Mig that induced chemotaxis in GM-CSF-stimulated 
CD34+ cells (Jinquan et al., 2000). The significance of this in an in vivo situation is not 
entirely clear, especially since high concentrations of up to 2000 ng/ml of SLC are required 
to induce chemotaxis.
It is apparent from the evidence discussed above that chemokines are prominent players in 
almost all aspects of haemopoietic cell function, starting from the regulation of the 
proliferation and/or differentiation of the earliest haemopoietic stem cells up to the 
regulation of mature leukocytes in various situations. It is therefore not surprising that these 
proteins have been a major focus for research into possible therapeutic applications for 
various conditions ranging from AIDS and other infectious diseases to the treatment of 
allergies, cancer and the alleviation of the impact of chemotherapy and the improvement of 
tissue transplants. An important prerequisite to the clinical application of these proteins is 
an understanding of their functions in relation to their structures. A wealth of information 
is now available on their three-dimensional structures and on motifs and residues important 
for their various functions as will be discussed in the next section.
1.2.5. The Structure of Chemokines
A wealth of information has been accumulated about the three dimensional structure of 
chemokines, the mechanism by which they interact with their receptors, with 
proteoglycans, and also with themselves during the process of oligomerisation. Each one of 
these aspects will be discussed in the following sections.
1.2.5.1. The Tertiary Structure of Chemokines
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The three dimensional structures have been solved by NMR and/or x ray crystallography 
for the following chemokines: PF4 (Mayo et al., 1995; St. Charles et al., 1989; Zhang et al.,
1994), IL-8 (Baldwin et al., 1991; Clore et al., 1989; Clore et al., 1990), MGSA/GROa 
(Fairbrother et al., 1994; Kim et al., 1994), SDF-1 (Crump et al., 1997; Dealwis et al.,
1998), MIP-2 (Shao et al., 1998), GROp (Qian et al., 1999) and NAP-2 (Malkowski et al.,
1995) in the CXC subfamily, MEP-ip (Lodi et al., 1994), RANTES (Chung et al., 1995; 
Skelton et al., 1995), MCP-1 (Handel and Domaille, 1996; Lubkowski et al., 1997), MCP- 
3 (Meunier et al., 1997), eotaxin (Crump et al., 1998), HCC-2 (Sticht et al., 1999), 1-309 
(Keizer et al., 2000) and M IP-la (MacLean, J. unpublished results) in the CC subfamily, 
Fractalkine (Hoover et al., 2000; Mizoue et al., 1999), the only member of the CX3C 
subfamily and vMIP-II (Liwang et al., 1999), a viral CC chemokine homologue. All of 
them were shown to possess a strikingly similar monomeric structure, the “chemokine 
fold” (see Fig. 1.2 for an example), which consists of an extended N terminal region, a 
triple-stranded, antiparallel p sheet, arranged in a Greek key motif, and a C terminal a  
helix which lies on top of the p sheet. This helix is of an amphipathic nature which allows 
it to pack closely on top of the p sheet via a number of conserved hydrophobic interactions, 
thus forming the hydrophobic core of the chemokines. The extended N terminal loop 
which, via a single helical turn, leads into the first p strand, consists of a collection of 
nonclassical turns and is anchored to the chemokine body via the two disulphide bridges. 
The extreme N and C termini are often disordered due to their highly flexible nature. 
Despite this very similar overall fold, there are certain structural differences within and 
between the different subfamilies which become apparent upon alignment of the 
monomeric units. These differences mainly reside in the more flexible parts of the 
molecules which are believed to be involved in receptor binding and activation (see 
below), especially in the residues preceding the first cysteine residue, but also in the 
remainder of the N terminal loop and the turns that connect the p strands. Other differences 
are found in the length and exact position of the C terminal a  helix and surrounding the 
cysteine motif, since the introduction of one or three intervening residues in the CXC and 
CX3C chemokines causes a bulge in the polypeptide chain which will also influence the 
conformation of the neighbouring residues.
Among the CC chemokines, there are three members, HCC-2,1-309 and SLC, that contain 
an additional, third disulphide bridge, the exact function of which is unknown. When the
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three dimensional structures of HCC-2 and 1-309 were solved, it was surprising to see that 
in the case of HCC-2, the additional disulphide bridge, which connects the base of the a  
helix with the helical turn preceding the first p strand, did not cause any major 
perturbations of the overall fold. On the contrary, it was suggested that it plays a role in 
stabilising the N terminus, thus compensating for the absence of a conserved tryptophan 
residue at position 53 that is thought to fulfil this function in other CC chemokines. In the 
case of 1-309, however, the additional disulphide bond is found in a completely different 
position, connecting the first p strand with the C terminal end of the a  helix. This results in 
the disruption of the helix, thus terminating it prematurely, and in the unique formation of a 
short p strand that runs perpendicular to the triple-stranded p sheet. Despite these 
differences, 1-309 still retains the overall chemokine fold, however, it may explain why 
only one receptor is known for 1-309 so far. Although the structure of SLC, the third 
chemokine to contain an additional disulphide bridge, has not been solved, sequence 
comparisons to HCC-2 and 1-309 suggest that it will closely resemble HCC-2 in that the 
third pair of cysteines is not expected to have a great impact on the overall structure.
1.2.5.2. Chemokine Aggregation
Most chemokines can self-associate to form aggregates of varying molecular weights 
depending on concentration, pH and solvent ionic strength (Clark-Lewis et al., 1995) which 
can be detected by gel filtration chromatography or ultracentrifugation sedimentation 
equilibrium analyses. The exact orientation of the monomeric units within the oligomers 
was revealed in the NMR and crystal structures.
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Figure 1.2: 3D Structure of SDF-1
Above is shown the solution structure of the SDF-1 monomer ( Tibbon-representation') as 
an example of the conserved chemokine fold. Different domains are represented by 
different colours and their names and boundaries (in residue numbers) listed in the box. 
The position of the two disulphide bridges is shown in the picture by ‘stick- 
representations’ of the cysteine residues and their residue numbers listed in the smaller 
box.
55
m M lP- l a
s ide  v iew
top view
Figure 1.3: Comparison of CC and CXC Chemokine Dimers
Above are shown ‘ribbon-representations’ of the murine MIP-la dimer (a CC chemokine; 
two panels on the left hand side) and the human IL-8 dimer (a CXC chemokine; two 
panels on the right hand side). The different subunits are shown in different colours.
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The three dimensional structures of PF4 and IL- 8  were the first ones to be published and 
revealed the tertiary as well as the quaternary structures of these proteins. The mode of 
dimerisation proved to be exactly the same for both of them and involves the formation of 
a six-stranded antiparallel p sheet in which the two subunits lie side by side and interact via 
their first p strand. The two helices are located on the top of the p sheet, running 
antiparallel to each other with their C terminal ends making contact with the other subunit, 
thus helping to stabilise the dimer. This quaternary structure is highly reminiscent of the 
fold of the a l /a 2  domains of the class I MHC antigen HLA-A2 (Clore et al., 1990) which 
led the authors to suggest that the mechanism by which HLA-A2 interacts with antigen and 
the T cell receptor may serve as a model for the way chemokines interact with their 
receptors. In that case, residues important for receptor binding and activation would be 
located in the region between and on the surface of the two a  helices. However, 
mutagenesis studies have since established that this is not the case (see below).
While IL- 8  is unable to aggregate past the dimeric state, PF4 is known to exist in a 
monomer-dimer-tetramer equilibrium in solution (Mayo and Chen, 1989). In the PF4 
tetramer, as revealed by the crystal structure (St. Charles et al., 1989; Zhang et al., 1994), 
two dimers associate back to back, thus forming a p bilayer with the helices found on 
opposite sides of the complex.
Since IL- 8  and PF4 were found to form identical dimers, it was assumed that this mode of 
dimerisation was conserved among all chemokines, and indeed some mutagenesis studies 
of MCP-1 were based on this assumption (Beall et al., 1992; Zhang et al., 1994). It 
therefore came as a surprise when the solution of the NMR structure of MIP-ip unveiled a 
completely different mode of dimerisation which is now believed to be conserved amongst 
almost all CC chemokines (see MCP-3 discussion below), whereas all CXC chemokines 
that form oligomers, do so via an IL-8 -type dimer. In contrast to the globular CXC 
chemokine dimer, the CC chemokine dimer is more elongated and of a cylindrical shape, 
with the two helices located on opposite sides of the complex (see Fig. 1.3 for examples of 
CC and CXC - type dimers). This completely dissimilar design stems from a different 
dimer interface which in the case of CC chemokines is mainly formed by residues in the 
extreme N- terminus (residues 2-13 in MIP-lp) and which causes the creation of another, 
short, p strand which associates with the p strand in the other monomer in an antiparallel 
fashion. It has rarely been observed that proteins which are almost identical in their 
polypeptide fold, form such completely divergent oligomers. However, a number of
differences in the primary sequence and the secondary structure of CC as compared to 
CXC chemokines may help to explain this observation. On comparing the distribution of 
hydrophobic charges between CC and CXC chemokines (Clore and Gronenborn, 1995; 
Lodi et al., 1994), it becomes apparent that the strongest clusters of hydrophobicity are 
found at equivalent positions in the two chemokine families which explains the almost 
identical monomeric structure since these hydrophobic residues are involved in the packing 
of the hydrophobic protein core. However, the pattern of surface hydrophobicity is 
strikingly different in CC versus CXC chemokines which offers an explanation for the 
different dimerisation mode since these hydrophobic surface residues become buried upon 
oligomerisation. This is supported by the calculation of the solvation free energy of 
dimerisation (Clore and Gronenborn, 1995; Lodi et al., 1994) which suggests that the 
driving force for the formation and stabilisation of dimers is the burial of hydrophobic 
charges. However, hydrogen bonds and salt bridges have also been shown to contribute 
towards dimer formation. Further contributions to the divergent quaternary structures are 
thought to be made by the different conformation of the turn between strand P2 and P3 and 
of the first disulphide bond (due to the insertion of an amino acid between the first two 
cysteine residues in CXC chemokines), as well as by the completely different direction of 
the residues preceding the first cysteine residue and the longer helix that can make contacts 
with the other subunit in CXC chemokines.
In the three dimensional structures, only PF4 (Clore et al., 1989; Mayo et al., 1995; Zhang 
et al., 1994), NAP-2 (Malkowski et al., 1995), MCP-1 (Lubkowski et al., 1997) and MIP- 
l a  (see below) have been detected as tetramers, while most of the other chemokines form 
dimers in the conditions employed for NMR studies or crystallisation. HCC-2 (Sticht et al.,
1999) and 1-309 (Keizer et al., 2000), both of which contain 3 disulphide bonds (see 
above), were detected as monomers when their structures were determined. HCC-2 was 
also determined to be a monomer over a wide range of concentrations (0.1 pM - 2 mM) by 
gel filtration studies at physiological pH which demonstrates that this chemokine does not 
oligomerise in solution, a finding which can at least in part be explained by a shorter N 
terminus and thus a shorter dimer interface (Sticht et al., 1999). Fractalkine (Hoover et al.,
2000) and SDF-1 (Dealwis et al., 1998) were both shown to be in a dimeric state in the 
crystal structures, but since they were monomers in solution (Crump et al., 1997; Mizoue et 
al., 1999), it can be assumed that the dimerisation of these two proteins was a product of 
crystal packing which is supported by the finding that Fractalkine can form neither a CC- 
type nor a CXC-type dimer (Hoover et al., 2000; Mizoue et al., 1999).
Contrary to the theory that the dimerisation mode is conserved within the chemokine 
subfamilies, MCP-3, a CC chemokine, was found to form a dimer in the crystal structure 
(Meunier et al., 1997) that resembled the IL-8 -type dimer more than the CC chemokine 
dimer. In that same study it was suggested that the MCP-3 monomer was unstable on 
account of a number of exposed core hydrophobic residues that become buried in the 
dimer. Yet again, the dimer observed in the crystal structure may well be a crystal artefact, 
since NMR and sedimentation equilibrium studies have shown MCP-3 to be monomeric at 
concentrations of up to 2 mg/ml (Kim et al., 1996). The fact that intersubunit interactions 
observed in crystal structures may not necessarily reflect native contacts is also 
demonstrated in the case of MCP-1. During crystallisation, two different forms of crystals 
were observed in the same droplet (Lubkowski et al., 1997), one containing a monomer, 
the other containing a dimer, which also differed somewhat from the previously published 
NMR structure of another MCP-1 dimer (Handel and Domaille, 1996). It can therefore be 
assumed that in a lot of cases the conditions employed for protein structure determination, 
such as high protein concentrations and nonphysiological pH and solvent ionic strength 
values, may favour intermolecular associations that are unlikely to occur in vivo. This has 
led to a controversy regarding the biological significance of chemokine oligomerisation 
with experimental data supporting a biological role for both monomers as well as 
oligomers.
When it was first discovered that CC and CXC chemokines form different dimers and that 
the type of dimer was largely conserved within the specific subfamily, it was proposed that 
these differences in quaternary structure may explain the lack of cross-reactivity of 
chemokines from one family with receptors from the other family (Clore and Gronenborn,
1995). This could either mean that the interaction with the receptor requires the presence of 
a dimer and that the receptors of one subfamily can only accommodate the chemokine 
dimer from the same subfamily. Alternatively, the same exposed hydrophobic surface 
residues that form the dimer interface and become buried upon dimerisation, may also be 
needed for interacting with the receptor. As the affinity of chemokines for their receptors is 
higher (nM range) than for their self-association (pM range), this would mean that the 
biologically functional unit is the monomer. However, this is more likely to be the case for 
CC chemokines, since in CXC chemokines the receptor binding site is remote from the 
dimer interface. Nevertheless, IL- 8  dimers were detected on receptors by cross-linking 
(Schnitzel et al., 1994), but mutagenesis studies have also shown that only one functional 
subunit is required for the cross-linked dimer to be active. This supports a model in which 
IL- 8  dimerisation does not interfere with receptor binding as cross-linked IL- 8  can still
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activate the receptor, but only one subunit at a time will interact with the receptor. This is 
reinforced by the fact that a mutant of IL- 8  that can no longer self-associate, is nevertheless 
fully functional (Rajarathnam et al., 1994). However, a nonfunctional MCP-1 variant in 
which residues 2 - 8  had been deleted, was believed to have a dominant negative effect since 
it inhibited receptor activation by wild type MCP-1, but not by cross-linked wild type 
MCP-1, thus suggesting that dimerisation is required and that the MCP-1 mutant 
sequestered wild type MCP-1 into nonfunctional dimers (Zhang and Rollins, 1995). Yet, in 
another study (Paavola et al., 1998), this same mutant was shown to act as a competitive 
inhibitor that simply displaces wild type MCP-1 from its receptor. These authors also 
generated a monomeric mutant of MCP-1 that was nevertheless still active, thus lending 
further support to the suggestion that dimerisation is not required for MCP-1 function.
Despite the fact that the concentration of circulating chemokines lies below the 
dimerisation constant, one can envisage situations in which the local concentration of 
chemokines is increased, thus favouring oligomerisation. This could be achieved by 
binding of chemokines to matrix and cell surface proteoglycans (Clore and Gronenborn, 
1995 and see section I.2.5.4.) or by concentrating them in granules, as is the case for PF4 
(St. Charles et al., 1989). Local environments may also be manipulated in a way that 
favours one aggregation state over another. For example, salt concentrations that were 
shown to shift the equlibrium towards a PF4 tetramer, resulted in the dissociation of the IL- 
8  dimer (Laurence et al., 1998). And in concentrations of 20 mM sodium phosphate and 
150 mM sodium chloride, similar to the ionic strength of blood, MIP-lp was 
predominantly present as a dimer (Laurence et al., 1998). It may also be the case that the 
ligand binding site on the receptor favours dimerisation. In such a scenario, a low 
dimerisation constant would prevent inappropriate activation of leukocytes at low 
chemokine concentrations and result in a much steeper gradient towards high local 
concentrations (Zhang and Rollins, 1995). However, as described above, it appears that 
most chemokines are able to activate their receptors as monomers.
While most chemokines cannot aggregate past the dimeric or tetrameric state, M IP-la, 
MIP-lp and RANTES can form high order aggregates at physiological conditions in a 
concentration-dependent manner (Lodi et al., 1994; Patel et al., 1993; Skelton et al., 1995). 
The MIP-ip aggregates can even be seen as helical fibrils (Lodi et al., 1994) in electron 
micrographs. This large scale aggregation seems to be largely controlled by electrostatic 
interactions (Patel et al., 1993), and acidic residues in RANTES have been identified that 
when mutated result in the disaggregation of RANTES. While these disaggregated mutants
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display wild type receptor binding, activation and chemotactic activity, they were shown to 
inhibit HIV entry only at very high concentrations (>1000 nM), at which wild type 
RANTES actually stimulates viral entry (Czaplewski et al., 1999). Furthermore, these 
mutants were deficient in RANTES-mediated T cell activation via a Protein Tyrosine 
Kinase pathway (Bacon et al., 1995) for which high concentrations, and therefore possibly 
aggregation, of RANTES are required.
Other functions that have been suggested for chemokine aggregation include increased 
resistance against proteolysis and thus increased stability and half-lives of chemokines 
(Paolini et al., 1994), as well as a mechanism for limiting the active amount of circulating 
chemokine in the blood (Paolini et al., 1994; Skelton et al., 1995). While the evidence 
provided above seems to suggest that oligomerisation is not necessary for the induction of 
G protein-coupled receptor-mediated chemotaxis by chemokines since some of them only 
exist in a monomeric state and monomeric variants of others are still biologically active, it 
could be that the relevance of aggregation may only be revealed by the use of the 
appropriate assay system, as shown for the role of aggregated RANTES in T cell 
activation. Therefore, future experiments may shed further light on the possible relevance 
of chemokine oligomerisation in vivo.
1.2.5.3. Chemokine - Receptor Interactions
The way chemokines bind and activate their receptors has been studied by a number of 
techniques. Before the three-dimesional structure of chemokines was known, researchers 
had to resort to comparing their primary sequences in order to highlight functionally 
relevant regions that are expected to be conserved among functionally related proteins, but 
fairly divergent in more distant members. Residues selected by that method were then often 
mutated in order to confirm their involvement in receptor interactions. However, not only 
was this a rather inefficient approach, it was also impossible to distinguish between 
residues that make direct contacts with the receptor and residues that occupy structurally 
crucial positions since their alteration can often result in identical phenotypes. However, 
knowing the exact location and orientation of these residues within the overall fold allows 
one to make this distinction and thus provides one with a more rational approach to 
identifying and targeting regions likely to be involved in receptor binding and activation. In 
addition, the superposition of the tertiary structures has led to the identification of regions 
that adopt slightly different conformations in different chemokines and may thus account 
for differing receptor specificities.
Alternatively, such regions can be identified by exchanging domains between different 
proteins with the aim of generating chimaeric molecules that have acquired novel functions 
that can be attributed to the presence of the inserted domain. This has been successfully 
applied to chemokines as well as to their receptors (see below). However, there is always 
the risk that a foreign domain is not well tolerated within the original protein framework, 
thus potentially leading to disturbances in the overall structure that will make the entire 
approach invalid. This is less likely if domains are exchanged between more related 
proteins, however in those cases there is the potential risk of overlooking functional 
contributions made by shared determinants. In most mutagenesis studies on chemokines 
and their receptors, individual residues have therefore been targeted and either replaced by 
amino acids found in other chemokines at equivalent positions or by alanine residues in a 
method called alanine scanning mutagenesis. Alanine is chosen because it has got a short 
and nonpolar side chain that is unlikely to impose severe constraints on folding. It also 
represents the most common amino acid found in proteins where it can occupy buried as 
well as solvent-exposed positions. In combination with such mutagenesis studies, NMR 
spectra are occasionally obtained for these mutants in order to detect any structural 
disturbances caused by the newly introduced residue.
NMR studies were employed in yet another approach for investigating chemokine-receptor 
interactions (Clubb et al., 1994) where the authors monitored changes in the spectra of 
individual residues caused by the binding of the N terminal fragment of the corresponding 
receptor. This allowed the precise mapping of the binding site for this receptor fragment, 
but may not precisely reflect the interaction of chemokines with the native receptors since 
other extracellular regions of the receptors are known to contribute to ligand binding (see 
below) and the unique environment near the membrane is not taken into account. This 
latter approach, however, has the advantage of being able to characterise the entire receptor 
binding surface, whereas in mutagenesis studies only residues that contribute strongly 
towards receptor binding will be detected. In addition to these chimaeric and peptide 
approaches, truncated variants of chemokines and chemokine receptors have also been 
generated in an attempt to define the minimal functional unit. The following section 
describes some of the findings that were produced by these different methodologies which 
resulted in a fairly detailed description of how chemokines interact with their receptors.
The general picture that emerged from all of these studies is that the interaction between 
chemokines and their receptors is a two-stage process that involves more than one domain 
in the ligand as well as in the receptor. Binding and activation occurs via two distinct
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regions that operate independently of each other, thus allowing the generation of potent 
antagonists by mutating the activation domain and creating a ligand that can compete for 
binding, but will no longer activate the receptor.
IL- 8  of the CXC chemokines and MCP-1 of the CC chemokines are the two most 
intensively studied proteins that have come to serve as models for the other family 
members. From these studies, it has emerged that despite the completely different mode of 
oligomerisation of the two subfamilies, the way they interact with their receptors is 
remarkably similar. Initial docking to the receptor appears to be mediated in both 
subfamilies by a region termed ‘N loop’ which comprises the amino acids between the 
cysteine motif and the 3io helical turn that leads into the first p strand (see Fig. 1.2). This 
region is highly variable and is thought to confer receptor specificity to chemokines. For 
example, by exchanging the N loop in GROa with the N loop in IL- 8  and vice versa, 
Lowman (Lowman et al., 1996) achieved an exchange of receptor affinities between these 
two proteins. It proved to be important, though, to exchange an additional residue found at 
position 49 in IL- 8  (leucine) and position 50 in GROa (alanine) since these make 
important contacts with the N loop and help position it in the correct orientation for 
receptor binding (Hammond et al., 1996; Hesselgesser et al., 1995; Lowman et al., 1996). 
This demonstrates the essential role played by residues that do not directly interact with the 
receptor but are part of the scaffold that is made up of the protein core and that supports the 
flexible N terminal region and presents it to the receptor in a fashion that optimises binding 
and activation (Crump et al., 1998). It has therefore been suggested that not only the 
sequence of the N loop itself, but also variations in the hydrophobic protein core which 
supports the conformation of the N loop, may contribute to the binding specificities of 
many chemokines (Mizoue et al., 1999). This scaffold is mainly held together in the right 
conformation by the two disulphide bridges which explains why changes made to any of 
the four conserved cysteine residues will render the protein completely inactive (Clark- 
Lewis et al., 1994).
Further support for a role of the N loop in tethering chemokines to their receptors prior to 
activation comes from studies in which the binding of a receptor-derived N terminal 
peptide to the corresponding ligand was investigated by NMR analysis. In two of those 
studies, a peptide derived from the N terminus of CXCR1, residues 1-40 (Clubb et al., 
1994) and residues 9-29 (Skelton et al., 1999), was demonstrated to bind to a hydrophobic 
cleft between the N loop and the third p strand of IL-8 , thus disturbing the NMR spectra of 
residues in the N loop, the turn preceding the third p strand and P3 itself. Those same
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regions, plus the 3io helical turn following the N loop, were also shown to be contacted in 
eotaxin by residues 1-35 from the N terminus of CCR3, thus indicating that the mechanism 
of receptor recognition is conserved among members of the two subfamilies (Ye et al.,
2000). A similar hydrophobic crevice was also detected in SDF-1 (Dealwis et al., 1998) 
which made the authors suggest that the pattern of a hydrophobic surface surrounded by a 
constellation of ionic residues may be a common characteristic of chemokines and the 
interaction with their receptors. A specific ‘docking motif’ has been identified in the N 
loop of SDF-1, consisting of the amino acids RFFESH and directly following the CXC 
motif, that is important for binding to CXCR4 (Crump et al., 1997). No such motif has 
been detected in any other chemokines so far.
There is a wealth of evidence pointing to the extreme N terminal residues, prior to the first 
cysteine, as being involved in receptor activation in both CC and CXC chemokines. In all 
neutrophil-activating CXC chemokines that display high affinity binding to CXCR2, a 
highly conserved three amino acid motif is found directly preceding the first cysteine, 
consisting of the sequence glutamic acid, leucine and arginine (see Table 1.1). This ELR 
motif, which also confers angiogenic properties (see above), is absolutely essential for 
receptor activation, as shown by the fact that mutating any one of the three residues will 
interfere severely with function (Hebert et al., 1991; Hesselgesser et al., 1995). It is not 
only the presence of these residues that is essential, but also their conformation and their 
orientation in relation to the rest of the molecule, since linear or circular peptides derived 
from the N terminus of IL- 8  and including the ELR motif are inactive (Clark-Lewis et al., 
1993). Therefore, residues that lie in close proximity to the ELR motif and help position it 
in the correct conformation, such as residues in the ‘30s loop’ (connecting 0 2  and P3), in 
particular the cysteine that forms a disulphide bond with the cysteine following the ELR 
motif, are also indispensable for function (Clark-Lewis et al., 1994; Hebert et al., 1991; 
Qian et al., 1999).
The importance of the ELR motif in neutrophil activation is stressed even further by work 
showing that a simple replacement of the corresponding residues in PF4 (DLQ) with ELR 
endows this chemokine with neutrophil-activating properties and the ability to displace IL- 
8  from its receptor (Clark-Lewis et al., 1993). However, PF4 must otherwise be very 
closely related to IL-8 , since the simple transfer of the ELR motif into IP10, another non- 
ELR CXC chemokine, does not confer neutrophil-activating abilities onto IP10, but instead 
requires almost the entire N terminal region (residues 4-22) and the two regions that help 
position the N terminal part (residues 30-35 and residue 49) of IL-8 .
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No other residues in the N terminus of IL- 8  have the same importance as the ELR motif. In 
fact, deletion of all the residues preceding the ELR motif makes it even more active (Clark- 
Lewis et al., 1991). This is in sharp contrast to non ELR-containing CXC chemokines, such 
as SDF-1, in which the first two residues are crucial for receptor activation, and the entire 
CC chemokine family where no such conserved motif exists, but instead all N terminal 
residues (preceding the first cysteine) seem to be of more or less equivalent significance 
(Arenzana-Seisdedos et al., 1996; Crump et al., 1998; Gong and Clark-Lewis, 1995; Gong 
et al., 1996; Oravecz et al., 1997; Weber et al., 1996; Zhang et al., 1994). Removal of as 
few as one or two residues from the N terminus of MCP-1 will not only substantially lower 
its activity, but also turn it into an antagonist, in accordance with the two-site model of 
chemokine-receptor interactions (Gong and Clark-Lewis, 1995; Zhang et al., 1994). 
Interestingly, the glutamate residue at position one in MCP-1 spontaneously converts into 
pyroglutamate which is, however, not essential for chemokine function and can be replaced 
by any other nonpolar residue as long as the N terminus remains intact (Gong and Clark- 
Lewis, 1995).
It is not only truncations but also extensions of the N terminus that severely compromises 
the function of CC (Proudfoot et al., 1996; Simmons et al., 1997) as well as CXC 
(Malkowski et al., 1995) chemokines. When RANTES was produced in E. coli, it was 
found to be functionally inactive due to the retention of the initiating methionine at the 
extreme N terminus (Proudfoot et al., 1996), despite still being able to interact with its 
receptors. This prompted a search for similarly N terminally modified RANTES analogues 
that could serve as receptor antagonists, and resulted in the generation of AOP-RANTES, a 
RANTES derivative which has an aminooxypentane group attached to its N terminus 
(Simmons et al., 1997). This antagonist was incapable of inducing chemotaxis, but proved 
to be a very potent inhibitor of HIV infection (Simmons et al., 1997) with slightly altered 
receptor specificities (Proudfoot et al., 1999).
The fact that the activity of chemokines can be easily influenced by only slight alterations 
to their amino termini is exploited by the immune system in vivo as a means of regulating 
immune responses. Naturally truncated forms of chemokines were identified before it was 
known that some chemokines serve as substrates for a number of peptidases. For example, 
the dipeptidyl peptidase CD26 has a substrate specificity of NH2 -X-Pro and cleaves 
chemokines such as MCP-1, eotaxin, IP10 and RANTES with this N terminal sequence 
after the penultimate proline residue (Oravecz et al., 1997). In the case of RANTES, this 
proteolytic cleavage results in a 3-68 variant that retains signalling through CCR5, but
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becomes an antagonist for CCR1 and CCR3 and hence a broad spectrum inhibitor for 
monocyte migration (Oravecz et al., 1997; Struyf et al., 1998). Members of the matrix 
metalloproteinase (MMP) family also recognise a number of chemokines as substrates. 
Processing of MCP-3, for example, by gelatinase A (MMP2), which is secreted by stromal 
cells, results in a 5-76 form that is incapable of signalling through CCR1 and CCR2 which 
has a dampening effect on inflammation (McQuibban et al., 2000). In contrast, cleavage of 
IL- 8  by gelatinase B (MMP9) produces a 7-77 variant that is even more active than full 
length IL- 8  and further stimulates the release of gelatinase B from neutrophils, thus 
resulting in a positive feedback loop that has an enhancing effect on inflammation (Van 
Den Steen et al., 2000). Matrix metalloproteinases can therefore serve as positive as well as 
negative regulators of inflammation. Other forms of proteolytic processing have been 
shown to convert PF4 into an inhibitor of endothelial cells (Gupta et al., 1995) and the 
CXC chemokines NAP-2 and CTAPIII into microbicidal proteins known as thrombocidins 
(Krijgsveld et al., 2000).
In contrast to the N terminus, alterations to the C terminal a  helix do not produce such a 
dramatic effect on activity. Deletion of residues from the C terminus results in a 
progressive loss of activity (Clark-Lewis et al., 1991; Zhang et al., 1994), yet substantial 
activity is retained even in the absence of the entire a  helix, thus demonstrating a role for 
this domain in stabilising the tertiary structure rather than interacting directly with the 
receptor (Clark-Lewis et al., 1991; Sticht et al., 1996). However, the a  helix in CXC 
chemokines has been shown to contain important proteoglycan binding sites (see below). 
Other important residues that have been identified by mutagenesis studies include a 
conserved tyrosine residue in CC chemokines (position 28 in MCP-1) and another tyrosine 
or charged residue two positions further downstream which is always hydrophobic in CXC 
chemokines and which is thought to contribute to cell specificity (Beall et al., 1992; Lusti- 
Narasimhan et al., 1995). Other more extensive studies have pinpointed receptor 
specificities to individual residues and thus drawn a map of distinct, yet overlapping 
receptor binding sites within the same chemokine (Hammond et al., 1996; Pakianathan et 
al., 1997).
Other studies have concentrated on the receptors in order to dissect the interaction between 
chemokines and their receptors. Again, the importance of conserved cysteine residues in 
maintaining the overall structure and in bringing otherwise remote domains together for 
cooperative binding was highlighted (Hebert et al., 1993; Tournamille et al., 1997) and 
further evidence for the two-site model of chemokine-receptor interactions accumulated
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(Monteclaro and Charo, 1997; Pease et al., 1998; Wu et al., 1996). From these studies it 
emerged that the main determinants for ligand specificity and for the initial binding of 
chemokines reside with in the N terminal extracellular domain of the receptor (Gayle et al., 
1993; Lu et al., 1995; Monteclaro and Charo, 1997; Samson et al., 1997; Wu et al., 1996). 
Especially important seems to be a motif consisting of a combination of tyrosine and acidic 
residues found in the N terminus of CCR5 and other receptors (Farzan et al., 1998; Ye et 
al., 2 0 0 0 ) which has also been found to be a site for posttranslational sulphation of the 
receptor (Farzan et al., 1999). Once the chemokine has been tethered to the receptor N 
terminus via its N loop, its flexible N terminal region can then make contact with other 
extracellular segments of the receptor, thus inducing the conformational change that results 
in G protein coupling and the initiation of downstream signalling events (Samson et al., 
1997; Wu et al., 1996).
1.2.5.4. Chemokine and Proteoglycan Interactions
All chemokines are known to be able to interact with proteoglycans with varying degrees 
of affinity and specificity. The biological significance and precise details of this interaction 
are still largely unclear, and conflicting results have made this field, like in the case of 
chemokine aggregation, very controversial, as can be seen from the following section.
Proteoglycans consist of glycosaminoglycan chains which are linked to a protein core via 
serine residues (Park et al., 2000; Ruoslahti and Yamaguchi, 1991; Tyrrell et al., 1995). 
There are four main forms of glycosaminoglycans, (1) heparin and heparan sulphate, (2) 
chondroitin sulphate and dermatan sulphate, (3) keratan sulphate and (4) hyaluronic acid 
which are all composed of repeating disaccharide units of which one is always an amino 
sugar, whereas the other one is usually a uronic acid. These basic units are subsequently 
modified by a number of different enzymes in reactions that do not normally reach 
completion, thus making this a very heterogeneous group of molecules. It is especially the 
addition of sulphate groups to the amino sugar that determines and influences the 
interaction of proteoglycans with chemokines. It appears that these modifications are cell 
type specific since every cell has a specific repertoire of glycosaminoglycan chain 
modifying enzymes. The location of proteoglycans is determined by the core protein which 
in certain cases contains a domain that allows membrane anchorage. Proteoglycans are 
found in the extracellular matrix, on cell surfaces and in the secretory granules of various 
types of haemopoietic cells where they perform a wide range of different functions. 
Heparin, despite being much more restricted in its localisation, has been widely used as a
model glycosaminoglycan, and a lot of the observations described below have been made 
with heparin or heparan sulphate fragments.
Because of the high degree of sulphation of these molecules, protein - glycosaminoglycan 
interactions are mainly of an electrostatic nature and involve clusters of basic charges in the 
proteins which are either arranged in a short linear peptide stretch or in topologically close 
regions. However, specific sugar sequences have been shown to play a role in the 
interaction with certain proteins such as antithrombin III and FGF-2 (Park et al., 2000). 
Heparin binding sites have been identified in M IP-la, MIP-ip, RANTES, MCP-1, IL-8 , 
PF4 and SDF-1 and shown to be surprisingly different in their location and in the number 
of residues involved which partly accounts for the differences in binding affinity. MIP-la, 
for example, which requires a salt concentration of 0.39 M NaCl (Kuschert et al., 1999) to 
be eluted from a heparin affinity column and is thus one of the weakest heparin binding 
chemokines, contains one heparin binding motif of positive residues in the loop connecting 
the second and third p strand and within P3 and one additional positive amino acid in the N 
loop which come together as a positive cluster in the three dimensional structure (Kolset et 
al., 1996; Wagner et al., 1998). RANTES, on the other hand, has another such cluster of 
positive residues in the C terminal a  helix in addition to the one also found in M IP-la 
(Burns et al., 1998) and can thus bind heparin with a much higher affinity, requiring 0.9 M 
NaCl (Kuschert et al., 1999) for its elution. Heparin binding of IL- 8  (Webb et al., 1993) 
and MCP-1 (Chakravarty et al., 1998) also seems be mostly due to basic residues found in 
the a  helix, while in PF4 basic amino acids both within and outside the helix have been 
implicated in proteoglycan interaction (Mayo et al., 1995; Stringer and Gallagher, 1997). 
The heparin binding motif of SDF-1 is found in yet another location, mainly comprising 
residues found in the first p strand (Amara et al., 1999).
MIP-lp has a binding site very similar to the one found in M IP-la, yet it binds heparin 
more avidly than M IP-la (Koopmann et al., 1999) which suggests that other factors are 
also likely to affect proteoglycan binding. These might include the overall charge of 
chemokines, since M IP-la is found to have a negative overall charge while most other 
chemokines are highly basic, or the possibility that the oligomerisation state has an 
influence on heparin binding. Studies carried out by Hoogewerf (Hoogewerf et al., 1997) 
seem to suggest that binding to glycosaminoglycans induces chemokine oligomerisation, 
thus displaying a biphasic chemokine binding curve at increasing chemokine 
concentrations that implies positive cooperation between binding sites from different
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subunits. Further evidence comes from studies on PF4 (Mikhailov et al., 1999; Stringer and 
Gallagher, 1997) where the amino acids implicated in glycosaminoglycan binding are seen 
to form a ring of positive charges on the outside of the tetramer which is thought to induce 
the glycosaminoglycan chain to wrap around the tetrameric complex, running in a direction 
perpendicular to the a  helices. A heparan sulphate fragment was isolated from fibroblasts 
which showed particularly strong binding to IL-8 . Since it contained two highly sulphated 
blocks of six monosaccharide units separated by a stretch of at least 14 unsulphated 
monosacharide units, the high affnity for IL- 8  was best fitted to a model in which the two 
sulphated units interact with the binding sites on the two a  helices that are located on 
opposite sides of the IL- 8  dimer with the unsulphated intervening stretch bridging the gap 
between the helices (Spillmann et al., 1998). This also demonstrates that in addition to 
oligomerisation, the degree and pattern of sulphation along the glycosaminoglycan chain 
and its actual length also contribute to proteoglycan binding affinities and specificities, an 
observation further supported by work from Witt (Witt and Lander, 1994).
A further level of specificity is added by the fact that chemokines have varying affinities 
for proteoglycans, depending on the type of glycosaminoglycan attached to the protein core 
(Kuschert et al., 1999). The complexity of this system therefore suggests that the 
interaction of chemokines with proteoglycans has an important function in vivo. However, 
mutants of M IP-la (Graham et al., 1996; Koopmann and Krangel, 1997), SDF-1 (Amara et 
al., 1999), MIP-ip (Koopmann et al., 1999) and MCP-1 (Chakravarty et al., 1998) that 
have lost their ability to interact with heparin, are still functional chemoattractants and bind 
to and signal through their receptors as efficiently as their native counterparts. Although the 
heparin binding mutant of M IP-la could no longer bind to CCR1 (Graham et al., 1996), 
this was explained by the fact that the actual mutation interfered with receptor binding, thus 
suggesting that their binding sites overlap, whereas they are clearly spatially distinct in 
SDF-1, MCP-1 and IL-8 .
Another way of determining the contribution made by glycosaminoglycans to the function 
of chemokines involves their removal from cell surfaces either by treating the cells with 
enzymes that cleave off the sugar moiety or by using cell lines that are deficient in 
glycosaminoglycan production. While a number of studies showed that glycosaminoglycan 
removal abolished the HIV inhibitory activities of RANTES and M IP-la (Oravecz et al.,
1997), reduced RANTES-stimulated intracellular calcium release (Burns et al., 1998) and 
reduced the apparent affinity of IL-8 , RANTES, MCP-1 and M IP-la for their receptors
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(Hoogewerf et al., 1997), others demonstrated that glycosaminoglycan-negative cells 
responded to SDF-1 as well as glycosaminoglycan-positive cells (Amara et al., 1999) and 
the affinity of M IP-la for CCR1 was not altered in glycosaminoglycan-negative cells 
(Graham et al., 1996).
Conflicting results were also obtained when chemokines were tested in bioassays in the 
presence of soluble glycosaminoglycans. While the presence of soluble heparan sulphate 
seemed to enhance IL-8 -induced calcium release and migration in neutrophils, it inhibited 
IL-8 -stimulated elastase release from the same cells (Webb et al., 1993). This is in contrast 
to another study, where soluble heparin appeared to inhibit calcium release in neutrophils 
in response to IL- 8  (Kuschert et al., 1999). Soluble glycosaminoglycans lacked any impact 
on the activity of SDF-1 (Amara et al., 1999) and on the binding of M IP-la to CCR1 
(Graham et al., 1996). The cause for these apparent discrepancies is not clear, but may be 
due to differences in bioassays, cell types and glycosaminoglycan composition, or the fact 
that other cell surface molecules, such as fibronectin, can immobilise chemokines (Pelletier 
et al., 2 0 0 0 ).
It has been suggested that glycosaminoglycan expression is not necessary for the biological 
activity of MEP-la, RANTES and MIP-lp, but that the presence of cell surface 
glycosaminoglycans does enhance the activity of low concentrations of these chemokines 
by a mechanism that appears to involve sequestration onto the cell surface (Ali et al., 2000; 
Oravecz et al., 1997). This may have the effect of raising the effective ligand concentration, 
and since the affinity of chemokines for glycosaminoglycans is usually in the pM range 
whereas the affinity for their receptors lies in the nM range, they will be readily transferred 
onto their receptors. Chemokines have been detected on endothelial cells (Tanaka et al., 
1993) and also on cells that lack normal receptor expression (Amara et al., 1999) which 
can be attributed to the presence of proteoglycans and is thought to allow their presentation 
to passing leukocytes. This would not only prevent chemokines from being washed away 
by the blood flow (Rot, 1992), but would also ensure that they only act over a short range 
(Ruoslahti and Yamaguchi, 1991). This seems to be supported by findings that 
proteoglycan-immobilised MIP-lp induces homing of T cells (Tanaka et al., 1993), and 
that only IL- 8  that has been secreted by endothelial cells, but not soluble IL-8 , will activate 
neutrophil integrins for firm adhesion (Tanaka et al., 1993). Chemokines are also found in 
complex with glycosaminoglycans when secreted from macrophages and platelets (Kolset 
et al., 1996) and within the cytolytic granules of CD8 + cytotoxic T cells (Wagner et al., 
1998). And since no G protein-coupled chemokine receptor has been identified so far for
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PF4, it was suggested that it may mediate its biological effects through surface 
proteoglycans (Petersen et al., 1998; Petersen et al., 1999). It therefore seems that different 
chemokines may have different dependencies on proteoglycans for their activities, 
however, further experimental data is still required in this field.
1.3. MIP-1a
M IP-la was first described in 1988 (Wolpe et al., 1988) as a heparin binding protein with 
neutrophil-activating activities that was purified from an endotoxin-stimulated macrophage 
cell line and ran as a doublet of bands on SDS polyacrylamide gels. The two bands were 
later fractionated into two separate, but highly homologous proteins, the cDNAs of which 
were then obtained and renamed M IP-la and MIP-ip (Davatelis et al., 1988; Sherry et al., 
1988). Since then, M IP-la has been shown to be produced by a wide range of cell types 
and capable of carrying out a number of functions both within and outside the immune 
system (see below).
1.3.1. Cellular Sources of MIP-1 a and its Role as an Inflammatory 
Mediator
The fact that M IP-la acts predominantly as a proinflammatory mediator is supported by 
the highly inducible nature of its production. Following stimulation with reagents such as 
bacterial endotoxins (Wolpe et al., 1988) and IL-3 (Li et al., 1996), M IP-la is produced 
and secreted by a great number of cells, including macrophages, neutrophils, basophils, 
eosinophils, fibroblasts and T lymphocytes, although constitutive expression may occur in 
a very localised fashion and thus be below detection levels. In fact, Langerhans cells, the 
skin-specific antigen-presenting cells, have been demonstrated to express M IP-la 
constitutively (Heufler et al., 1992), however this has been associated with M IP-la’s 
ability to inhibit keratinocyte proliferation (Parkinson et al., 1993) and may not actually 
occur in the context of an inflammatory response.
Although M IP-la was originally described as a neutrophil-activating protein, it has since 
been established that its activity on neutrophils is rather poor (Zhang et al., 1999) and that 
its main targets for chemoattraction and activation include monocytes, specific subsets of T 
lymphocytes (Schall et al., 1993; Taub et al., 1993), eosinophils, Natural Killer cells and 
basophils. These findings have implicated M IP-la in a range of infammatory disorders.
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For example, the production of M IP-la by stimulated basophils (Li et al., 1996) and the 
observation that it induces eosinophil attraction and activation (Rot et al., 1992) seems to 
suggest a role for this chemokine in allergic inflammation and parasitic infection. Elevated 
levels of M IP-la have also been detected in patients with chronic inflammatory lung 
diseases (Smith et al., 1994; Standiford et al., 1993) and in the brains of patients with 
inflammatory neurological disorders such as Multiple Sclerosis where it is thought to cause 
leukocyte infiltration which is associated with these disease states. This was supported by 
the use of animal models in which mice stimulated with lipopolysaccharides (bacterial 
endotoxins) displayed MIP-la-mediated recruitment of leukocytes into the lungs of these 
animals which caused severe lung injury (Standiford et al., 1995). A similar experimental 
model raised the possibility that M IP-la, MIP-ip and RANTES produced by T cells, 
macrophages and astrocytes in the brain lead to infiltration of inflammatory cells into the 
central nervous system during the acute phase of experimental autoimmune 
encephalomyelitis, a mouse model for Multiple Sclerosis (Karpus et al., 1995; Miyagishi et 
al., 1997). A similar involvement has been shown for M IP-la in rheumatoid arthritis 
(Koch et al., 1994), and it has also been implicated in mediating macrophage infiltration 
during the process of wound repair (DiPietro et al., 1998).
However, definite proof for the involvement of M IP-la in disease states came from the 
generation of mice in which the gene for M IP-la had been deleted (Cook et al., 1995). 
These mice, which are apparently normal under nonpathological conditions, are resistant to 
Coxsackievirus-induced myocarditis and exhibit reduced pneumonitis and delayed 
clearance of viral particles during infections with influenza virus which demonstrates that 
M IP-la plays an important role as a mediator of virus-induced inflammation in vivo. More 
recently, M IP-la was also identified as the osteoclast stimulatory factor that is found in the 
bone marrow of multiple myeloma patients and which may be responsible for the bone 
destruction associated with this disease (Clements et al., 1992).
1.3.2. MIP-1 a in Haemopoiesis
Apart from its role as a proinflammatory mediator where its target cells mainly comprise 
mature leukocytes, M IP-la can also modulate the activity of a number of more immature 
haemopoietic stem and progenitor cells. The exact effect that M IP-la has on these cells 
very much depends on the type of cell, its maturation state, the presence of a number of 
other factors such as haemopoietic growth factors and the precise assay system used to
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investigate these functions. Because of the fact that the study of haemopoietic stem and 
progenitor cells is still largely dependent on the use of in vitro assays and that only minor 
variations in the conditions of the assays can result in a completely different outcome, 
conflicting observations have been made as to the specific target cells of M IP-la and the 
precise effect it has on these cells.
However, the overall picture that has emerged and been confirmed by a number of groups 
now, indicates that M IP-la inhibits the proliferation of immature cells, such as the day 12 
CFU-S cells that sit at the primitive end of the myeloid lineage, while it does not seem to 
have any effect on the most immature pluripotent stem cells (Keller et al., 1994). Once the 
cells have reached a certain maturation state when they can give rise to only one lineage of 
mature blood cells, their response to M IP-la changes and instead of being inhibited, their 
proliferation is enhanced by this chemokine (Van Ranst et al., 1996), as illustrated in 
progenitor assays in which only a single growth factor is included for the promotion of 
colony formation from more mature progenitors (Clements et al., 1992; Graham et al., 
1990). In addition, there have been reports showing that M IP-la can cause an expansion of 
long term culture-initiating cells in ex vivo cultures (Verfaillie and Miller, 1995) as well as 
a rapid mobilisation of early haemopoietic progenitor cells (CFU-S and cells with marrow 
repopulating ability) from the bone marrow into the peripheral blood (Hunter et al., 1995; 
Lord et al., 1995).
The first data demonstrating M IP-la‘s inhibitory activity were published in 1990 (Graham 
et al., 1990) when the active agent present in the conditioned medium of the murine 
macrophage cell line J774.2, that was shown to inhibit haemopoietic stem cells, was 
purified and identified as the chemokine M IP-la. In that report, inhibitory activity of MIP- 
l a  was demonstrated on CFU-S day 12, CFU-A (an in vitro equivalent of CFU-S day 12) 
and to a lesser extent on CFU-S day 8  cells, but not on more mature GM-CFC progenitors. 
Other stem cell types that have been shown to be inhibited include HPP-CFC in some cases 
(Eaves et al., 1993), but not in others (Keller et al., 1994), BFU-E (Maze et al., 1992; 
Quesniaux et al., 1993), CFU-GEMM in some studies (Cooper et al., 1994), but not in 
others (Keller et al., 1994), and CFU-GM (Maze et al., 1992), as long as the formation of 
colonies in these in vitro assays is stimulated with more than one growth factor. 
Interestingly, in a few cases, the inhibition induced by M IP-la could be blocked by the 
addition of MIP-1(3 as an antagonist (Broxmeyer et al., 1993; Broxmeyer et al., 1991; 
Eaves et al., 1993) which seems to suggest that MIP-ip can bind to the stem cell inhibitory
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receptor, but fails to activate it. Studies on the time course of inhibition established that 
M IP-la acted within 3-24 hours (Maze et al., 1992), which could even be reduced to one 
hour at 4°C (Broxmeyer et al., 1993; Broxmeyer et al., 1991) and was reversible within 48 
hours (Maze et al., 1992). The inhibition was shown to be caused by blocking the cell cycle 
prior to DNA synthesis as demonstrated by a suicide assay in which actively cycling cells 
undergoing DNA replication are killed by the addition of the base analogue cytosine 
arabinoside (Graham et al., 1990).
A later report not only detected the same activity in the human analogue of M IP-la 
(LD78), but also confirmed the in vivo myeloprotective effect that these proteins have on 
haemopoietic stem cells since stem cells that were induced to proliferate after a cytotoxic 
insult to the haemopoietic system were protected from a second dose of the cytotoxic drug 
5-fluorouracil in the presence of M IP-la (Dunlop et al., 1992). This and the observation 
that haemopoietic stem cells from chronic myeloid leukaemia patients seemed refractory to 
the inhibitory effect of M IP-la (Chasty et al., 1995; Eaves et al., 1993; Holyoake et al., 
1993) led to the suggestion that M IP-la may prove to be a useful agent given to patients 
who are undergoing chemotherapy since it would not only lessen the negative impact of the 
drugs on healthy haemopoietic stem cells followed by a faster recovery, but would also 
allow higher and more effective doses of chemotherapy drugs to be administered. The role 
of M IP-la as a potential myeloprotective agent would not just be restricted to the treatment 
of leukaemia, but woul lessen the negative impact of chemotherapy treatment for any type 
of cancer. And, indeed, clinical trials were initiated with a non-aggregating variant of MIP- 
la ,  called BB10010, that had improved pharmacological properties (Hunter et al., 1995). 
And although this variant showed haemopoietic stem cell mobilising activities in mice 
(Lord et al., 1995), myeloprotective properties in a chemotherapy mouse model (Lord et al.,
1996) and was generally well tolerated in patients (Bernstein et al., 1997; Marshall et al.,
1998), it failed to produce the expected results in human patients in stem cell mobilisation 
and chemoprotection (Bernstein et al., 1997; Clemons et al., 1998) in phase II clinical trials 
which resulted in the termination of the clinical trials.
A number of different sources for the production of M IP-la in the bone marrow have been 
suggested. Immunohistochemical staining detected the expression of M IP-la mRNA and 
production of the mature protein in eosinophilic myelocytes, the precursors of eosinophils, 
and osteoblasts (Kukita et al., 1997). Other proposed cellular sources for M IP-la in the 
bone marrow include macrophages (Maltman et al., 1993) and stromal cells (Sensebe et al.,
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1997). Expression was demonstrated to be induced by a number of factors, including GM- 
CSF and IL-3 (Jarmin et al., 1999), IL-1|3 (Sensebe et al., 1997) and neurokinin A, a 
neuropeptide that also stimulates the production of TGFp (Rameshwar and Gascon, 1996). 
Interestingly, TGFp is another haemopoietic stem cell inhibitor which has a target cell 
population that overlaps with the one inhibited by M IP-la, but which is a generally more 
potent inhibitor that has more widespread effects (Keller et al., 1994; Mayani et al., 1995; 
Soma et al., 1996; Van Ranst et al., 1996). It was also demonstrated to inhibit the 
expression of M IP-la and its receptors, while M IP-la was shown to increase the 
production of TGFp (Maltman et al., 1996; Maltman et al., 1993). This seems to suggest 
that TGFp may be a physiologically more relevant stem cell inhibitor than M IP-la, 
although neither TGFp nor M IP-la null mice have any overt defects in the proliferation of 
haemopoietic stem cells (see above). Nevertheless, the fact remains that M IP-la has been 
shown to possess inhibitory activity in a number of different studies, a role that may be 
compensated for by other factors in the knockout mice, thus suggesting some degree of 
redundancy which, as mentioned above, may be a common feature of the chemokine 
family.
Very little is known about the signalling pathway employed by M IP-la to exert its various 
functions on haemopoietic stem and progenitor cells, and the identity of the receptor 
through which M IP-la mediates its inhibitory effects still remains elusive, as supported by 
experimental data provided elsewhere in this thesis. The main reason for the lack of 
information on the signalling pathways involved is the difficulties associated with the study 
of stem cells. As mentioned above, a lot of the studies carried out on M IP-la’s effects on 
haemopoietic stem cells have relied on in vitro colony forming assays, a system that makes 
the dissection of individual signalling pathways almost impossible. Cell sorting protocols 
for haemopoietic stem cells exist that rely on the presence or absence of certain cell surface 
markers, however these only result in a relative enrichment for stem cells which are still 
too heterogeneous to allow the study of individual signalling events.
In order to circumvent this problem, established haemopoietic cell lines have been used, 
yet these not only have the tendency to give variable results, it is also possible that they do 
not exactly behave like primary cells in their bone marrow microenvironment. One such 
cell line is the human haemopoietic cell line M07e which has been reported to be inhibited 
by M IP-la and IP10 via a mechanism that involves the elevation of intracellular cAMP
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levels, the inhibition of Raf-1 phosphorylation and activation of the MAPK pathway 
(Aronica et al., 1997; Aronica et al., 1995).
The most representative method for delineating MIP-la-stimulated pathways so far has 
been the study of the response elicited by M IP-la in the bone marrow cells obtained from 
mice that are deficient in components of the putative signalling pathway (see also in the 
Results section). In one such study it was shown that primitive myeloid progenitor cells 
obtained from mice that were deficient for CCR1 expression, still exhibited inhibition by 
M IP-la, whereas more mature CFU-GM progenitors were no longer enhanced in their 
proliferation by M IP-la and myeloid progenitor cells were no longer mobilised into the 
peripheral blood (Broxmeyer et al., 1999). This seems to suggest that while CCR1 does not 
mediate M IP-la’s inhibitory signal, it is nevertheless required for mobilisation and 
enhancement of proliferation. As illustrated in a later section, none of the other known 
M IP-la receptors is involved in stem cell inhibition either.
1.3.3. Structural Features of MIP-1 a
One of the first structural studies carried out on M IP-la aimed at elucidating the processes 
involved in its aggregation (Patel et al., 1993). This report which relied on techniques such 
as analytical ultracentrifugation, circular dichroism and fluorescence spectroscopy showed 
that human M IP-la, LD78, exists as soluble, heterogeneous, multimeric complexes of 100 
to 250 kD at physiological ionic strength and high concentrations (0.5 mg/ml). These 
complexes were disrupted by varying the buffer conditions which established that a 
breakdown of complexes down to the tetrameric level can be achieved in conditions that 
disrupt ionic interactions whereas dimers and tetramers are mainly stabilised by 
hydrophobic forces. Another report also showed that the aggregation of M IP-la is a 
dynamic and reversible process that is influenced by the concentration of the protein and 
the surrounding buffer environment (Graham et al., 1994). However, while this report 
seems to confirm that ionic interactions lead to high order aggregates since the 
neutralisation of a single acidic residue in the C terminal helix (glutamic acid at position 6 6  
in murine M IP-la to glutamine) led to a mutant that could not aggregate past the tetrameric 
state, the neutralisation of additional negative charges, E6 6 Q + D64N and E6 6 Q + D64N + 
E60Q, generated dimeric and monomeric mutants, respectively. Although this seems to 
contradict the previous report, it could be envisaged that the neutralisation of negative 
charges affects the overall charge distribution in such a way that it interferes with
76
oligomerisation. This is further supported by the fact that the neutralisation of two positive 
charges in the loop between the second and the third p strand also results in a mutant that is 
predominantly in a dimeric state (Graham et al., 1996). Another nonaggregating mutant of 
human M IP-la that seems to be in a monomer-dimer-tetramer equilibrium was created by 
changing the aspartic acid residue at position 26 to an alanine residue (Hunter et al., 1995). 
All of these nonaggregating mutants, however, have biological activities that are 
comparable to the wild type protein, thus once again supporting the notion that aggregation 
is not required for normal chemokine function.
As mentioned in the earlier section on chemokine-proteoglycan interactions, the heparin- 
binding determinants of M IP-la (for a picture of the heparin binding site within the three 
dimensional structure of M IP-la, see Fig. 4.1) are located in the loop connecting P2 and P3 
(residues Lys44 and Arg45 within a positive cluster) and in the N loop (Argl7). Mutations 
at these positions severely interfere with M IP-la binding to heparin, however seem to 
leave its biological functions largely unaffected (Graham et al., 1996; Koopmann and 
Krangel, 1997). The mutant in which Lys44, Arg45 and Arg47 were changed to asparagine 
and serine, respectively, did lose its ability to interact with CCR1 which seems to suggest 
that this site is involved in the interaction with this receptor either directly or indirectly 
through its proximity to the N loop. Compared to other chemokines, M IP-la is a relatively 
weak heparin binding protein with NaCl concentrations of only 0.39 M (Kuschert et al.,
1999) required to elute it from a heparin column. This may be taken as another piece of 
evidence to suggest that proteoglycan binding properties are possibly not essential for its 
activity.
Very little is known about specific residues of M IP-la that are involved in receptor 
interactions. One could assume that in agreement with findings in other chemokines, the N 
loop of M IP-la (residues 13-20) may be important for its initial docking to the receptor 
whereas residues preceding the CC motif (residues 1-10) are involved in receptor 
activation. However, studies on M IP-la and MIP-ip chimaeras seem to implicate a region 
encompassing the second and third p strand and the a  helix and specifically lysine 37 and 
leucine 43 (human M IP-la) in the second p strand in CCR1 binding (Crisman et al., 1999). 
As mentioned above, the two residues that are found in the adjacent loop and that are 
heparin-binding determinants, may also be involved in CCR1 interactions. In the human 
genome, two isoforms of M IP-la are found, LD78a and LD78P, which differ in only three 
amino acids at position 2, 39 and 47. Despite their high degree of sequence identity, their
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affinities for the known M IP-la receptors are strikingly different (Menten et al., 1999; 
Nibbs et al., 1999). While LD78a is a better ligand for CCR1, LD78p has a much higher 
affinity for CCR5 and D6 . These differences seem to be mainly determined by the presence 
or absence of a proline residue at position 2  which is further supported by receptor binding 
studies with truncated versions of both LD78a and LD78P which have the four most N 
terminal amino acids deleted (Nibbs et al., 1999). This once again stresses the sensitivity of 
the extreme N terminus of CC chemokines to modifications.
The three-dimensional structure of murine M IP-la has been determined recently by x ray 
crystallography (MacLean, J unpublished results). This was brought about by the 
availability of monomeric, dimeric and tetrameric mutants of M IP-la which facilitated its 
crystallisation which had up until then been impossible due to the formation of 
heterogeneous aggregates at higher concentrations. The tertiary structure of all three 
mutants displays the common monomeric chemokine fold of an extended N terminal 
region, a central p sheet and a C terminal a  helix that lies on top of the p sheet. The 
dimeric structure is very similar to the ones found for other CC chemokines, whereas the 
tetramer is quite different from the only other known CC chemokine tetramer, MCP-1 (see 
above). In fact, two different tetramers were identified for M IP-la occasionally even 
within the same droplet, which facilitated the distinction between “true” contacts and 
“crystal” contacts. However, the biological significance of the two tetramers is unknown. 
The quaternary structure confirmed that the majority of monomer-monomer and dimer- 
dimer interactions are of a hydrophobic nature. Yet, it also showed that Glu6 6  and Asp26, 
the mutation of which individually prevented the formation of high order aggregates, are 
part of two salt bridges that are crucial for intersubunit contacts, whereas Asp64 and 
Glu60, the other two residues implicated in the oligomerisation process, point away from 
the rest of the molecule and can therefore not directly be involved in intermolecular 
interactions, which supports the hypothesis that it is their charge, rather than their position 
that affects multimer formation. Interestingly, calcium ions were found to be associated 
with the tetramers and proposed to be important in mediating the oligomerisation process 
for three reasons, (1 ) they were found in almost exactly the same position in the two 
different tetramers, (2 ) the presence of calcium was necessary for the crystallisation of the 
tetramer, but not of the dimer or monomer, and (3) it could not be replaced by any other ion 
tested. Part of the work leading to this thesis dealt with the question of whether calcium 
was important for aggregation experimentally (see Results section). The three dimensional 
structure also revealed that the positive residues implicated in heparin binding come
together to form a so-called cationic cradle, a common heparin binding motif, and that they 
are also involved in intersubunit contacts as suggested from the mutagenesis studies 
(Graham et al., 1996).
The availability of the crystal structure of M IP-la formed the basis for most of the work 
carried out during the course of this PhD since it allowed a rational approach to the 
investigation of the structure-function relationship in M IP-la.
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AIM
M IP-la was the first chemokine to be implicated in the control of haemopoietic stem cells. 
However, the way in which M IP-la inhibits the proliferation of these cells on the 
molecular level still remains largely unknown. This thesis therefore aimed at elucidating 
certain aspects of the relationship between the structure of M IP-la and its function as an 
inhibitor of transiently engrafting haemopoietic stem cells (cells detected in the CFU-A 
assay). In the first instance, two well known properties of M IP-la, its ability to bind to 
heparin and its tendency to aggregate at increasing concentrations, were considered. 
Although mutants of M IP-la that have lost these properties retain full inhibitory capacity 
in the CFU-A assay, thus suggesting that aggregation and proteoglycan binding is not 
essential for stem cell inhibition in vitro, these characteristics may nevertheless play an 
important role in vivo in the context of the bone marrow microenvironment. For example, 
proteoglycans are essential components of the haemopoietic stem cell niche (see 
Introduction) where they may interact with regulatory molecules such as M IP-la, possibly 
in processes of sequestration and presentation. Therefore, in order to increase our current 
knowledge of the mechanism by which M IP-la self-associates and interacts with heparin 
and a possible relationship between the two processes, experiments were carried out to 
address these points and are described in the following chapters.
As mentioned in the Introduction, the receptor, through which M IP-la exerts its inhibitory 
function, has not been characterised. Experiments were therefore undertaken in order to 
definitely rule out the involvement of any one of the four known murine M IP-la receptors. 
Furthermore, in order to shed some light on the molecular mechanism underlying stem cell 
inhibition, experiments were carried with the aim of identifying the region within M IP-la 
that confers stem cell inhibition. It is hoped that such information will contribute to the 
identification of the inhibitory receptor and the downstream signalling events which may 
enhance our current knowledge of the regulation of haemopoietic stem cells and how this 
control breaks down in proliferative disorders, such as leukaemia.
Chapter 2. MATERIALS & METHODS
80
2.1. Materials
2.1.1. Plasmids
Name Insert Source
pSK.mMIP-la murine M IP-la cDNA 
280 bp
Xhol / EcoRI
S. Wylie 
Beatson Institute 
Glasgow, UK
pSK.hRANTES human RANTES cDNA 
410 bp
EcoRI/Hindlll
S. Wylie 
Beatson Institute 
Glasgow, UK
pVL1392/1393 
Baculovirus Transfer Vector
Becton Dickinson UK Ltd. 
Plymouth, UK
2.1.2. Primers for Overlap PCR Mutagenesis
l.
c c
\ X
—  c — MIP-la
X X 2.
--------------CC------------------------------C -----------------C--------------  RANTES
XX X
Name Description
M5* (1. on above figure) amplifies M IP-la from the 5’ end
5’ ATGAAGGTCTCCACCACTGCC 3’
M3’ (2.) amplifies M IP-la from the 3’ end
5’ CTCAGGCATTCAGTTCCAGGTC 3’
R5’ (5.) amplifies RANTES from the 5’ end
5’ ATGAAGGTCTCCGCGGCAGC 3’
R3’ (6.) amplifies RANTES from the 3’ end
5’ CTAGCTCATCTCCAAAGAGTTG 3’
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M-CC-R (3.) chimaeric internal primer; spans the CC
motif; amplifies the N terminus of M IP-la 
fused to the RANTES sequence C terminal to 
the CC motif
5’ GGGCAATGTAGGCAAAGCAGCAGGCAGTCGGGGTGTCAGC 3’
R-CC-M (7.) chimaeric internal primer; spans the CC
motif; amplifies the N terminus of RANTES 
fused to the M IP-la sequence C terminal to 
the CC motif
5’ CCGGCTGTAGGAGAAGCAGCAGGGTGTGGTGTCCGAGG 3’
R-C-M (4.) chimaeric internal primer; spans the final C
motif; amplifies the C terminus of M IP-la 
fused to the RANTES sequence N terminal to 
the C motif
5’ CTAAGAGAAACCGGCAGATCTGTGCCAACCCAGAGAAGAAATGG 3’
M-C-R (8.) chimaeric internal primer; spans the final C
motif; amplifies the C terminus of RANTES 
fused to the M IP-la sequence N terminal to 
the C motif
5 ’ CCCGAAAGAACCGCCAAGTGTGCGCTGACTCCAAAGAGACCTGG 3 ’
2.1.3. Tissue Culture Supplies
Supplier Material
Beatson Institute, Central Services 
Glasgow, UK
Sterile phosphate buffered saline (PBS)
Sterile PBS+EDTA
Sterile Glassware and Pipettes
R2, Beatson Institute L929 Conditioned Medium (CM) 
AF1 CM
Becton Dickinson, UK Ltd. 
Plymouth, UK
Falcon Tubes
Tissue Culture Dishes
Needles and Syringes
24 well plates
Agarplaque Agarose
Transfection Buffer A and B Set
BaculoGold linearised Baculovirus DNA
Biowhittaker UK Ltd. 
Wokingham, UK
Insect Cell Culture Medium 
(TNM-FH and Protein-free medium)
Coulter Ltd. 
Luton, UK
Zapoglobin
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Costar
Cambridge, MA USA
DIFCO Laboratories 
Detroit, USA
Gelman Sciences 
Northampton, UK
Gibco Life Technologies 
Paisley, UK
Harlan Sera-Lab Ltd. 
Belton, UK
Merck 
Poole, UK
Nalge Nunc International 
Roskilde, Denmark
Sigma Chemical Co. 
Poole, UK
Stem Cell Technologies Inc.
British Columbia, CANADA
Sterilin Ltd.
Hounslow, UK
Techne
Cambridge, UK
2.1.4. Cytokines and Antibodies
Supplier
ARES Serono 
Geneva, Switzerland
Cell Scrapers
Agar Noble
Sterile acrodisc syringe filters 
(0.2 pm and 0.45 pm)
MEM alpha stock 
L-glutamine (200 mM) 
Sodium Bicarbonate (7.5%) 
Trypsin (2.5 %)
Special Liquid Medium
Foetal Calf Serum
Giemsa stain
2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenyl 
tetrazolium chloride (INT) 
microscope slides
Tissue Culture Flasks 
Cryotubes
Donor Horse Serum 
DMEM 
Fura-2-AM 
Neutral Red
Methylcellulose 
(no growth factors)
Culture Plates
Stirrer Culture Vessels
Material
recombinant human Fractalkine 
recombinant human HCC-4 
recombinant human HCC-2 
recombinant human LARC 
recombinant vMIP-II
Gryphon Sciences 
South San Franscico, USA
AOP-RANTES
Human Genome Sciences 
Maryland, USA
Peprotech EC Ltd. 
London, UK
R & D Systems Europe 
Abingdon, UK
R2, Beatson Institute
Recombinant murine CIO 
Recombinant human Ckp-1 (HCC-1) 
Recombinant human Ckp-4 (LARC) 
Recombinant human Ckp-6 (MPIF2) 
Recombinant human Ckp-12 (HCC-4)
Recombinant murine Eotaxin 
Recombinant murine Exodus-2 (SLC) 
Recombinant human 1-309 
Recombinant murine MDC 
Recombinant human M IP-la 
(full length LD78a)
Recombinant human MIP-3 (MPIF-1) 
Recombinant human MIP-3a (LARC)
Recombinant anti-murine M IP-la antibody 
Recombinant anti-human RANTES antibody 
Recombinant human DCCK-1 
Recombinant human HCC-1 
Recombinant mouse GM-CSF 
Recombinant human IL-8 (72aa) 
Recombinant human IL-8 (77aa) 
Recombinant human IP-10 
Recombinant human MCP-1 
Recombinant human MCP-2 
Recombinant human M-CSF 
Recombinant human M IP-la 
(full-length LD78P)
Recombinant human M IP-la 
(LD78a-4)
Recombinant murine M IP-la 
Recombinant human MIP-ip 
Recombinant human RANTES 
Recombinant murine SCF 
Recombinant murine SDF-1 
Recombinant murine TECK
PM1, PM2, PM3 (Graham et al., 1994) 
(mutants of murine M IP-la)
Recombinant human M IP-la 
(LD78P-4) (Nibbs et al., 1999)
Sigma Immunochemicals 
Poole, UK
Anti-goat IgG (HRP-conjugated)
2.1.5. Molecular Biology
2.1.5.1. Bacterial Culture
Supplier
Beatson Institute, Central Services 
Glasgow, UK
DIFCO Laboratories 
Michigan, USA
Fisher Scientific UK Ltd. 
Loughborough, UK
GIBCO BRL 
Paisley, UK
Qiagen Inc.
Chatsworth, USA
Sigma Chemical Co.
Poole, UK
Stratagene Ltd.
Cambridge, UK
2.1.5.2. Enzymes and Nucleotides
Supplier
GIBCO BRL 
Paisley, UK
Promega Ltd.
Southampton, UK
Stratagene Ltd.
Cambridge, UK
Transgenomic Ltd.
Crewe,UK
Material
Luria-Broth (L-Broth)
Bactoagar
Ethanol
Isopropanol
DMSO
Sodium Acetate 
DH5a competent cells
QIAGEN plasmid preparation kits 
QIAquick gel extraction kit
Ampicillin 
X gal, IPTG
pCR-Script Amp SK(+) Cloning Kit 
Material
all restriction enzymes and buffers
Deoxynucleotide Triphosphates
Pfu DNA Polymerase
T4 DNA Ligase 
Alkaline Phosphatase
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2.1.5.3. Gel Electrophoresis
Supplier
GIBCO BRL 
Paisley, UK
Material
Agarose
lkb and lOObp DNA ladders 
DNA mass ladders
Sigma Chemical Co.
Poole,UK
Fisher Scientific UK Ltd. 
Loughborough, UK
2.1.6. Protein Studies
2.1.6.1. Kits 
Supplier
R & D Systems Europe 
Abingdon, UK
2.1.6.2. Chromatography
Supplier
Fisher Scientific UK Ltd. 
Loughborough, UK
Perkin Elmer 
Warrington, UK
Pharmacia Biotech Ltd.
St. Albans, UK
Bromophenol Blue 
Ethidium Bromide
EDTA, EGTA 
glycerol
Material
murine M IP-la ELISA kit
Material
Acetonitrile 
Sodium Chloride
Trifluoroacetic acid (TFA)
5ml HiTrap Desalting Column 
lml HiTrap Heparin Column 
Heparin Sepharose CL-6B 
MonoQ HR 5/5 column 
ProRPC HR 5/2 column 
Sephacryl S-200HR
Sigma Chemical Co. Bovine Serum Albumin (BSA)
Poole, UK Heparin-Agarose
(attached through reductive amination)
12,000-200,000 molecular weight marker kit 
soluble heparin
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2.1.6.3. Cross-linking
Supplier Material
Sigma Chemical Co. Glutathione-S-Transferase
Poole, UK L-Histidine
T ris(2,2 ’ -bipy ridy l)Ruthenium(II)chloride
2.1.6.4. SDS-Polyacrylamide Gel Electrophoresis and Silver Staining
Supplier
Amersham Pharmacia Biotech 
Little Chalfont, UK
Material
14,300-220,000 rainbow markers
10,000-250,000 rainbow markers
Fisher Scientific UK Ltd. Acetic Acid
Loughborough, UK Ammonium Persulphate
Formaldehyde
Glycine
Methanol
Sodium Carbonate (anhydrous) 
Sodium Dodecyl Sulphate 
Tris
Severn Biotech Ltd. 
Kidderminster, UK
Design-a-gel 30% (w/v) Acrylamide, 
0.8% (w/v) bis-Acrylamide solution
Sigma Chemical Co. 
Poole, UK
Dithiothreitol (DTT) 
Silver Nitrate 
TEMED
TAAB
Adermaston Reading, UK
2.1.6.5. Western Blotting 
Supplier
Amersham Pharmacia Biotech 
Little Chalfont, UK
Calbiochem Novabiochem UK NP-40
Nottingham, UK
Kodak Scientific Imaging Systems Ltd. X-OMAT AR X-ray film
Cambridge, UK
glutaraldehyde
Material
ECL Western Blotting Reagents
Millipore Corp. 
Bedford, USA
Immobilon-P transfer membranes
Sigma Chemical Co. 6-amino-n-caproic acid
Poole, UK
Whatmann International Ltd. 3MM blotting paper
Maidstone, UK
2.1.7'. Solutions
2.1.7.1. Bacterial Culture
SOC medium 2% (w/v) bactotryptone
0.5% (w/v) yeast extract 
10 mM NaCl
2.5 mM KC1 
20 mM MgCl2 
20 mM MgSC>4 
20 mM glucose
2.1.7.2. Calcium Flux Assay
SR buffer (pH 7.2): 136 mM NaCl
4.8 mM KCL 
5 mM Glucose 
20 mM Hepes 
1 mM CaCl2 
0.05% BSA
2.1.7.3. CFU-A Assay
2x medium (50ml) 21 ml aMEM
25 ml donor horse serum 
1 ml L-glutamine (200 mM)
3 ml Sodium Bicarbonate (7.5%)
2.1.7.4. Chromatography
Heparin Affinity Chromatography buffers/: A: 0.1 M NaCl / 0.02 M Tris pH 7.6
Ion Exchange Chromatography buffers B: 2 M NaCl / 0.02 M Tris pH 7.6
(Mono Q)
Reversed Phase Chromatography buffers: A: H20  / 0.1 % TFA
B: Acetonitrile / 0.1% TFA
2.1.7.5. Agarose Gel Electrophoresis
50x TAE 2 M Tris-acetate 
50 mM EDTA
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DNA loading buffer 30% glycerol
Bromophenol blue to colour
2.1.7.6. SDS PAGE
17.5% Polyacrylamide gel (separating) 
(volumes for 2 gels)
6.5% Polyacrylamide gel (stacking) 
(volumes for 2 gels)
Running Buffer
SDS PAGE loading buffer 
(per 20 pi sample)
2.1.7.7. Western Blotting
Anode Buffer 1 
Anode Buffer 2 
Cathode Buffer
3.0 ml H20
11.6 ml 30% Acrylamide mix
5.0 ml 1.5 M Tris (pH 8.8)
0.2 ml 10% SDS
0.2 ml 10% Ammonium Persulphate 
8 pi TEMED
5.5 ml H20
1.3 ml 30% Acrylamide mix
1.0 ml 1.0 M Tris (pH 6.8)
80 pi 10% SDS
80 pi 10% Ammonium Persulphate 
8 pi TEMED
200 mM Glycine 
25 mM Tris 
0.1% SDS (w/v)
5 pi 20% SDS / 250 mM DTT 
5 pi glycerol / Bromophenol blue
0.3 M Tris / 20% methanol (pH 10.4)
25 mM Tris / 20% methanol (pH 10.4)
40 mM e-amino-n-caproic acid /
20% methanol (pH 7.2)
2.1.8. Cell Lines and Bone Marrow
Supplier Cells
Becton Dickinson UK Ltd. Sf9 Insect Cells
Plymouth, UK
Dr. R.J. Nibbs Human Embryonic Kidney cells, stably
Beatson Institute transfected with hCCR5
Dr. D.N. Cook 
New Jersey, USA
D6 bone marrow
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Dr. A. Humbles CCR17', CCR3_/" bone marrow
Boston, USA
Dr. W.A. Kuziel CCR57' bone marrow
Texas, USA
2.2. Methods
2.2.1. DNA Methodology
2.2.1.1. PCR Mutagenesis
PCR reactions were carried out in a final volume of 100 pi, containing 10 pi lOx Pfu 
buffer, 10 pi DMSO, 10 pi 50% glycerol, 4 pi dNTPs at 10 mM, 3 pi of each primer at 330 
ng/ml, 1 pi of the template at 110 ng/ml and 1 pi Pfu polymerase (made up to the final 
volume with water). In a second round of PCR where the double-stranded product of the 
first round was included as an additional primer, the amount of this double-stranded primer 
and of the template added to the reaction was reduced to 10 ng, and the concentrations of 
the single-stranded extreme 5’ and 3’ end primers was 0.1 pM. The reactions were overlaid 
with 100 pi paraffin and products obtained after 25 cycles of a one minute denaturing step 
at 94°C, a one minute annealing step at 55°C and a one minute extension step at 72°C. 
After the 25 cycles, the reactions were left at 72°C for 10 minutes.
2.2.1.2. Restriction Digests
Restriction digests were carried out in a final volume of 20 pi, containing 2 pi of lOx 
reaction buffer, ~1 pg of plasmid DNA and 0.5 pi of each restriction enzyme (made up to 
the final volume with water). The digests were incubated at optimal temperature 
(depending on the restriction enzyme - usually 37°C) for 2 hours. Vectors that were 
prepared in this way for the ligation of inserts, were treated with 1 pi Alkaline Phosphatase 
for the last half hour of the incubation in order to block the reannealing of the vector.
2.2.1.3. Visualising DNA by Agarose Gel Electrophoresis
1.5% (for DNA analytical gels) and 1.2% (for DNA preparative gels) agarose gels were 
prepared by adding the required amount of agarose (w/v) to lx  TAE buffer and boiling 
until the agarose was dissolved. Upon cooling, Ethidium Bromide (10 mg/ml stock
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solution) was added to a final dilution of 1 in 40,000 and the gel left to set in a gel cast. 
Samples to be analysed were prepared by adding one tenth of the total volume of DNA 
loading buffer. Size markers and the samples were loaded into the wells and the gel run in 
lx  TAE buffer at -150 V constant voltage. DNA bands were visualised using a UV 
transilluminator, photographed and, in the case of preparative gels, the bands were excised 
and the cDNA purified (see below).
2.2.1.5. Purification of DNA from Agarose Gels
The DNA was extracted from gel slices using the QIAGEN QLAquick Gel Extraction Kit 
and following the manufacturer’s instructions. Briefly, the excised gel slices were weighed 
and 3 volumes of Buffer QG added to 1 volume of gel (100 mg -  100 pi). The gel was 
dissolved by heating at 50°C for 10 minutes. One gel volume of isopropanol was added, the 
mix applied to QLAquick spin columns and centrifuged for 1 minute. Excess agarose was 
removed with 0.5 ml Buffer QG and the columns subsequently washed with 0.75 ml Buffer 
PE. The DNA was eluted into 50 pi of water and the yield determined by running a sample 
on an agarose gel in the presence of a DNA mass ladder.
2.2.1.5. Cloning of DNA fragments into pCR Script
Blunt-ended PCR products were cloned into pCR-Script using the Stratagene pCR-Script 
Amp SK(+) Cloning Kit and following the manufacturer’s instructions. Briefly, the 
following components were mixed together in the following order: 1 pi of the pCR-Script 
Amp SK(+) cloning vector (at 10 ng/pl), 1 pi of pCR-Script lOx reaction buffer, 0.5 pi of 
10 mM rATP, 4 pi of the blunt-ended PCR product (at 10 ng/pl), 1 pi of Srf I restriction 
enzyme (5 U/pl), 1 pi of T4 DNA ligase and 1.5 pi distilled water. The reaction was 
incubated at room temperature for 1 hour, subsequently heated to 65°C for 10 minutes and 
stored on ice until used for transformation.
For each transformation reaction, 40 pi of Epicurian Coli XLl-Blue MRF’ Kan 
supercompetent cells were mixed with 0.7 pi of p-mercaptoethanol and incubated on ice 
for 10 minutes. 2 pi of the above cloning reaction were then added and the transformation 
reaction incubated on ice for a further 30 minutes. It was then heat pulsed at 42°C for 45 
seconds and incubated on ice for 2 minutes. 0.45 ml of pre-warmed SOC medium was 
added to the transformation reaction which was then incubated at 37°C for 1 hour with 
shaking at 225 rpm. 50-200 pi of the transformation reaction were spread on ampicillin-
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containing agar plates (1.5% bactoagar in L-Broth, containing 50 pg/ml ampicillin) in the 
presence of 40 pi X gal (at 20 mg/ml) and 40 pi IPTG (at 20 mg/ml). The plates were 
incubated overnight at 37°C and white colonies picked the following evening for further 
analysis.
2.2.1.6. Cloning of DNA fragments into the Baculovirus Transfer Vector 
pVL1392/1393
The ligation of DNA inserts into the vector was carried out in a reaction volume of 20 pi, 
containing 1 pi T4 DNA Ligase, 2 pi lOx Ligase Buffer and insert and vector DNA in 
molar ratios of 1:1 or 4:1, respectively. The ligation reactions were incubated overnight at 
15°C.
100 pi of E. coli DH5a competent cells were thawed per transformation reaction. These 
were mixed with 1.7 pi p-mercaptoethanol (25 mM final concentration) and incubated on 
ice for 10 minutes. 1 pi of the above ligation reaction was then added to the cells and the 
reaction incubated on ice for a further 30 minutes. Following a heat shock at 42°C for 50 
seconds, the reactions were returned to ice for 2 minutes. 0.9 ml of pre-warmed SOC 
medium was added to each reaction which were subsequently incubated at 37°C for 1 hour, 
with shaking at 225 rpm. After that incubation period, 100-200 pi of each transformation 
reaction was spread on ampicillin-containing agar plates and the plates incubated overnight 
at 37°C. The following evening, colonies were picked and grown in 4 ml of ampicillin- 
containing L-Broth overnight for further analysis and further production of plasmid.
2.2.1.7. Growth of Plasmids
Large amounts of plasmid were obtained from 250 ml transformed bacterial cultures using 
the QIAGEN Maxi Kit and following the manufacturer’s instructions. Briefly, bacterial 
cells were collected by centrifugation for 10 minutes at 3000 rpm in a Sorvall GS-3 rotor. 
The cell pellet was resuspended in 10 ml of RNase-containing PI buffer. 10 ml of buffer 
P2 was added to that and the mixture incubated at room temperature for 5 minutes. After 
the incubation, 10 ml of pre-chilled buffer P3 was added, the mixture incubated on ice for 
20 minutes and subsequently centrifuged for 30 minutes at 10,000 rpm in a Sorvall SS-34 
rotor. The supernatant was applied to a QIAGEN-tip 500 column that had previously been 
equilibrated with 10 ml buffer QBT. The column was washed with 2x30 ml buffer QC and 
the DNA eluted with 15 ml buffer QF. To the eluate were added 0.7 volumes (10.5 ml) of
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isopropanol and the precipitated DNA collected by centrifugation at 10,000 rpm for 30 
minutes. The pellet was resuspended in 300 pi of water. To the suspension, one tenth of 
volume (30 pi) of 3M Sodium Acetate and 3 volumes (900 pi) of ethanol were added and 
the precipitated DNA collected by centrifugation at 13,000 rpm for 10 minutes in a bench 
top microcentrifuge. The pellets were resupended in 800 pi distilled water and the yield 
determined by measuring the optical density at 260 nm wavelength.
2.2.2. Production of Recombinant Protein in the Baculovirus 
System
2.2.2.1. Growth and Maintenance of Sf9 Cells - Monolayers
Cells were grown in monolayers in TNM-FH medium and subcultured (cells were 
harvested using cell scrapers) 1:2 or 1:3 when they reached confluence (2-3 times a week). 
They are kept at 27°C.
2.2.2.2. Growth and Maintenance of Sf9 Cells - Suspension
Sf9 cells can be adapted to the growth in suspension cultures in spinner flasks that are 
stirred continuously at 60 rpm. They were initially seeded at 5x10s cells/ml, but once they 
were adapted to suspension, this could be reduced to 1x10s cells/ml on subculturing (when 
they reached a density of 2xl06 cells/ml). The cells tended to grow better and reach higher 
densities in suspension cultures.
2.2.2.3. Generation of Recombinant Baculoviruses by Co-Transfection
0.5 pg of linearised baculovirus DNA was mixed with 2-5 pg of recombinant Baculovirus 
Transfer Vector containing the gene of interest and incubated at room temperature for 5 
minutes before adding 1 ml of Transfection Buffer B. The medium on a 60 mm plate 
seeded with 2xl06 cells was replaced with 1 ml of Transfection Buffer A. To this, the 1 ml 
of Transfection Buffer B/DNA solution was added drop-wise, and the plate incubated at 
27°C for 4 hours. After the incubation period, the medium was removed and the plate 
washed once with 3 ml TNM-FH. 3 ml of fresh TNM-FH was then added and the plates 
incubated at 27°C for 5 days. At the end of the 5 days, the medium containing the 
recombinant viral particles was collected and stored at 4°C. An aliquot was tested in 
Western Blotting for the expression of the protein of interest.
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2.2.2A. Plaque Assay
This assay was used to obtain viral clones by plaque purification and to determine the viral 
titres of viral stocks. Sf9 cells were seeded the night before on 35 mm plates at a density of 
lxlO6 cells in an even monolayer. 10'4, 10"5 and 10'6 dilutions of the viral stocks were 
prepared in TNM-FH. Once the old medium was removed from the culture plates, the cells 
were overlayed with 100 pi of the dilutions and the plates left at room temperature for 1 
hour. After the incubation period, the virus inoculum was removed and the cells overlayed 
with 2 ml of a 1:1 mixture of 2% (w/v in protein-free insect cell medium) Agarplaque 
Agarose and TNM-FH. After the agarose had set, a 1 ml liquid overlay (TNM-FH) was 
added and the plates incubated at 27°C for 4 days. The plates were stained by adding 1 ml 
of 0.025% (w/v in PBS) Neutral Red for 4 hours, then the liquid overlay decanted and the 
colour developed overnight at room temperature in the dark. The viral titre (pfu/ml) was 
obtained by multiplying the number of plaques on a plate by the dilution factor.
2.2.2.5. Amplifying Virus
For an initial amplification of virus, 2xl07 cells were seeded on 15 cm plates and 0.1-1 ml 
of the low titre stock added. The plates were incubated at 27°C for 3 days, the supernatant 
was then harvested and its viral titre determined in the plaque assay.
2.2.2.6. Preparation of Large High-Titre Viral Working Stocks
These were prepared in suspension as this produces higher titres. 1x10s cells/ml were 
seeded in a volume of 300 ml in a spinner flask and left stirring at 27°C until the cell 
density reached 5x10s cells/ml (2-3 days). The cells were then infected with 0.1-0.2 pfu/ml 
and incubated for 7-9 days (aerated every 2-3 days). The supernatant was collected, stored 
at 4°C and its viral titre determined by plaque assay.
2.2.2.7. Large Scale Protein Production
Cells were seeded in suspension at a density of 5xl05 cells/ml in a volume of 300-500 ml. 
The cells were left until the density reached lxlO6 cells/ml and then infected with 
recombinant virus at an MOI (multiplicity of infection = no. of vims/no. of cells) of 5. The 
cells were left for 6 days (aerated every 2-3 days), the supernatant then collected and the
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protein production assessed by Western Blotting. Prior to protein purification, the viral 
particles were removed by centrifugation at 18,000 rpm for 30 minutes.
2.2.3. Protein Detection
2.2.3.1. SDS Polyacrylamide Gel Electrophoresis
Gel mixtures were prepared according to the recipes described in the ‘Materials’ section. 
The 17.5% separating gel was poured first between two glass plates to within 2 cm from 
the top and overlayed with water-saturated isobutanol to ensure a smooth gel surface. Once 
the separating gel had set, the isobutanol was washed off with water. The 6.5% stacking gel 
layer was then poured on top of the separating layer and a well-forming comb inserted. 20 
pi samples were mixed with 10 pil SDS/DTT loading buffer and heated at 100°C for 3 
minutes. 5 pi of coloured molecular weight markers and 25-30 pi of the samples were then 
loaded into separate wells and the gels electrophoresed in SDS-containing running buffer 
in an Attoll minigel system at 50-100 mA constant current until the bromophenol blue band 
reached the bottom of the gel (for about 1 Vi hours). The gels were then either silver stained 
or Western blotted.
2.2.3.2. Silver Staining
Proteins in the gels were detected by silver staining. This involved soaking the gel for 10 
minutes in 50% methanol/10% acetic acid, followed by 10 minutes in 10% ethanol/10% 
acetic acid and 10 minutes in 10% glutaraldehyde. The gels were then washed for 30 
minutes in several changes of distilled water. Subsequently, they were soaked in 60 pM 
DTT for 10 minutes and 0.1% (w/v) silver nitrate for another 10 minutes. They were then 
briefly rinsed in water and the bands finally developed by rinsing the gels several times in 
3% sodium carbonate/0.1% formaldehyde. When the bands had developed sufficiently, the 
gels were rinsed several times in water and then stored in fresh H2 O.
2.2.3.3. Western Blotting
Proteins to be detected by Western Blotting were transferred onto a PVDF membrane in a 
semi-dry blotting cassette as follows. Filter papers and membrane were cut to the same size 
as the gel. 6 pieces of filter paper were soaked in Anode Buffer 1 and placed at the bottom 
of the apparatus, next to the anode. On top of those were stacked three pieces of filter paper
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soaked in Anode Buffer 2. The membrane was then soaked in methanol and placed on top 
of the anode stack. The gel was removed from the glass plates, briefly rinsed with water, 
the stacking gel removed and the separating gel placed directly on top of the membrane, 
followed by 9 pieces of filter paper soaked in Cathode Buffer. The apparatus was finally 
assembled by placing the Cathode on top of the stack and the proteins transferred for 1 
hour at 50 mA constant current. After the transfer, nonspecific antibody binding sites in the 
membrane were blocked in several changes of BLOTTO (5% w/v milk powder/0.1% NP- 
40 in PBS) for 1 hour with shaking. After that, it was incubated with the primary antibody 
(diluted 1 in 2000 in BLOTTO) for 1 hour at room temperature, and then blocked again in 
several changes of BLOTTO for 1 hour, before being incubated with the secondary 
antibody (HRP-linked; diluted 1 in 2000 in BLOTTO) for 1 hour, again all with shaking. 
The membrane was then washed for 10 minutes in BLOTTO and subsequently for 1 hour 
in PBS/0.1% NP-40. The HRP enzyme reaction was initiated by adding ECL Western 
Blotting reagents for 1 minute and the bands detected by exposing the membrane to x ray 
film.
2.2.3.4. ELISA
Low concentrations of M IP-la (picograms) were detected in a murine M IP-la sandwich 
enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems), following the 
manufacturer’s instructions. Briefly, samples had to be diluted (in chromatography buffer) 
to below 10 ng/ml to allow accurate readings. 50 pi of the assay diluent were then added to 
individual wells of a 96-well plate coated with an anti-murine M IP-la antibody, followed 
by 50 pi of the diluted samples, and the plates then incubated at room temperature for 2 
hours. At the end of the incubation period, the wells were washed 5 times with wash 
buffer, before adding 100 pi of an anti-murine M IP-la antibody-HRP conjugate. The 
plates were again incubated for 2 hours at room temperature. Excess conjugate was then 
removed by another 5 washes with wash buffer and the enzyme substrate added to each 
well in a 100 pi volume. The colour reaction was then allowed to proceed for 30 minutes 
before it was terminated by the addition of 100 pi of stop solution per well. The optical 
density of each well was then determined at 450 nm. ELIS As were repeated with different 
dilutions of the samples in order to confirm the consistency of the results.
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2.2A. Chromatography
All chromatography was carried out using an FPLC system (Pharmacia Biotech, St. 
Albans, UK).
2.2.4.1. Heparin Affinity Chromatography - Analytical
The heparin binding affinity of M IP-la at various concentrations, of M IP-la mutants and 
of cross-linked M IP-la was determined by using a 1 ml HiTrap Heparin Column which 
was run at a flow rate of 1 ml/min. Elution of M IP-la was achieved by developing a 
continuous gradient either between 0.1 M NaCl/0.02 M Tris pH 7.6 and 2 M NaCl/0.02 M 
Tris pH 7.6 (‘salt elution’) or from 0 to 5 mg/ml soluble heparin in 0.1 M NaCl/0.02 M 
Tris pH 7.6 (‘heparin elution’). The heparin affinity of various concentrations of M IP-la 
and of cross-linked M IP-la was also determined on a HR 5/5 (1 ml) column packed with 
Heparin-Agarose in which the heparin chains were end-coupled to the agarose beads by 
reductive amination (Sigma). The column was run at 0.5 ml/min and M IP-la eluted with 
salt or with soluble heparin (as above). Protein elution was followed by either A2 8 0  
measurement, Western Blotting or M IP-la ELISA. Column runs were repeated, 
occasionally with slight variations in the elution conditions, in order to confirm the 
consistency of the results.
2.2.4.2. Heparin Affinity Chromatography - Preparative
For the purification of M IP-la, RANTES and the different chimaeric proteins from large 
volumes of cell supernatant (300-500 ml), an XK50 column (Pharmacia Biotech) was 
packed with ~200 ml of Heparin Sepharose CL-6B and run at a flow rate of 5 ml/min. The 
samples were loaded with a peristaltic pump and elution of the proteins achieved by 
establishing step gradients or a continuous gradient between 0.1 M NaCl/0.02 M Tris pH
7.6 and 2 M NaCl/0.02 M Tris pH 7.6 (although individual steps were varied according to 
the requirements of the each recombinant protein as summarised in the ‘Results’ section). 
Elution of protein was followed by A2 8 0  and Western Blotting, and fractions containing 
recombinant protein were subjected to further purification.
2.2.4.3. Ion Exchange Chromatography (IEC)
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Ion Exchange Chromatography was carried out using a 1 ml MonoQ column that was run 
at a flow rate of 1-2 ml/min. Protein elution was achieved by developing a continuous 
gradient between 0.1 M NaCl/0.02 Tris pH 7.6 and 2 M NaCl/0.02 M Tris pH 7.6 and 
monitored by A 2 8 0  measurement and Western blotting. Positive fractions were again 
subjected to further purification.
2.2.4.4. Reversed Phase Chromatography (RPC)
Final purification was carried out on a 400 pi ProRPC HR 5/2 column which was run at 1 
ml/min. The running buffers used were A: water/0.1% TFA and B: Acetonitrile/0.1% TFA, 
and protein eluted by a gradual increase in Acetonitrile concentration. Recombinant protein 
was detected by Western Blotting and the purity of the preparation confirmed by gel 
electrophoresis and silver staining. Sufficiently pure fractions were concentrated by freeze- 
drying and resuspending in PBS.
2.2.4.5. Gel Filtration Chromatography
The aggregation state of M IP-la was analysed using an HR 10/30 column packed with 
Sephacryl S-200 and run at 0.5 ml/min with PBS/0.1% BSA. Different dilutions of M IP-la 
were applied to the column in a volume of 0.5 ml and 1 ml fractions collected. M IP-la was 
detected by analysing the fractions using a MIP-la-specific ELISA, and the aggregates 
sized by comparison with molecular weight standards. For the analysis of the effects of 
calcium removal on the aggregation of M IP-la, the running buffer also contained EDTA 
and EGTA (PBS/0.1% BSA/1 mM EDTA/2 mM EGTA). Sizing experiments were 
repeated on different columns in order to confirm the consistency of the results.
2.2.4.6. Desalt Column
The 5 ml HiTrap Desalt column contained Superfine Sephadex 25 and was run at a flow 
rate of 2 ml/min. It was employed during the experiments that looked into the effects of 
calcium on M IP-la aggregation, and served to separate M IP-la from acetic acid. M IP-la 
was loaded in a volume of 100 pi and run in a buffer containing PBS/1 mM EDTA/2 mM 
EGTA. 250 pi fractions were collected, and M IP-la was seen to elute over 2-3 fractions.
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2.2.5. Disaggregation of MiP-1 a
10 pg of M IP-la was resuspended in 110 pi of 100 pM acetic acid in order to disaggregate 
it completely and to make the calcium ions accessible for removal. The acetic acid and the 
calcium ions were removed by desalting (see above).
2.2.6. Cross-linking of MIP-1 a
The cross-linking experiments were based on a photoactivatable chemical cross-linking 
method described previously (Fancy and Kodadek, 1999) and were carried out in the 
presence of 0.125 mM Tris(2,2’-bipyridyl)Ruthenium(II)chloride (Ru(bpy)3 Cl2) and 2.5 
mM Ammonium Persulphate (APS). In preliminary experiments, different light sources, 
exposure times, dampening agents and concentrations of M IP-la, its aggregation mutants 
and Glutathione-S-transferase (GST; as a positive control) were tested, and the reaction 
quenched by adding SDS/DTT gel loading buffer to the samples. The best results were 
obtained with a mercury lamp as a light source, an exposure time of 1 sec and 0.1 mM 
Histidine as a dampening agent. To test the heparin binding affinities of stable M IP-la 
oligomers, 10 pg of murine M IP-la was suspended in 100 pi PBS and cross-linked under a 
mercury lamp for 1 sec in the presence oF 10 pi 1 mM histidine, 10 pi of 1.25 mM 
Ru(bpy)3 Cls and 10 pi 25 mM APS. The sample was then immediately diluted by adding 
970 pi PBS and directly run on a 1 ml HiTrap heparin affinity column (see above).
2.2.7. Calcium Flux Assay
HEK293 cells stably transfected with human CCR5 were grown in DMEM. Once they 
reached confluence, they were harvested by trypsinisation and resupended in 12 ml SR 
buffer per confluent 175 cm2  tissue culture flask. To this, 25 pi of Fura-2-AM (at 4 mg/ml 
in DMSO) was added and the cells incubated at 37°C for 1 hour in the dark. The cells were 
then washed twice with SR buffer and resuspended in a final volume of 20 ml SR buffer. 
The fluorescence of the Fura-2-AM-loaded cells was determined in a fluorimeter at an 
excitation wavelength of 340 nm and an emission wavelength of 500 nm with 
measurements carried out every 0.1 sec under continuous stirring. Measurements were then 
carried out on 2 ml aliquots of cells that were allowed to equilibrate to 37°C before starting 
the time course. Once the time course was started, chemokine (at varying concentrations) 
was added in a volume of up to 100 pi after 50 sec and the fluorescence measured for ~200
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sec in total If desensitisation was assessed, different chemokines were added in 50 sec 
intervals during the same time course. Fluxes were repeated with different preparations of 
recombinant proteins and with different cell lines in order to confirm the consistency of the 
results.
2.2.8. CFU-A Assay
The murine CFU-A assay was basically carried out as described previously (Pragnell et al., 
1988), with a few amendments as detailed below. In all of the CFU-A assays, the plates 
were set up in triplicates or quintuplicates for each point and the assays repeated several 
times in order to confirm the consistency of the results.
2.2.8.1. Preparation of Bone Marrow
Bone marrow was obtained from B6D2F1 mice (Harlan UK Ltd., Oxon, UK). The mice 
were killed by cervical dislocation and their femora removed and cleaned free from muscle. 
The ends of the bones were cut off, a needle (0.45x10 mm) attached to a syringe filled with 
PBS inserted at one end and the bone marrow flushed out. The cells were counted on a 
CASY 1 cell counter (Scharfe System) after first lysing the red cells with Zapoglobin. Each 
femur normally yielded about 3xl0 6 cells.
2.2.8.2. Two-layer CFU-A assay
This was the CFU-A assay employed for almost all of the experiments unless stated 
otherwise. 3 cm petri dishes were used and the appropriate chemokine added to the bottom 
of the plate in a volume of up to 200 pi. The under layer was then prepared by mixing 
equal volumes of 2x medium and 1.2% agarose (Agar Noble) and allowing the mixture to 
cool to 37°C before adding a tenth volume of L929 conditioned medium (source of M- 
CSF) and a tenth volume of AF1 conditioned medium (source of GM-CSF). In later 
experiments, the conditioned media were replaced by recombinant growth factors which 
were added at concentrations of 12 ng/ml for murine SCF, 6  ng/ml for human M-CSF and 
0.2 ng/ml for murine GM-CSF. 1 ml of this underlayer mixture was then added to each 
dish and allowed to set at room temperature.
The upper layer was prepared by mixing equal volumes of 2x medium and 0.6% agarose 
and the mixture cooled to 37°C before adding bone marrow cells to a concentration of 5-
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lOxlO3 cells/ml of upper layer for fresh bone marrow or 5xl0 4  cells/ml of upper layer for 
defrosted bone marrow cells. 1  ml of this upper layer mixture was then added to each dish 
and the plates incubated at 37°C in a humid atmosphere of 5% 0 2 / 1 0 % CO2  for 11 days to 
allow colonies to develop. These were stained overnight with 200 pi of INT solution (1 
mg/ml in PBS) per plate, and colonies with a diameter of 2 mm and larger scored as CFU- 
A colonies.
2.2.8.3. One-layer CFU-A Assay
In order to reduce the amount of chemokine needed to detect inhibition, in some 
experiments a one-layer CFU-A assay was carried out in 24-well plates. Chemokine was 
added to the bottom of the wells in a volume of 6.25-25 pi and 250 pl/well added of a 
mixture containing 50% 2x medium, 50% 0.6% agarose, 3 ng mSCF, 1.5 ng hM-CSF and 
0.05 ng mGM-CSF. The plates were incubated at 37°C in a humid atmosphere of 5% 
0 2 / 1 0 % CO2 for 1 1  days and the colonies stained and scored as above.
2.2.8.4. CFU-A Assay with Methylcellulose
The upper layer of a CFU-A assay was replaced with methylcellulose in order to be able to 
pick individual CFU-A colonies for cytospins and for counting the number of cells per 
colony. CFU-A assays were again set up in 3 cm petri dishes and underlayers prepared as 
described above. For the upper layer, methylcellulose was defrosted in a 37°C waterbath, 
mixed with enough fresh bone marrow cells to give a concentration of lxlO 4 cells/dish and 
then 1  ml of the cell-containing methylcellulose plated on top of the underlayer in each 
dish. The plates were again incubated at 37°C in a humid atmosphere of 5% 0 2 / 1 0 % CO2  
for 1 1  days.
5-10 colonies per plate were then picked under a dissecting microscope, pooled in 500 pi 
ice-cold PBS and washed twice with 1 ml ice-cold PBS. The cells were then resuspended 
in PBS and counted in a Scharfe System CASY 1 cell counter. For cytospins, colonies were 
picked and washed as above and resuspended in 500 pi PBS. This suspension was 
cytospun at 500 rpm for 5 min onto polysine slides. The slides were air-dried, fixed in 
100% methanol for 10 min at room temperature and then air-dried again. The cells on the 
slides were stained in 10% GIEMSA for 10 min at room temperature, washed briefly with 
water and allowed to dry. They were mounted under a cover slip with a drop of glycerol, 
and the cell types determined by inspection under a light microscope.
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Chapter 3: RESULTS - Aggregation of MIP-1a
3.1. Introduction
Most chemokines have the ability to self-associate and form oligomers of varying sizes 
(see Introduction). While the majority of these cannot aggregate past the dimeric or 
tetrameric state, M IP-la, MIP-1|3 and RANTES have been demonstrated to form higher 
order aggregates under certain conditions (Lodi et al., 1994; Patel et al., 1993; Skelton et 
al., 1995). A number of factors have been found to influence the aggregation process of 
chemokines and include protein concentration (Graham et al., 1994), salt concentration 
(Graham et al., 1992; Laurence et al., 1998), pH and hydrophobic environments (Graham et 
al., 1992; Patel et al., 1993). It has also been shown that aggregation is reversible and 
dynamic as it can be decreased or increased by varying the conditions listed above (Graham 
et al., 1994). It was determined that the formation of dimers and tetramers of M IP-la is 
dominated by hydrophobic interactions, whereas aggregation past the tetrameric state is 
controlled by electrostatic interactions (Patel et al., 1993). Indeed, aggregation mutants of 
RANTES and M IP-la were generated by mutating acidic residues (Czaplewski et al., 
1999; Hunter et al., 1995, Graham, 1994 #218). In the case of M IP-la, it was even possible 
to isolate different aggregation states by progressively neutralising acidic residues in the C 
terminal a  helix. Thus, a mutant in which the glutamate residue at position 6 6  was 
neutralised (E6 6 Q) could not aggregate past the tetrameric state, while mutants in which 
either two (E6 6 Q + D64N) or three (E6 6 Q + D64N + E60Q) acidic residues had been 
neutralised could not aggregate past the dimeric or monomeric state, respectively (Fig. 3.1). 
The effect of the latter two mutants seems to contradict the discovery that the forces 
stabilising the dimeric and tetrameric structures are exclusively of a hydrophobic nature. 
However, the alteration in the overall charge distribution of M IP-la upon the neutralisation 
of two or three acidic residues may possibly interfere with self-association.
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Figure 3.1: Sequence alignment of murine M IP -la  and human RANTES
Above are shown the primary amino acid sequences of murine M IP - la  and human 
RANTES. Basic residues are coloured in red, while acidic residues are coloured in blue. 
The numbers above the M IP - la  sequence highlight the residues that have been implicated 
in heparin binding (! 7, 44, 45, 47) and in aggregation (60. 64, 66).
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A number of functions have been suggested for chemokine aggregation, including 
increased resistance to proteolysis (Paolini et al., 1994), a mechanism for limiting the 
active amount of circulating chemokine in the blood (Skelton et al., 1995) and the 
activation of specific signalling pathways at high chemokine concentration (Czaplewski et 
al., 1999). It was therefore decided to carry out a number of experiments that would further 
characterise the conditions that influence the aggregation of murine M IP-la (as described 
in the following sections).
3.2. Effect of Dilution on MIP-1a Aggregation
Since the aggregation of human M IP-la has previously been demonstrated to be influenced 
by its concentration (Graham et al., 1994), investigations were made into whether the self­
association of murine M IP-la is regulated in a similar way. The following dilutions of a 10 
pg/ml stock solution (referred to as “neat” in later sections) of murine M IP-la were 
prepared in PBS: 5 pg/ml (“1 in 2”), 1 ^g/ml (“1 in 10”), 0.5 pg/ml (“1 in 20”) and 0.1 
pg/ml (“1 in 100”). The aggregation state of each dilution was analysed by gel filtration 
chromatography, using an HR 10/30 Sephacryl S200 column (fractionation range (Mr):
5,000-250,000) that was pre-equilibrated with PBS containing 1 mg/ml BSA. 0.5 ml of 
each dilution was applied to the column and the different aggregation states assessed by 
running the column at a flow rate of 0.5 ml/min in PBS containing 0.1% BSA, which was 
included in order to minimise non-specific interactions of M IP-la with the gel matrix 
which had previously resulted in a poor resolution. 1  ml fractions were collected and 
analysed for the presence of M IP-la using a murine MIP-la-specific ELISA, as the 
presence of high BSA concentrations and low M IP-la content in higher dilutions made it 
impossible to detect M IP-la elution by absorbance measurements at 280 nm or Western 
Blotting. Fractions had to be substantially diluted in running buffer (500 fold for “1 in 2”, 
100 fold for “1 in 10”, 50 fold for “1 in 20” and 10 fold for “1 in 100”) in order to bring 
them into the detection range of the ELISA. Fig. 3.2 shows the results of the ELISA as 
measured at 450 nm. Peaks were assigned to the different aggregation states (M IP-la 
monomer- 8  kD, dimer-16 kD, tetramer-32 kD, octamer-64kD, dodecamer-96 kD etc.) in 
comparison to a linear standard curve that had been derived from the elution points of a 
range of molecular weight standards which are indicated at the top of the figure. It is 
apparent from Fig. 3.2 that the isolation of different M IP-la aggregation states can be 
achieved by diluting the protein to varying degrees, and at concentrations below 0.5 |ig/ml, 
murine M IP-la is almost entirely monomeric.
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Figure 3.2: Effect of dilution on the aggregation of M il*-la
Different dilutions (see legend) of murine M IP - la  were prepared in PBS and the 
aggregation state of M IP - la  within these preparations analysed by applying 0.5 ml of 
each dilution to a HR 10/30 Sephacryl S-200 gel filtration column which was run at a How 
rate of 0.5 ml/min in PBS/0.1% BSA. 1 ml fractions were collected and analysed for their 
M IP - la  content in a murine M IP-la-specific ELISA (A4so). Peaks were assigned to 
specific aggregation states by comparison to the elution profiles of a range of molecular 
weight standards (see top of the figure in kD).
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This is a slightly higher value than the one previously reported for human M IP-la, which 
disaggregates into monomers at around 0 . 1  pg/ml and therefore displays a slightly higher 
tendency for self-association than murine M IP-la. These differences in aggregation are 
likely to be due to the charge differences between these two homologues, as human MIP- 
l a  is more negatively charged. At concentrations of 1 pg/ml, murine M IP-la is 
predominantly dimeric, while at 5 pg/ml it is mainly tetrameric with some evidence of 
higher order aggregates. At 10 pg/ml, murine M IP-la exists in a range of higher order 
aggregates (data not shown).
However, the fact that the peaks are not entirely symmetrical and that there is a certain 
degree of overlap indicates that the starting populations may not be completely 
homogeneous populations of oligomers. The aggregation state of the samples may also 
have been slightly altered on their way through the column due to further dilution, since the 
protein is eluted over a volume of up to 1 0  times greater than the volume of the original 
sample. Therefore, it is not entirely clear how accurately the elution peaks represent the 
starting population. Nevertheless, Fig. 3.2 shows that the different aggregation states of 
murine M IP-la can be isolated by making dilutions of defined concentrations, with 5 
pg/ml providing a preparation of mainly tetramers, 1 pg/ml mainly dimers and 0.5 pg/ml or 
below mainly monomers. Above 5 pg/ml, higher order aggregates of murine M IP-la can 
be obtained. Thus, like in the case of its human counterpart, the aggregation of murine 
M IP-la is controlled by its concentration, with slightly weaker forces stabilising the 
murine oligomers due to the charge differences between the two homologues.
3.3. Effect of Calcium on MIP-1a Aggregation
Further insights into possible ways of regulating the aggregation of murine M IP-la were 
derived from observations made during its crystallisation. As described in the Introduction, 
calcium ions were found in association with the M IP-la tetramer in the crystal structure 
(see Fig. 3.3). One of these two ions is coordinated by the two backbone carbonyl groups 
on either side of Cys34 between two different tetramers. Its presence results in the loop 
being considerably more ordered in the tetramer and in a slightly different dimer. The 
second calcium ion is coordinated by Asp64 and Leu67 which causes the remaining 
residues (after Gln6 6 ) to adopt a nonhelical conformation. The interaction of the calcium 
ions with the tetramer was believed to be an interaction relevant for M IP-la aggregation 
for the following reasons; ( 1 ) the presence of calcium was necessary for the crystallisation
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of the M IP-la tetramer (not the dimer or monomer), (2) it could not be replaced by any 
other ions, and (3) the position of the calcium ions was almost identical in the two different 
tetramers that were observed during the crystallisation of murine M IP-la. The role of 
calcium ions in chemokine aggregation has so far not been investigated and would 
therefore represent a novel observation in this field. It may exemplify a novel mechanism 
by which the aggregation of chemokines is controlled by fluctuations in the local 
concentration of calcium ions. The self-aggregation of other proteins has, however, been 
shown to be influenced by the presence of calcium. For example, the self-aggregation of 
the surfactant protein SP-A is induced at 37°C and physiological ionic strength in the 
presence of trace amounts of calcium (Ruano et al., 2000). In order to determine whether 
calcium ions do indeed mediate oligomerisation of M IP-la by an as yet undescribed 
mechanism, the effect of calcium removal on aggregation was tested.
The calcium ions were first made accessible by suspending 10 pg of murine MEP-la in 110 
pi of 100 pM acetic acid. It has previously been shown that a complete disaggregation of 
M IP-la can be achieved through acidification with at least 10 pM acetic acid (Graham et 
al., 1992), and thus it can be assumed that M IP-la, even at a concentration of as high as 
0.1 mg/ml, will be completely disaggregated in the presence of 100 pM acetic acid. 
Disaggregated M IP-la was then applied to a 5 ml Sephadex 25 Superfine Desalt column 
and run at a flow rate of 2 ml/min in PBS containing 1 mM EDTA and 2 mM EGTA. The 
desalting process will remove the acetic acid, and as EDTA and EGTA are both chelators 
of divalent cations with high affinities for Ca2+ (association constants at pH7 for EDTA is 
logioKa=7.27 and for EGTA=6.68), they will effectively sequester any calcium ions in 
either M IP-la or PBS. EDTA and EGTA, however, also complex other divalent cations, 
such as Mg2+, albeit with lower affinities. The concentrations of EDTA and EGTA that 
were employed in this context are commonly used for the removal of divalent cations 
(James et al., 2000). Even if all of the M IP-la molecules present in the Sephadex G25 
eluate were in a tetrameric state or higher with 2 calcium ions associated with every 
tetramer, EDTA and EGTA would still be present in a molar excess of at least 100 and 200 
fold, respectively, which should result in a complete removal of calcium ions. Although 
crystallisation studies have suggested that no other ions are involved, the presence of both 
EDTA and EGTA also ensured the removal of other divalent cations which may replace 
calcium as a mediator of aggregation.
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Figure 3.3: Position of the calcium ions in the M IP-la  tetramer
Ribbon diagram of the M IP - la  tetramer with the position of the calcium ions shown in 
red. The one on the left is coordinated by the two backbone carbonyl groups on either side 
of Cys34. while the one on the right is coordinated by Asp64 and Leu67.
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Figure 3.4: Effect of Calcium Removal on M IP-la aggregation
0.7 ml of murine M IP-la (~13 mg/ml) was run on an HR 10/30 Sephacryl S200 sizing 
column in the presence of 1 mM EDTA, 2 mM EGTA and 0.1% BSA (in PBS) at a flow 
rate of 0.5 ml/min. 1 ml fractions were collected and analysed for their M IP-la content 
using a murine MIP-la-specific ELISA ( A 4 5 0 ) .  Sizes were determined using a range of 
molecular weight standards (see top of figure).
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The protein was eluted from the desalt column in a volume of 750 pi, 0.7 ml of which was 
loaded onto a Sephacryl S-200 sizing column, pre-equilibrated with PBS again containing 
1 mM EDTA and 2 mM EGTA (to maintain a calcium-free environment) and 0.1% BSA, 
which was included in order to minimise non-specific interactions of M IP-la with the gel 
matrix, and the column run at a flow rate of 0.5 ml/min. 1 ml fractions of the eluate were 
collected and analysed for the presence of M IP-la using an ELISA as above. As shown in 
Fig. 3.4, by comparison to the elution profiles of molecular weight standards, it was 
determined that the cation-depleted M IP-la was present in a range of aggregation states, 
from monomers up to 16mers (128 kD) and higher, with the bulk of the protein eluting as 
oligomers of more than four monomeric units. Since the concentration of M IP-la that was 
loaded onto the sizing column was between 10-13 p.g/ml, the elution profile is as expected 
for this protein which is largely aggregated at that concentration. It compares with the 
elution profiles obtained previously for murine M IP-la at 10 pig/ml (data not shown) 
which suggests that the presence of calcium (or possibly other divalent cations) is not 
required for the formation of higher order aggregates. These results also demonstrate that 
aggregation and disaggregation are reversible processes since completely dissociated MIP- 
l a  (in the presence of 100 pM acetic acid) will re-aggregated upon removal of the acid.
3.4. Summary
Above is given an account of what is currently known about chemokine aggregation, in 
particular the aggregation of M IP-la. It was previously known that the ionic and 
hydrophobic strength and the pH of the buffer as well as a number of negative (Graham et 
al., 1994) and positive (Graham et al., 1996) charges in the molecule, some of which form 
important salt bridges in the oligomers, have a profound effect on the ability of M IP-la to 
form self-aggregates. In addition, serial dilutions of human M IP-la not only demonstrated 
the effect of concentration on aggregation, but also made it possible to isolate differentially 
aggregated human M IP-la (Graham et al., 1994). The above findings show that the same is 
possible for murine M IP-la, where different dilutions of this protein and their subsequent 
analysis by gel filtration chromatography demonstrated that at 5 p.g/ml, murine M IP-la is 
predominantly in a tetrameric state which disaggregates further to dimers at 1 pg/ml, while 
at concentrations below 0.5 pg/ml, the protein is almost entirely monomeric. Since human 
M IP-la needs further dilution to below 0.1 [xg/ml in order to be completely disaggregated, 
it seems that forces stabilising the aggregates in human M IP-la are slightly stronger than 
in murine M IP-la. The above findings also show that divalent cations, in particular
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calcium ions, are not essential for the aggregation of murine M IP-la, as their removal by 
the chelators EDTA and EGTA has no effect on the ability of M IP-la to form higher order 
aggregates as expected from the concentrations of murine M IP-la used in this experiment. 
Finer dissociation constant measurements, however, are required in order to demonstrate 
whether these ions have any influence on the aggregation process. The function of the two 
calcium ions associated with the murine M IP-la tetramer therefore remains unknown and 
may just represent a phenomenon caused by the conditions under which the tetramer was 
crystallised. The fact that the ions could not be removed without disrupting the crystal 
indicates that their presence may be required for the crystallisation of the tetramer, however 
not for its formation under physiological conditions.
The physiological relevance of chemokine aggregation in vivo is not entirely clear (see 
Introduction), especially since the dissociation constants (IQ) for the oligomers lie in the 
pM range while the IQ’s for binding of chemokines to their receptors lie in the nM range. 
However, local concentrations of chemokines during or following secretion may be high 
enough to induce a certain amount of aggregation. It has also been suggested that 
aggregation of chemokines may be relevant for their interaction with proteoglycans 
(Hoogewerf et al., 1997) as will be analysed for murine M IP-la in the following chapter.
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Chapter 4. RESULTS - Effect of Aggregation on the 
Heparin Binding Affinity of MIP-1a
4.1. Introduction
Chemokines bind to heparin with varying affinities, ranging from a relatively strong 
interaction found between RANTES and a heparin matrix, needing salt concentrations of 
0.9 M NaCl to be disrupted, to relatively weak interactions as are characteristic for M IP-la 
- heparin binding which can be disrupted by 0.39 M NaCl (Kuschert et al., 1999). Heparin 
binding sites have been defined in a number of chemokines and are characterised by 
clusters of basic residues in the proteins that are thought to interact with the negatively 
charged sulphate groups of the glycosaminoglycan chains. In most cases, the number of 
positive charges and therefore the extent of the heparin binding surface have been shown to 
positively correlate with the strength of the chemokine - heparin interaction. Furthermore, 
in some cases, such as PF4 (Mikhailov et al., 1999; Stringer and Gallagher, 1997) and IL-8 
(Spillmann et al., 1998), positive cooperativity was observed between the binding sites on 
different monomers which resulted in a higher affinity for heparin in the oligomers as the 
heparin binding area was increased. For example, in PF4, individual binding sites come 
together in the tetramer to form a ring of positive charges around the molecule that runs 
perpendicular to the a  helices. It has even been suggested that the interaction between 
chemokines and glycosaminoglycans can mediate the oligomerisation of these proteins 
(Hoogewerf et al., 1997). The following sections describe experiments that were carried 
out in order to establish whether the aggregation of murine M IP-la is also accompanied by 
an increase in heparin binding affinity, as this may represent another mechanism by which 
M IP-la aggregation is controlled and may also be relevant for the way M IP-la is 
presented to its target cells in the context of the bone marrow microenvironment.
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Figure 4.1: Position of the Heparin Binding Sites
Above are shown space-fill models of the murine M IP - la  monomer, dimer and tetramer. 
The residues implicated in heparin binding (Argl7, Lys44, Arg45, Arg47) are coloured in 
order to demonstrate their relative positions in the molecules. The heparin binding sites in 
the individual monomeric units in the tetramer are represented in different colours.
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4.2. The Heparin Binding Site in murine MIP-1a
To see whether a similar cooperativity of individual binding sites takes place in M IP-la 
upon self-association, the orientation of these sites relative to each other was first of all 
examined in the crystal structure of the monomer, dimer and tetramer. As can be seen in 
Fig. 4.1, the four residues that have been implicated in the interaction of M IP-la with 
heparin, Lys44, Arg45, Arg47 and, to a lesser extent, Argl7 (Graham et al., 1996; 
Koopmann and Krangel, 1997), form a positive cluster at one end of the monomeric 
molecule. Although these sites are slightly twisted away from each other in the dimer, a 
glycosaminoglycan chain may still be accommodated within the cleft between the two 
monomers, simultaneously interacting with the two different binding sites. In the tetramer, 
the binding sites form a ring on one face of the molecule. A glycosaminoglycan chain that 
runs across this circle (top left to bottom right in Fig. 4.1) may be able to make extensive 
contacts with more than one binding site in the tetramer. The following experiments were 
therefore intended to formally check whether there is a relationship between aggregation 
and heparin binding.
4.3. Heparin Binding Affinities of mMIP-1a Aggregation 
Mutants
In a first approach to determining whether aggregation has any impact on heparin binding 
affinity, three aggregation mutants (see Introduction and previous section) of M IP-la were 
tested for their binding to a 1 ml HiTrap heparin affinity column. These three differentially 
aggregating mutants had been previously derived by the sequential neutralisation of 
negative charges in the C terminus of murine M IP-la (Graham et al., 1994). A mutant that 
could not aggregate past the tetrameric state (PM1) was obtained by the neutralisation of 
one acidic residue, E66Q, while the neutralisation of additional negative charges, E66Q + 
D64N and E66Q + D64N + E60Q, generated mutants that could not aggregate past the 
dimeric (PM2) and monomeric state (PM3), respectively. 500 pi of each mutant at a 
concentration of 0.1 mg/ml in PBS, a concentration at which they should have reached 
their maximal aggregation (see Fig. 3.2), was applied to the heparin column that had been 
washed with 0.1 M NaCl/0.02 M Tris (pH 7.6) and a subsequent step to 2 M NaCl/0.02 M 
Tris (pH 7.6) and then, prior to the run, been equilibrated with the starting buffer (0.1 M 
NaCl/0.02 M Tris pH 7.6). The proteins were eluted using a flow rate of 1 ml/min and by 
developing a continuous gradient from 0.1 M NaCl to 0.5 M NaCl with a subsequent step
114
to 2 M NaCl. This particular continuous gradient from 0.1-0.5 M NaCl was chosen, as it 
was known that wild type M IP-la can be dissociated from a heparin matrix using 0.39 M 
NaCl (Kuschert et al., 1999). The subsequent step to 2 M NaCl ensured that any protein 
still attached to the matrix would be eluted. The elution of the mutants was followed by 
absorbance measurements at 280 nm, as the protein concentrations were sufficiently high 
to be detected by this method and as there was no BSA included in the running buffer that 
would otherwise complicate the A2 8 0  readings. The elution profiles are shown in Fig. 4.2 
and demonstrate that the different mutants do indeed bind heparin with differing affinities. 
All three of them eluted completely over the continuous gradient (between 0.1-0.5 M 
NaCl) with no further elution detected following the step to 2 M NaCl. The symmetrical 
nature of the peaks indicates that the preparations applied to the column are indeed 
homogeneous populations of aggregates that have not dissociated any further. Interestingly, 
and contrary to expectations, the tetramer (PM1) displayed the lowest affinity for heparin, 
eluting at 0.34 M NaCl, followed by the dimer (PM2) at 0.4 M NaCl and the monomer at 
0.45 M NaCl with the strongest binding. It is unlikely that these differences in elution 
represent molecular sizing effects as the matrix chosen for affinity chromatography is of an 
inert and very porous nature and will not resolve proteins that are greater than 5kD.
Therefore, one possible interpretation of these results is that, in contrast to PF4, 
aggregation of M IP-la interferes progressively with heparin binding, perhaps by partially 
restricting access to the binding sites. An alternative interpretation is provided by the fact 
that the interaction of chemokines with proteoglycans is mainly of an electrostatic nature, 
with positive residues in the proteins interacting with the negatively charged sulphate 
groups of the glycosaminoglycan chains. Thus, the neutralisation of repelling negative 
charges may alter the overall charge of M IP-la in a way that favours the interaction with 
heparin which would explain the higher affinity of the monomeric mutant in which three 
negative charges have been neutralised. This latter possibility may also explain why MIP- 
la ,  which has a net negative charge unlike other chemokines, such as RANTES, which are 
basic proteins (see Fig. 3.1), is a weak heparin-binding protein. This would also mean that 
clusters of positive charges are not the only determinants for heparin binding affinities, but 
that the overall charge distribution of a protein is also important. In order to be able to 
discriminate between an aggregation or a charge effect on the binding affinities of the three 
mutants, further experiments were carried out, as described below.
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Figure 4.2: Binding of aggregation mutants to heparin
Differentially aggregated M IP - la  mutants were applied (0.5 ml at 0.1 mg/ml) to a HiTrap 
heparin column and eluted with a 0.1-0.5 M NaCl gradient at a flow rate of 1 ml/min. 
Protein elution was monitored by absorbance measurements at 280 nm.
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Figure 4.3: Effect of dilution on heparin binding of M IP-la
Differentially aggregated M IP - la  was applied (0.3 ml) to a HiTrap heparin column and 
eluted using a 0.1 -0.6 M NaCl gradient and a flow rate of 1 ml/min. 0.25 ml fractions were 
collected over the gradient and analysed for their M IP - la  content using a murine M IP-la-  
specific ELISA. Note, the differences in peak sizes was caused through the necessity of 
extensively diluting the samples prior to their analysis in the ELISA.
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4.4. Heparin Affinities of Differentially Aggregated MIP-1a
The first step in trying to resolve the above question involved finding an alternative method 
for obtaining differentially aggregated preparations of murine M IP-la that circumvented 
the problem of altering the overall charge of the molecule. As shown in Fig. 3.2 in the 
previous chapter, progressively diluting M IP-la produces preparations that contain 
predominantly monomers, dimers or tetramers as analysed on a Sephacryl S200 sizing 
column and subsequently in a murine M IP-la ELISA. Thus, at concentrations of 5 pg/ml, 
M IP-la is predominantly tetrameric with some evidence of higher order aggregates, whilst 
at 1 pg/ml it is dimeric and at concentrations of 500 ng/ml or less it is almost entirely 
monomeric. As explained in section 3.2., further dilution of the samples may occur on their 
way through the column and the elution profile of the eluate may not be a completely 
accurate representation of the original sample composition. Therefore, gel filtration 
fractions that were known to contain the different aggregation states (as illustrated in the 
ELISA measurements) were directly applied in a volume of 0.5 ml to a 1 ml HiTrap 
heparin affinity column in order to analyse the heparin binding affinities of the different 
oligomers. However, when the fractions collected from the heparin column were analysed 
in an ELISA, it became apparent that a further dilution of the samples had occurred which 
made it increasingly difficult to detect the protein in the ELISA and no clear picture of the 
elution profiles of the different oligomers could be obtained (data not shown).
To circumvent this problem, dilutions that had produced monomers, dimers, tetramers and 
higher order aggregates on the gel filtration column (i.e. 0.5 pg/ml, 1 pg/ml, 5 pg/ml and 
10 pg/ml, respectively) were directly applied to the HiTrap heparin column. As mentioned 
above, dilution of the samples and possibly a further disaggregation may have occurred 
during their path through the sizing column, which would mean that the preparations 
before gel filtration may also contain oligomers of slightly higher molecular weights, 
however, a similar dilution effect also occurs on the heparin column, which makes the 
approach of taking the original dilution a valid one. The samples were applied to the 
heparin column in a volume of 500 pi and the protein eluted over a gradient from 0.1 M 
NaCl to 0.6 M NaCl with a subsequent step to 2 M NaCl. 250 pi fractions were collected 
over the gradient and diluted aliquots again analysed in an ELISA for their M IP-la 
content, as the protein concentrations were too small to be detected by absorbance 
measurements. As shown in Fig. 4.3, no effect of aggregation was seen on the affinity of 
binding to heparin with all of the differentially aggregated dilutions eluting on average at a
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concentration of 0.36 M NaCl which is similar to the elution point of PM1 (Fig. 4.2) and 
wild type M IP-la (Kuschert et al., 1999). The different sizes of the protein peaks were 
brought about by the necessary and extensive dilutions of the fractions prior to the ELISA. 
It also appears from Fig. 4.3 that the elution peak of the dimer is shifted slightly with 
respect to the peaks of the monomer and tetramer. However, that shift is unlikely to be 
relevant, as all three peaks display an extensive overlap with each other and all coincide 
with the peak of the 10 pig/ml preparation. It is more likely due to a pipetting error that 
occurred during the dilution of the fractions prior to the ELISA which would also explain 
the lack of symmetry in the peaks.
The fact that all the different wild type M IP-la aggregates tested bound to heparin with 
similar affinities suggests that it is indeed the differences in overall charge rather than the 
different aggregation status of the three mutants PM1, PM2 and PM3 that cause these 
proteins to elute at different times from the heparin column. However, one slight concern 
with the findings described above is the possibility that the salt concentrations used to elute 
the proteins off the column may in fact cause a partial disaggregation of the oligomers 
which has been observed in the past at NaCl concentrations of 1-2 M (Graham et al., 
1992). Therefore, in order to verify the above observations, stable, covalently linked MIP- 
l a  oligomers were generated by a novel chemical cross-linking method (Fancy and 
Kodadek, 1999) as described below.
4.5. Heparin Affinities of Cross-linked MIP-1a
Most commercially available cross-linkers are unsuitable for the cross-linking of M IP-la 
due to the fact that their side chain specificity and the size of their linker arms requires the 
presence of specific residues at a defined distance from each other within the three- 
dimensional structure of the protein which are not available in M IP-la. The method by 
Fancy and Kodadek (Fancy and Kodadek, 1999) circumvents these problems by using a 
completely different cross-linking mechanism. It relies on the absorption of visible light 
(452 nm) by the photoactivatable compound ruthenium(II) tris-bipyridyl cation 
(Ru(II)bpy3 2+) which converts it into an excited state that allows it to donate an electron to 
an acceptor such as persulphate, thus resulting in the generation of Ru(II)bpy3 3+ (a potent 
oxidant) and a sulphate radical. These two very reactive species have been proposed to 
induce the cross-linking of protein side chains by various mechanisms involving a number 
of radical intermediates and nucleophilic attacks. Thus, this process of oxidative coupling
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results in the direct coupling of nearby residues without an intervening linker arm which 
makes this a very local, short distance effect that is unlikely to perturb the overall structure 
of the protein. There is some evidence to suggest that the amino acid side chains that can 
be cross-linked in this fashion include tyrosine, lysine, cysteine, tryptophan and possibly 
others as well (Kodadek, personal communication).
Due to limitations in the available equipment and because of the fact that the details of the 
cross-linking reaction are still largely unknown which makes it impossible to predict the 
efficiency with which a given protein is cross-linked by this method, the best conditions for 
the cross-linking of murine M IP-la had first of all to be determined empirically. In a first 
trial, the cross-linking of murine M IP-la was attempted using different light sources and 
irradiation times in order to establish the best conditions. To 16 pi of murine M IP-la at 10 
pg/ml in PBS was added 2 pi of 1.25 mM Ru(bpy)3 Cl2  and 2 pi of 25 mM Ammonium 
Persulphate. Light was then shone for various time lengths directly into the top of the open 
Eppendorf screw cap tube. Two different light sources were tested, a mercury lamp with 
irradiation times of 1, 5 and 30 sec, and a weaker 2.5V-0.5A krypton lamp, with irradiation 
times of 5 sec, 30 sec and 5 min. The reactions were quenched immediately by adding 5 pi 
of SDS and DTT-containing SDS PAGE loading buffer. DTT is easily oxidised and 
therefore serves as a good quenching reagent. 5 pi of bromophenol blue/glycerol were then 
also added to each reaction and the samples analysed on a 17.5% SDS PAGE gel and 
subsequently visualised by Western Blotting using a polyclonal anti-murine M IP-la 
antibody. As shown in Fig. 4.4, murine M IP-la can indeed be cross-linked by this method, 
as evident from the presence of monomers, dimers, tetramers, octamers and even higher 
order aggregates. It seems to be a highly specific interaction since no trimers could be 
detected. Nevertheless, in subsequent experiments, Histidine, an electron-donating amino 
acid that has been shown to be able to “tone down” the degree of cross-linking and sort out 
tight contacts from weak or transient associations (Fancy and Kodadek, 1999), was 
included at 0.1 mM in the reaction in order to keep the amount of nonspecific cross-linking 
at a minimum level. The best cross-linking results were obtained using a mercury lamp as a 
light source and an irradiation time of approximately one second. Longer irradiation times 
resulted in a disappearance of the protein band on the Western Blot, as shown in Fig. 4.4, 
lanes 8 and 9. A possible explanation for this may be that a very high degree of cross- 
linking has altered the overall structure of the protein to such a degree that it was no longer 
recognised by the specific antibodies.
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3 4 5 6 7 8 9 lanes
octamer
tetramer
monomer
Figure 4.4: Chemical cross-linking of M IP -la
lanes 1,2: molecular weight markers; lane 3:uneross-linked M IP-la ; lanes 4-6 :M IP-la  
cross-linked with a 2.5V-0.5A krypton lamp for 5 see, 30 sec, 5 min; lanes 7-9 :M IP-la  
cross-linked with a mercury lamp for I, 5, 30 see
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Figure 4.5: Binding of cross-linked M IP-la  to immobilised heparin
M IP -la  was cross-linked as described in the text, and the cross-linked material applied to 
a HiTrap heparin column. Protein was eluted by a salt gradient (0.1-0.6 M NaCl) and 
fractions analysed by Western Blotting using a M IP-la-specific polyclonal antibody.
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Once the optimal conditions had been established, this technique was used to cross-link 
wild type murine M IP-la at a concentration of 100 pg/ml in a volume of 100 pi in PBS 
with 10 pi of 1.25 mM Ru(bpy)3 Cl2 , 10 pi of 1 mM Histidine and 10 pi of 25 mM 
Ammonium Persulphate. As the cross-linked material was then to be analysed for heparin 
binding, it was not possible to quench the reaction through the addition of DTT since that 
would have disrupted the disulphide bridges which may have an impact on the protein’s 
tertiary structure. The reaction was therefore immediately diluted through the addition of 
970 pi of PBS and 1 ml of the reaction instantly applied to a HiTrap heparin column (same 
chromatography method as above). The material was eluted with increasing salt 
concentrations from 0.1 M NaCl to 0.6 M NaCl and the elution profile analysed by SDS 
gel electrophoresis and Western Blotting of the 250 pi column fractions. Western Blotting 
was employed for the detection of the protein since the concentrations were high enough 
for detection and the different covalently-linked oligomers could be visualised by this 
method. Fig. 4.5 shows that aggregation again has no effect on the heparin binding affinity 
of M IP-la, with the stable monomers, dimers and tetramers eluting at identical points from 
the column, peaking at fraction 24 which corresponds to a salt concentration of 
approximately 0.36 M NaCl which is again very similar to PM1 and wild type MEP-la. It 
can thus also be assumed that the process of cross-linking M IP-la did not cause any major 
structural disturbances, as the proteins are still able to bind to heparin with the affinity of 
the wild type protein.
4.6. Heparin Elution of Differentially Aggregated MIP-1a
Immobilised heparin can act as an ion exchange matrix as well as an affinity matrix. It is 
therefore possible that in the experiments described above the heparin chains, which are 
attached to the beads of the matrix at several points along their chains in the HiTrap 
column and may therefore not be free to interact in a more specific and physiologically 
relevant manner with M IP-la, acted predominantly as ion exchangers, especially under 
those buffer conditions (using increasing ion concentrations for protein elution). One way 
of addressing this possibility is by using increasing concentrations of soluble heparin (a 
competing ligand) rather than salt to elute the protein from the column, thus giving a more 
accurate estimate of the heparin binding affinity. Thus, murine M IP-la dilutions were 
prepared and applied to the HiTrap column as before (see section 4.4.), but eluted with a 
gradient of 0-5 mg/ml (sufficient for the elution of the majority of proteins) of soluble 
heparin in 0.1 M NaCl/0.02 M Tris pH 7.6, over which 250 pi fractions were collected.
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Figure 4.6: Binding of differentially aggregated M IP -la  to heparin
Differentially aggregated M IP -la  was loaded (0.5 ml) onto a HiTrap heparin column and 
eluted with increasing concentrations of soluble heparin (0-5 mg/ml) at a How rate of 1 
mg/ml. 0.25 ml fractions were collected over the gradient and analysed for their M IP - la  
content using a MIP-la-specific ELISA ( A 4 5 0 ) .
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Analysing the fractions in an ELISA showed that again there was no difference in the 
avidity with which the different M IP-la aggregates interacted with heparin (Fig. 4.6), as 
they all eluted at approximately 3 mg/ml soluble heparin. Some further protein elution 
seems to occur at 5 mg/ml heparin. However, that was not seen consistently, and repeating 
the experiment with a gradient of 0 - 1 0  mg/ml soluble again showed that the aggregation 
state has no impact on the heparin binding affinity (data not shown).
4.7. Interaction of murine MIP-1a with a Heparin Matrix 
Produced by Reductive Amination
Another method for testing the affinity of differentially aggregated M IP-la for heparin in a 
way that more closely represents an affinity-based interaction was employed and involved 
the use of a matrix to which heparin chains had been attached by reductive amination. This 
is an end-coupling method that attaches heparin to the agarose matrix by its reducing end, 
leaving the remainder of the molecule unmodified and free to interact with its ligand in a 
more physiological manner, thus reducing the amount of non-specific binding (Funahashi 
et al., 1982). A 1 ml HR 5/5 column was packed with this type of heparin-agarose resin and 
equilibrated with 0.1 M NaCl/0.02 M Tris pH 7.6 at a flow rate of 0.5 ml/min. The 
experiments described above were repeated using this new matrix
Murine M IP-la dilutions (10 p-g/ml, 5 pg/ml, 1  |xg/ml, 0.5 fxg/ml) were prepared in PBS as 
above, 0.5 ml of each loaded onto the new column and eluted with a salt gradient (0.1-0.6 
M NaCl) as before, but at a flow rate of 0.5 ml/min. 250 pi fractions were collected over 
the gradient and analysed for the MIP-1 a  content in an ELISA. The results of the ELISA, 
as shown in Fig. 4.7, demonstrate that again there was no difference in the heparin binding 
affinities of the different M IP-la aggregates even on this matrix. They did, however, elute 
on average at a slightly later point, needing a salt concentration of approximately 0.4 M 
NaCl. The peaks were also somewhat broader, indicating a slightly different mode of 
interaction.
The behaviour of stable oligomers was also analysed on the new matrix. Cross-linked 
murine M IP-la was therefore generated as above and also applied to and eluted from the 
new column as before. The Western Blot analysis of the fractions, as shown in Fig. 4.8, 
provides further evidence that the aggregation status of M IP-la does not have any effect on 
heparin binding, with the monomer, dimer and tetramer eluting at identical points, at
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approximately 0.36 M NaCl. The reason why the cross-linked material in Fig. 4.8 elutes at 
a slightly earlier point (identical to the elution points of the stable oligomers on the HiTrap 
column - Fig. 4.5) from the column than the native protein in Fig. 4.7 is not clear.
The observation that, even with a matrix that mimics more closely the interaction between 
M IP-la and heparin in vivo, different aggregates of murine M IP-la display identical 
binding affinities was also confirmed by the elution of different dilutions of murine MIP- 
l a  with increasing concentrations (0-5 mg/ml) of soluble heparin (Fig. 4.9). However, as it 
had been observed for the salt elution of different M IP-la dilutions (Fig. 4.7), binding to 
the matrix prepared by reductive amination was stronger than to the HiTrap column with 
broader elution profiles. In this case the shift in the elution peaks was even more 
pronounced with 4 mg/ml of soluble heparin, instead of 3 mg/ml (Fig. 4.6), needed for 
competing M IP-la off the matrix-bound ligand which explains why elution had not been 
completed by the end of the run (at 5 mg/ml heparin). Thus, native murine M IP-la seems 
to interact more strongly with this matrix as compared to the HiTrap matrix, and the actual 
point of elution differs with different ways of eluting the protein. However, these 
differences are conserved among the different aggregates, thus lending further support to 
the assumption that aggregation has no impact on the heparin binding affinity of murine 
MIP-la.
4.8. Summary
Using several different approaches, it was demonstrated that M IP-la’s affinity for heparin 
does not change upon aggregation and that it rather seems to depend on the overall charge 
of the protein. Even the use of different heparin matrices (HiTrap and reductive amination- 
prepared), different methods of protein elution (salt and heparin) and different ways of 
producing differentially aggregated murine M IP-la (dilution and cross-linking) still always 
produced results that all led to the same conclusion that, unlike in the PF4 tetramer, in the 
M IP-la oligomers the individual heparin binding sites on the different monomeric units do 
not display positive cooperativity, but rather act as independent units, resulting in a heparin 
affinity that does not change upon oligomerisation. For that reason, it can be assumed that 
the different elution profiles of the three aggregation mutants, PM1, PM2, PM3, are not 
caused by an obstruction of the heparin binding site in the oligomers, but are related to 
changes in the overall charge of the proteins that were induced when the acidic residues 
were replaced by neutral ones. This demonstrates for the first time that the affinity of
chemokines for heparin is not only determined by the presence of clusters of positive 
charges that can interact with the sulphate groups of the glycosaminoglycan chain, but is 
also influenced by the overall charge of the protein, with the number of negative charges 
being negatively correlated with the strength of the interaction.
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Figure 4.7: Binding of differentially aggregated M IP -la  to a heparin matrix 
prepared by reductive amination
0.5 ml samples of differentially aggregated murine M IP - la  (see figure legend) were 
loaded onto a heparin column (with a matrix prepared by reductive amination) and eluted 
using increasing salt concentrations (0.1-0.6 M NaCl) and a How rate of 0.5 ml/min. 250 
pi fractions were collected over the gradient and analysed in a murine MIP-la-specific 
ELISA ( A 4 5 0 ) .
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Figure 4.8: Binding of cross-linked M IP -la  to a heparin matrix prepared by 
reductive amination
M IP -la  was cross-linked as described in the text and the cross-linked material (1 ml) run 
on a heparin column at a How rate of 0.5 ml/min. The protein was eluted by developing a 
gradient between 0.1 and 0.6 M NaCl. 250 pi fractions were collected over the gradient 
and analysed for the presence of M IP - la  by Western Blotting.
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Figure 4.9: Heparin elution of differentially aggregated murine M IP -la  from a 
heparin matrix prepared by reductive amination
Differentially aggregated murine MI P- l a  (see figure legend for concentrations in PBS) 
was loaded in 0.5 ml samples onto a heparin affinity column containing a matrix prepared 
by reductive amination. The protein was eluted at a flow rate of 0.5 ml/min wdth 
increasing concentrations of soluble heparin (0-5 mg/ml). 0.25 ml fractions were collected 
over the gradient and analysed for their MI P- l a  content in an ELISA (A45o).
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Chapter 5. RESULTS - The MIP-1a Inhibitory 
Receptor
5.1. Introduction
The last two chapters dealt with two properties of M IP-la, its ability to aggregate and to 
interact with proteoglycans, which can potentially influence M IP-la‘s inhibitory activity in 
vivo. However, the key players in this process, apart from M IP-la itself, are the receptor 
that conveys M IP-la‘s inhibitory signal as well as the downstream signalling events that 
follow receptor activation. As described in the Introduction, M IP-la was the first 
chemokine to be shown to affect the proliferation of haemopoietic stem cells (Graham et 
al., 1990). Since then, it has been demonstrated to have even more wide-spread effects on 
primitive as well as more mature cells. The inhibitory function of M IP-la is conveniently 
studied in the CFU-A assay which is an in vitro assay for the detection of transiently 
engrafting haemopoietic stem cells, thus termed CFU-A cells. This assay involves the 
plating of total murine bone marrow in the presence of the growth factors murine SCF, 
human M-CSF and murine GM-CSF which support the development of colonies from 
CFU-A cells that become visible as large colonies of 2 mm or more in diameter after 11 
days of incubation. Very little is known about the molecular mechanism underlying MIP- 
la-mediated CFU-A cell inhibition, and the receptor responsible for conveying this activity 
has not been studied. The following sections present data that add to the current knowledge 
of M IP-la’s mode of action and may prove to be instrumental in the identification of the 
inhibitory receptor. The knowledge of the receptor and signalling mechanisms involved in 
stem cell inhibition is not only important for the understanding of the regulation of stem 
cell proliferation and their possible clinical applications in bone marrow transplants and 
gene therapy, it may also shed some light on how these processes have been altered in 
diseases such as leukaemia, as stem cells from Chronic Myeloid Leukaemia patients have 
been shown to be refractory to the inhibitory effect of M IP-la (Eaves et al., 1993; 
Holyoake et al., 1993).
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5.2. Effects of MIP-1a and other chemokines on the 
proliferation of CFU-A cells
In order to study the possible involvement of any of the known chemokine receptors in 
stem cell inhibition, the following chemokines/ligands were included in CFU-A assays, by 
adding 200 pi of each at a concentration of 1 pg/ml in PBS to the bottom of the plates. This 
was intended to establish whether any of them, at the final concentration of 1 0 0  ng/ml, are 
capable of influencing the proliferation of these transiently engrafting haemopoietic stem 
cells.
CC chemokines: two of the m M IP-la aggregation mutants (PM1 and PM2; see section 
4.3.), hMIP-laP (LD78|3), hMIP-ip, hMCP-1, hMCP-2, hHCC-1, hHCC-2, hHCC-4, 
hLARC, hMPIF-1, hMPIF-2, mClO, hI-309, hDCCK-1, mEotaxin, mESkine, mMDC, 
hRANTES, mSLC, mTECK;
CXC chemokines: hIP-10, mSDF-1, hIL- 8  (72 and 77 amino acid isoforms);
CX3 C chemokines: hFractalkine; 
viral chemokine homologues: vMIP-II.
As can be seen in Fig. 5.1, only the addition of M IP-la (the two murine aggregation 
mutants or the human homologue) results in a marked and reproducible inhibition of the 
proliferation of CFU-A cells, as reflected in the reduced number of large CFU-A colonies 
while none of the other chemokines display any effects. From Fig. 5.1 and data published 
previously (Graham et al., 1994), it is also apparent that mutations in M IP-la that interfere 
with its ability to aggregate do not influence its inhibitory function. Interestingly, MIP-ip, 
which is highly related to M IP-la, and DCCK-1, the sequence of which following the CC 
motif is highly homologous to the corresponding sequence in M IP-la, do not, however, 
share its inhibitory effect on CFU-A cells. Similarly, chemokines that have previously been 
shown to inhibit the proliferation of certain haemopoietic stem cell subtypes, such as 
MPIF-1 and MPIF-2 (Patel et al., 1997), have, nevertheless, no effect on the proliferation 
of CFU-A cells.
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In a separate experiment, ligands for all the currently known CC chemokine receptors were 
tested in a CFU-A assay in order to establish whether any of them showed stem cell 
inhibitory activity, thus implicating one of the known CCRs in stem cell inhibition. 
However, Table 5.1 shows that none of them displays any consistent activity that was 
comparable to M IP-la, thus suggesting that a novel, currently uncharacterised, receptor is 
involved. It seems, therefore, that M IP-la (human as well as murine) is unique among 
chemokines in its ability to inhibit CFU-A cell proliferation which suggests that these cells 
may carry a MIP-la-specific receptor through which this effect is mediated. This also 
makes the CFU-A assay suitable for specifically studying MIP-la-mediated inhibition 
since no other chemokines display any activity in this assay.
5.3. MIP-1a does not utilise CCR5 or D6 for Stem Cell 
Inhibition
Murine M IP-la has been shown to bind to four murine receptors, to CCR5 and D6  with 
high affinity and to CCR1 and CCR3 with low affinity (Nibbs et al., 1997), however a 
number of observations suggest that none of these receptors mediate M IP-la’s inhibition 
of CFU-A cells. One of the first indications came from studies on a mutant of M IP-la 
which has lost its ability to bind to heparin (Graham et al., 1996). The mutation that 
destroyed the heparin binding site, also completely abolished binding of this mutant to 
CCR1 and resulted in lower affinities for CCR3, CCR5 and D6 . Yet this mutant was just as 
potent as wild type M IP-la in the inhibition of CFU-A cells, suggesting that the inhibitory 
signal is not conveyed by CCR1. Furthermore, the fact that all four M IP-la receptors also 
bind other ligands (see Table 1.1 and Table 5.1), none of which have any effect on CFU-A 
cell proliferation, further supports the suggestion that stem cell inhibition is mediated 
through a novel, possibly MIP-la-specific receptor. For the same reason, none of the other 
known CC chemokine receptors are likely to be involved since none of the ligands for 
CCR1-CCR11 display CFU-A cell inhibition activity (see above and Table 5.1).
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Chemokine Systematic % colony Receptors
(lOOng/ml) name growth used
hM IP-ip CCL4 75.0+18.8 CCR5, D6
hRANTES CCL5 111.4±26.3 CCR1, 3, 5,
hM CPl CCL2 112.6±18.8 CCR2, D6
hMCP2 CCL8 93.4+9.4 CCR1, 2, 3,
hHCCl CCL14 93.4+9.4 CCR1 (D6)
hHCC2 CCL15 88.9+20.8 CCR1, 3
hHCC4 CCL16 102.2+18.2 CCR1
hM PIFl CCL23 76.3+16.5 CCR1
mEotaxin CCL11 107.9+25.7 CCR3
mMDC CCL22 83.3±17.1 CCR4
hLARC CCL20 104.5±34.8 CCR6
mSLC CCL21 109.2+11.0 C C R 7,11
hI-309 CCL1 106.5+43.1 CCR8,
mTECK CCL25 101.3+12.8 CCR9, 11
mESkine CCL27 90.8+27.7 CCR10
Table 5.1: Effect of ligands for all of the CC chemokine receptors on CFU-A cell 
proliferation
Above are listed the results (in % colony growth) of a CFU-A assay in which the listed CC 
chemokines (common names and systematic names; h=human, m=murine) were tested for 
stem cell inhibition at a final concentration of 100 ng/ml. Listed are also the receptors these 
chemokines bind to which include all of the currently known CC chemokine receptors.
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Recently, two human isoforms of M IP-la have been characterised (Menten et al., 1999; 
Nibbs et al., 1999), known as LD78a and LD78p. These two proteins differ in only three 
amino acids, at position 2 (Ser/Pro), 39 (Gly/Ser) and 47 (Ser/Gly), in the mature protein 
(see figure below).
LD78a/MIP-laS
a S l a a d t p t a |c c 1f s y t s r q i p q n f i a d y f e t s s q 1c ]s k p G v i f l t k r S r q v |£]a d p s e e w v q k y v s d l e l s a
a P l a a d t p t a |c c 1f s y t s r q i p q n f i a d y f e t s s q |c1s k p S v i f l t k r G r q v [C1a d p s e e w v q k y v s d l e l s a
LD78p/MIP-laP
The two studies have established that the functional differences between these two 
isoforms and their different affinities for CCR1, CCR5 and D6 can be almost exclusively 
attributed to the amino acid found at position 2, which in LD78a is a serine residue, 
whereas LD78P has a proline at that position, which makes the latter isoform more similar 
to murine MIP-la. For that reason, these proteins will be referred to as M IP-laS and MIP- 
laP , respectively, for the remainder of this thesis. Sequence analysis of M IP-laS has 
predicted two alternative signal sequence cleavage sites (Nibbs et al., 1999), producing a 
protein with the putative full-length amino terminus (with serine at position 2) as well as a 
protein in which the four amino terminal amino acids are missing (-4 variant). However, so 
far, only the -4 variant has been isolated from natural sources (Menten et al., 1999). 
Despite sequence analysis predicting only the full-length M IP-laP protein, both full-length 
and a -4 variant were purified from natural sources (Menten et al., 1999), however in our 
lab only the full-length M IP-laP has been detected. Functional differences observed 
between the full-length and -4 variants further support the findings regarding the 
importance of the penultimate amino acid. When the two full-length isoforms were 
analysed for their binding to CHO cells stably transfected with murine CCR1, CCR5 or D6 
(Nibbs et al., 1999), it was found that M IP-laS was a slightly better ligand for CCR1 than 
MIP-laP, while the latter had a much higher affinity for CCR5, for which it is the highest 
affinity ligand yet identified, and for D6 than MIP-laS. Thus, M IP-laP resembles murine 
M IP-la more closely in its binding to CCR5 and D6, while MIP-laS has a CCR1 affinity 
more similar to murine M IP-la. The M IP-laS-4 and MIP-laP-4 variants display 
indistinguishable binding activities for all three receptors. They have a slightly increased 
affinity for mCCRl (higher than full-length M IP-laS and comparable to murine M IP-la), 
while their affinities for mCCR5 and mD6 were greatly reduced, thus resembling full- 
length MIP-laS.
A 
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Because of the differences with which the four isoforms interact with the three murine 
receptors for M IP-la, all four human isoforms were tested for stem cell inhibition in the 
CFU-A assay in order to shed some light on the possible identity of the inhibitory receptor. 
As shown in Fig. 5.2, all four isoforms are potent inhibitors of CFU-A cell proliferation, 
with no significant differences observed between them. This suggests that CCR5 and D6 
are unlikely to be involved in stem cell inhibition as the marked differences in binding 
affinities for the four ligands would be expected to be reflected in their potencies as stem 
cell inhibitors. It also demonstrates a rather limited role for the extreme N terminus of 
M IP-la in stem cell inhibition, as a truncation of up to four amino acid residues does not 
have a negative influence on the potencies of the four proteins. This is very unusual since 
the integrity of the N terminus of CC chemokines has been shown to be essential for 
receptor activation in several cases. It suggests that the inhibitory receptor may be quite 
divergent from the other known murine M IP-la receptors.
5.4. MIP-1 a does not employ any of its known Receptors 
for Stem Cell Inhibition
Although the data in sections 5.2. and 5.3. suggest that none of the known murine M IP-la 
receptors are involved in stem cell inhibition, as none of the other ligands for these 
receptors show any activity in the CFU-A assay and the human M IP-la isoforms are all 
equally potent as inhibitors, different ligands have been shown to elicit different responses 
through the same receptor (Zhang et al., 1999; Zimmermann et al., 1999) and one ligand 
has been demonstrated to elicit two different responses via the same receptor (Poznansky et 
al., 2000). This raises the possibility that M IP-la uses one of its known receptors in a 
different way for stem cell inhibition. Therefore, the most reliable way of testing whether 
any of the known M IP-la receptors are involved in haemopoietic stem cell inhibition is to 
obtain bone marrow from mice in which the genes for the receptors have been deleted and 
test whether their CFU-A cells are still responsive to M IP-la when analysed in the CFU-A 
assay. Mice in which the gene for CCR1 was deleted show protection against pancreatitis- 
associated lung injury (Gerard et al., 1997), they have defects in neutrophil trafficking and 
in steady state and induced trafficking and proliferation of myeloid progenitors (Gao et al., 
1997), and their more mature myeloid progenitors do not undergo MIP-1 a-induced 
stimulation and mobilisation, while the inhibition of more immature stem cells appeared 
normal (Broxmeyer et al., 1999). CCR5 null mice develop normally, but display reduced 
efficiency in the clearance of Listeria infections (Zhou et al., 1998) and defects in innate
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immunity and organ-specific leukocyte trafficking (Huffnagle et al., 1999). CCR37 
(Humbles et al, manuscript in preparation) and D6_/" (Cook et al, manuscript in 
preparation) mice have only just been generated but appear to develop normally. Bone 
marrow was isolated from these mice, frozen for transport and then thawed for the CFU-A 
assays. CFU-A cells tolerate the freezing and thawing process generally well, but 5-10 fold 
higher bone marrow cell numbers had to be used in order to obtain the same number of 
colonies per plate as with freshly isolated bone marrow. As shown in Fig. 5.3, the CFU-A 
cells from all four receptor-null mice are inhibited by M IP-la, suggesting that none of 
these receptors are involved in stem cell inhibition. It appears as if CFU-A cells from 
CCR3‘ ‘ mice are slightly refractory to inhibition, needing up to 200 ng/ml of M IP-la for 
complete inhibition. However, this seems to be due to these cells forming unusually large 
colonies which complicates the scoring of these colonies despite the fact that they show 
clear signs of inhibition.
Although the data presented above strongly indicates that a novel receptor is involved in 
stem cell inhibition, it remains possible that M IP-la is able to utilise more than one 
receptor for the inhibition of CFU-A cells. In that case, the absence of one receptor in the 
knock-out mice may be compensated for by another MEP-la receptor. In order to test for 
this possibility, the chemokine variant AOP-RANTES which can bind to CCR1, CCR3, 
CCR5 and D6 (Eisner et al., 2000 and data not shown) was included in the CFU-A assays 
in order to compete with M IP-la for its receptors since it has been shown to act as a 
dominant negative chemokine. As shown in Fig. 5.4, AOP-RANTES is inactive as a stem 
cell inhibitor even at concentrations as high as 500 ng/ml. It was therefore included in the 
presence of M IP-la at a 5-10 fold excess in order to compete with M IP-la for its four 
receptors. However, the presence of AOP-RANTES did not in any way influence M IP-la’s 
ability to inhibit CFU-A cell proliferation (Fig. 5.4), thus providing further evidence for the 
proposed existence of a novel receptor through which M IP-la mediates its inhibitory 
effect.
5.5. Summary
Data presented above have established that M IP-la inhibits the proliferation of transiently 
engrafting haemopoietic stem cells (CFU-A cells) via a novel, as yet uncharacterised 
receptor. It was shown that it is unlikely to be any of the known CC chemokine receptors, 
as their ligands are unable to produce the same response in CFU-A assays as M IP-la. This
also demonstrates that M IP-la (both murine as well as human) is unique in its ability to 
inhibit CFU-A cells since this function is not shared by any of the CC, CXC, CX3 C and 
viral chemokines tested. This suggests that the novel receptor on CFU-A cells, through 
which M IP-la mediates its inhibition, may be MIP-la-specific and also quite divergent 
from the other known M IP-la receptors, since the integrity of the M IP-la N terminus is 
not required for its activation, as it has been demonstrated to be the case for most other CC 
chemokine receptors. The assumption that the inhibitory receptor is a novel receptor is 
further supported by the fact that CFU-A cells obtained from bone marrow of mice which 
had each individual known M IP-la receptor (CCR1, CCR3, CCR5 and D6) deleted, were 
still inhibited by M IP-la, even in the presence of AOP-RANTES, a chemokine homologue 
that can compete with M IP-la for its four receptors.
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Figure 5.3: CFU-A assay with bone marrow cells from M IP-la receptor null mice
The ability of murine M IP-la (concentrations in PBS provided in figure legends) to inhibit 
CFU-A cell proliferation in the absence of each one of its known receptors was tested in 
CFU-A assays (see Methods section) using a) wild type, b) CCRl7’, c) CCR37 , d) CCR57 , 
e) D67" bone marrow cells.
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Figure 5.4: Ability of M IP-la to inhibit CFU-A cell proliferation in the presence of 
an antagonist
CFU-A assays were carried out as described in the Methods section, using a) wild type 
bone marrow (BM), b) CCRl ' BM, c )  CCRS'BM, d) CCR5 ' BM, and e) D6+BM. 
Chemokine concentrations (in PBS) are given in the figure legends.
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Chapter 6. RESULTS - Molecular Dissection of the 
MIP-1 a Inhibitory Motif
6.1. Introduction
Since the identity of the inhibitory receptor still remains elusive, an alternative approach to 
gathering some knowledge of the molecular mechanism underlying MIP-la-mediated stem 
cell inhibition was initiated and involved experiments aimed at identifying the responsible 
region within M IP-la itself and possibly characterising an inhibitory motif. It is hoped that 
the identification of a more or less contiguous inhibitory motif may lead to the design and 
generation of a peptide which can interact with the inhibitory receptor and may thus have 
agonistic or antagonistic properties in CFU-A cell inhibition. This peptide could be further 
useful for raising “inhibition-specific” antibodies and for cloning out the inhibitory 
receptor.
To this aim, chimaeras were designed in which structural domains were exchanged 
between murine M IP-la and the highly related CC chemokine human RANTES. As the 
crystal structure of murine M IP-la has recently been solved (MacLean, J unpublished 
results) and shown to be virtually superimposable on the NMR structure of human 
RANTES (Skelton et al., 1995) with almost identical domain borders, a rational basis for 
the construction of the chimaeras was provided and domains exchanged in a way that tried 
to minimise structural disturbances. M IP-la and RANTES were divided into three basic 
units (see Fig. 6.1 for an alignment of the two sequences): (1) the N terminal region up to 
the CC motif, (2) the main body of the chemokine, including the loop following the CC 
motif and the triple-stranded p sheet, and (3) the C terminal a  helix.
6.2. Generation of MIP-1 a/RANTES Chimaeras
The three basic units were exchanged between murine M IP-la and human RANTES using 
a technique known as Overlap PCR (see Fig. 6.2 for schematic diagram). Briefly, in a first 
round of PCR, a chimaeric primer spanning the region of exchange and a primer to the 
extreme amino or carboxy terminus were used to amplify either the N or C terminus, 
resulting in a double-stranded chimaeric product. This product from the first round was 
subsequently used in a second round of PCR, together with primers against the N and C
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termini, resulting in the full-length chimaeric cDNA. These chimaeric cDNAs were also 
used as templates for the generation of double domain swaps. The PCR reactions were 
carried out using Pfu polymerase as outlined in the Materials and Methods section. Fig. 6.3 
lists the final constructs which included the two wild type cDNAs (full length murine MIP- 
l a  and human RANTES), the four single domain swaps (two amino terminal swaps and 
two carboxy terminal swaps) and the two double swaps, all of which were named 
according to the domains they contained, e.g. RRR for wild type RANTES and RMR for 
the main body of M IP-la attached to the RANTES N and C termini. The final double­
stranded, blunt-ended PCR products were subcloned into pCR-Script, which is specifically 
designed for blunt-ended ligations and also contains T3 and T7 promoter sites for 
sequencing, which was carried out by the Beatson Sequencing Service.
Once their correct sequences had been confirmed, they were transferred into the 
pVL1392/1393 Baculovirus Transfer Vector (using Notl and BamHI restriction), 
sequenced again for correct orientation and the vectors prepared for transfection into Sf9 
insect cells.
6.3. Production of Recombinant Proteins
A brief outline of the basic principles of the Baculovirus System is provided in Fig. 6.4. 
The large size of the baculovirus genome excludes the possibility of cloning cDNAs 
directly into it. For that reason, the transfer vector containing the gene of interest is co­
transfected with the linearised baculovirus genome, both of which are incapable of 
replicating on their own. They have to undergo homologous recombination within the 
nucleus of Sf9 cells which generates a complete, functional baculovirus genome containing 
the gene of interest (under the high-expressing promoter of the polyhedrin gene which 
normally produces a structural protein) and capable of producing recombinant protein. 
Simultaneously, recombinant viral particles are produced which can bud from the cell and 
infect neighbouring cells, thereby spreading the virus and amplifying protein production. 
As Sf9 cells are eukaryotic cells, they are capable of carrying out posttranslational 
modifications and, most importantly in the case of chemokines, they can process and 
secrete proteins containing a signal sequence. The cell culture medium can then be tested 
for the expression of recombinant protein by Western Blotting.
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Figure 6.1: Comparison of the murine M IP -la  and human RANTES primary and 
tertiary structures
Tertiary structure (upper part): Ribbon diagrams of the monomeric units of murine 
M IP -la  and human RANTES. In red are shown the four cysteine residues that form the 
two disulphide bonds. In black, blue and green are shown the three domains that were 
exchanged in the M IP-1 o/RANTES chimaeras; the N terminus, the main body (loop and 
triple-stranded (3 sheet) and the C terminus ( a  helix), respectively.
Primary sequence (lower part): The bold and underlined amino acids represent residues 
implicated in heparin binding, while the asterisks denote non-conservative changes 
between M IP-la . MIP-1(3 and RANTES. The borders of the individual domains (denoted 
by bold capital letters) are represented by the arrows above the sequences.
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Figure 6.2: Principles of generation of chimaeras by Overlap PCR
Schematic diagram of the generation of single, N terminal domain swaps by Overlap PCR 
(as described in the text). A similar chimaeric primer spanning the region around the final 
cysteine residue and running in the opposite direction was employed for single C terminal 
swaps. Single domain chimaeras were used as templates in the generation of double swaps.
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c c =  c =  c =  MRM
Figure 6.3: Summary of final constructs
List of the final PCR products that were prepared for transfection into Sf9 cells. The letters 
M and R stand for M IP -la  and RANTES, respectively and describe the domain 
composition of the chimaeras, with RRR and MMM being the wild type sequences.
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Figure 6.4: Overview of the Baculovirus System
Diagram adapted from the PharMingen Baculovirus laboratory manual.
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Figure 6.5: Protein production by the Final clones
20 jliI samples of murine M IP - la  (PM2) and recombinant human RANTES (rRANTES) 
(both at 5 pg/ml in PBS) as controls and 20 pi samples of the undiluted supernatant from 
cells infected with the final recombinant viral clones were run on a 17.5% SDS gel and 
Western blotted with a mixture of M IP-la-  and RANTES-specific antibodies 
(bRANTES/bM IP-la = RANTES/MIP- l a  produced in the baculovirus system).
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For the expression of the recombinant proteins in the baculovirus system, 2-5 p,g of the 
Baculovirus Transfer Vectors containing the wild type and chimaeric cDNAs were 
contransfected with 0.5 pg of the linearised baculovirus DNA into 2xl06 Sf9 cells. The 
cells were incubated at 27°C for 5 days and the cell supernatant then tested for the 
expression of recombinant protein by Western Blotting. To obtain high expressing viral 
clones, 2-3 rounds of plaque assays and plaque ‘pick-ups’ were carried out and the 
expression followed by Western Blotting.
Fig. 6.5 shows a Western Blot of the expression of recombinant proteins by the selected 
final clones, using a mixture of polyclonal anti-murine M IP-la and anti-human RANTES 
antibodies in a 1:1 ratio in order to assure the detection of all of the chimaeric proteins. The 
secondary antibody was coupled to Horseradish Peroxidase in order to allow for the 
detection of the antibody complexes with the Amersham Pharmacia Biotech Enhanced 
Chemiluminescence (ECL) System and their visualisation on x ray films. It is immediately 
noticeable that there are marked differences in the level of expression, with wild type MIP- 
l a  produced in the baculovirus system (bMIP-la) showing the highest expression, while 
RANTES is expressed at the lowest level. There is no obvious pattern behind the levels of 
expression, and the reason for these differences is unknown.
Aliquots of different sizes (in order to compensate for the discrepancies in expression) of 
these recombinant protein-containing supernatants were directly tested in a CFU-A assay 
for stem cell inhibition. However, apart from the observation that baculovirus-produced 
murine M IP-la was a competent stem cell inhibitor, no obvious activity was detected in 
any of the other preparations. It was therefore decided that the preparations were too crude 
to allow for the perception of subtle differences in activity and that large preparations of 
relatively pure protein were needed, in which active protein had been separated from 
inactive protein. For that purpose, large working stocks of high titre recombinant virus 
were first prepared in suspension culture by infecting cells at a density of 5xl05 cells/ml 
with 0.1-0.2 plaque-forming units (pfu)/ml and the virus-containing supernatants harvested 
after 7-9 days. Aliquots of those were used to infect 300-500 ml suspension cultures of Sf9 
cells (at lxlO6 cells/ml) and the recombinant protein-containing supernatant harvested after 
6 days. Viral particles were removed by centrifugation.
6.4. Purification of Recombinant Proteins
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After a first attempt, the production and purification of recombinant wild type human 
RANTES was discontinued because of the difficulties associated with its low expression. 
The recombinant human RANTES used in subsequent experiments has therefore been 
obtained from commercial sources. For all of the other recombinant proteins, the 
purification protocols had to be derived from first principles as they all behaved quite 
differently and unpredictably during the chromatography process (see below and Fig. 6.6). 
In an initial purification protocol, the first step involved running 300-500 ml of the cell 
supernatant through a 200 ml heparin affinity column at a flow rate of 5 ml/min and eluting 
the proteins by a stepwise increase of the salt concentration in the running buffer. The size 
of the steps was varied according to the requirements of the individual proteins (see Fig. 
6.6 for the conditions used for each individual protein). The elution of proteins was 
followed by absorbance measurements at 280 nm and the eluate collected over protein 
peaks. As shown in Fig. 6.6, there were marked differences in the strength with which 
individual chimaeras bound to the heparin column as reflected in the concentration of salt 
needed to elute the protein. Salt concentrations for elution ranged from 0.2 M for MMM 
and MRM to 0.8 M for MMR, with stronger binding generally being related to the presence 
of the RANTES C terminal domain which contains two additional positive charges and two 
fewer negative charges when compared to the M IP-la C terminus (see Fig. 3.1). Fractions 
containing the protein of interest (as determined by Western Blotting) were further purified 
on a MonoQ anion exchange column, and the proteins eluted by a continuous increase in 
salt (NaCl) concentration. Again there were marked differences in the behaviour of the 
individual chimaeras on this column, with RRM and MRM not even being able to bind to 
the column and therefore eluting in the flow through and with RMR eluting over the entire 
gradient, including the flow through. In the latter case, the interaction with the cationic 
matrix may have caused some degree of denaturation. The remaining proteins displayed 
moderate binding, needing 0.2-0.3 M NaCl for elution.
Positive fractions were then subjected to further purification on a reversed phase 
chromatography column and proteins eluted by a continuous increase in acetonitrile. The 
concentration of acetonitrile needed to elute the proteins from the column were generally 
very similar, ranging from 30-40%. Fractions were analysed for the presence of the protein 
of interest by Western Blotting and positive fractions analysed for purity by silver staining 
of the protein gel. In a few cases, such as RRM (RANTES with a M IP-la carboxy
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terminus) and MRM (RANTES with a M IP-la C and N terminus), the protein was 
sufficiently pure and the fractions could therefore be pooled, freeze-dried and resuspended 
in PBS. In all of the other cases, the proteins needed further purification and were therefore 
run on a 1 ml HiTrap heparin affinity column, eluted in a continuous gradient and positive 
fractions cleaned up in a final reversed phase chromatography step. Wild type M IP-la and 
RMM were then sufficiently pure to be dried down, while so little protein remained of 
MMR, RMR and MRR that further production and the use of an alternative purification 
protocol were required.
Therefore, instead of eluting the protein from the initial 200 ml heparin column by a 
stepwise increase of the salt concentration, a continuous gradient was used which has the 
advantage of producing a higher resolution of the protein peaks resulting in a higher purity, 
while having the disadvantage of potentially increasing the volume over which a specific 
protein is recovered. The positive fractions were then further purified on a reversed phase 
chromatography column as before and the recombinant protein-containing fractions freeze- 
dried and resuspended in PBS. Fig. 6.6 provides a summary of the purification steps 
applied to each recombinant protein and show7s that the conditions were different for each 
one of them and therefore had to be tailored to the individual needs. Fig. 6.7 contains 
images of the silver-stained 17.5% SDS PAGE gels on which the final preparations in PBS 
were run in order to assess their purity and to estimate their concentrations in the presence 
of known amounts of murine M IP-la (PM2). While the preparations of wild type M IP-la 
and MRM were completely pure, the preparations of the other chimaeras contained various 
amounts of contaminating proteins. However, a concentration of the recombinant proteins 
into a smaller volume was achieved by the purification and the final concentration for each 
one of them was 14 pg/ml of wild type M IP-la, 15 pg/ml of MRM, 20 pg/ml of RMR, 10 
pg/ml of MMR, 15 pg/ml of RMM, 15 p,g/ml of RRM and 40 pg/ml of MRR, as assessed 
by comparison to known amounts of murine M IP-la (PM2). An aliquot of each protein 
was sent to Alta Bioscience (Birmingham, UK) for N terminal sequencing (the first 5 
amino acid residues). It showed that all N termini were correct and intact (data not shown).
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MMM - 0.2M NaCl step heparin, 0.25M NaCl gradient MonoQ, 30-35% 
Acetonitrile rpc gradient, heparin gradient, rpc gradient
RMM- 0.3M NaCl step heparin, <0.13M NaCl gradient MonoQ,, 30-35% 
Acetonitrile gradient rpc, heparin gradient, rpc gradient
MMR 0.8M NaCl step heparin, 0.3M NaCl gradient MonoQ, 40%
Acetinitrile rpc gradient; big heparin gradient, rpc gradient
RMR 0.5M NaCl step heparin, smear over MonoQ, smear over rpc; big gradient 
heparin, gradient rpc
RRR - discontinued
MRR- 0.6M NaCl step heparin, 0.2-0.3M NaCl gradient MonoQ, 
gradient rpc; big heparin gradient, rpc gradient
RRM- 0.4M NaCl step heparin, FT MonoQ, 30-35% Acetonitrile rpc 
gradient
MRM- o  .2M NaCl step heparin, FT MonoQ, 30-33% Acetonitrile rpc 
gradient
Figure 6.6: Purification Protocol
Summary of the purification strategy applied to each individual recombinant protein. 
(FT=flow through)
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Figure 6.7: Silver-stained gel showing the purified chimaeras
20 pi samples of the purified recombinant proteins (undiluted, lin2, linlO in PBS) were 
analysed on a silver-stained 17.5% SDS gel as to their purities. Estimates of their 
concentrations were made by comparing them to known amounts of murine M IP - la  
(PM2). The concentration of each undiluted preparation is given in the table.
6.5. Functional Test in Calcium Flux Assay
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In order to determine whether the purified chimaeras were properly folded, functional 
proteins, they were tested for the ability to induce the release of intracellular calcium in 
HEK293 cells that were stably transfected with human CCR5. In this so-called calcium 
flux assay, cells are loaded with the calcium-sensitive fluorescent dye Fura-2-AM, the 
fluorescence of which changes upon binding of calcium. Bursts of intracellular calcium 
release, induced by stimuli such as chemokine binding, can thus be measured as transient 
increases in fluorescence. Murine M IP-la as well as human RANTES are capable of 
binding to (with similar affinities) and eliciting a calcium flux through human CCR5 at a 
final concentration of 50 ng/ml (Fig. 6.8 and see below) which makes this assay ideally 
suitable for testing the functionality of the chimaeric proteins. Another feature of the 
calcium flux assay which is important in this context is that it also provides a test for 
specificity in a process known as desensitisation. When a chemokine binds to its receptor 
and elicits a transient calcium signal, then a second stimulus provided either by the same 
chemokine or another ligand for the same receptor will not result in another calcium burst 
when added immediately after the first. This occurs because the receptor has been 
desensitised by the first stimulus and also typically indicates that both stimuli utilise the 
same receptor. As shown in Fig. 6.8, both human RANTES and PM2 (murine M IP-la) 
induce a calcium flux of similar magnitude through hCCR5. The same was found for 
baculovirus-produced M IP-la, MRM, MMR and MRR, all of which did so through CCR5 
since subsequently administered PM2 did not induce a second flux. With RRM and RMR 
which also fluxed through CCR5, the desensitisation was not complete, as a second flux 
induced by PM2 was observed, albeit of lower magnitude than PM2 on its own. RMM only 
gave a signal when 100 pi were added to the reaction. It did, however, desensitise the 
receptor against subsequent stimulation by RANTES. It therefore seems that RMM may be 
at least ten fold less active than the other chimaeras and it was therefore decided to use this 
protein at a higher concentration in the experiments that followed.
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Figure 6.8: Calcium Flux Assays
Calcium flux assays with human CCR5-transfected, Fura-2-AM-loaded HEK293 cells 
were performed as described in the Methods section. All proteins were tested undiluted 
(unless stated otherwise). For desensitisation tests, a second stimulus (“+ chemokine” ) was 
added at a specific time point as indicated by the arrow.
156
6.6. CFU-A Cell Inhibition by MIP-1o/RANTES Chimaeras
In order to examine whether any of the recombinant proteins are capable of inhibiting stem 
cells, they were tested by direct addition to CFU-A assay plates. Fig. 6.9 gives the results 
obtained with titrations of all the recombinant proteins as compared to titrations of PM2 
and commercially obtained RANTES. The preparation of M IP-la that was produced in the 
Baculovirus System (bMIP-la) was a very powerful inhibitor with complete inhibition 
observed at 100 ng/ml and half maximal activity at about 25 ng/ml. It even had a higher 
activity than the control preparation of murine M IP-la (PM2). The only one that showed 
consistent inhibition of CFU-A colony formation similar to M IP-la itself, albeit not as 
potently, was RMR. Despite the fact that it also showed half maximal inhibition at 25 
ng/ml, inhibition was not complete at 100 ng/ml. MRM, MRR, RRM and MMR which had 
all produced a robust flux in CCR5-transfected cells, were nevertheless inactive as stem 
cell inhibitors. The poor performance of RMM in the calcium flux assays suggested that 
only a portion of the protein was active, therefore making it necessary to use it at a higher 
concentration in the CFU-A assay. In order to be able to use it at a higher concentration, it 
was first concentrated four fold by desalting it, drying it down and resuspending it in a 
volume that was four times smaller than the original. It was then tested in a one-layer CFU- 
A assay that was set up in a 24-well plate in order to reduce the amount of protein needed. 
Fig. 6.10 shows the result of this assay which indicates that even at concentrations 30-60 
fold higher than used normally with chemokines, RMM does not inhibit CFU-A cells to 
any significant level, although there may be some residual activity within the bulk of 
mostly inactive protein.
The observation that RMR was the only chimaeric protein with inhibitory activity suggests 
that the main determinants for CFU-A cell inhibition are located within the main body of 
M IP-la between the CC motif and the C terminal a  helix which seems to be supported by 
the fact that MRM, which lacks the M IP-la main body but retains the rest of the M IP-la 
framework, was a potent inducer of intercellular calcium release, but showed no activity in 
the CFU-A assay. A dominant role for the M IP-la N and C termini was also ruled out by 
the fact that MRR and RRM, both of which induced a robust calcium flux, were inactive in 
the CFU-A assay. However, the fact that RMR is not as potent as native M IP-la in stem 
cell inhibition may have several causes. The conformation of the main body of M IP-la 
may be slightly altered when attached to the RANTES N and C termini, therefore resulting 
in a suboptimal interaction with the receptor. It could also be that a proportion of the
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protein in the RMR preparation is inactive as suggested by its aberrant behaviour on the 
chromatography columns and the relatively low calcium flux induced through CCR5 (see 
Fig. 6.6 & 6.8), which would then suggest that the active portion of the preparation is in 
fact a very potent stem cell inhibitor. Alternatively, the fact that RMR, which only contains 
the M IP-la main body, is not quite as potent an inhibitor as wild type M IP-la, may also 
suggest that other important residues either in the M IP-la N or C terminus are required in 
combination with residues in the main body for full inhibitor activity. In this context, it is 
surprising to note that neither RMM nor MMR display any significant inhibitory activity, 
despite the presence of the M IP-la main body in these proteins. This may mean, that these 
particular combinations of RANTES and M IP-la domains produce proteins with slightly 
altered conformations which may explain why the expression of MMR was relatively low 
(Fig. 6.5) and the activity of RMM in the calcium flux assay reduced (Fig. 6.8).
In order to determine whether RMR inhibits stem cells by a mechanism similar to the one 
employed by M IP-la, i.e. by inhibiting cell proliferation, a CFU-A assay was set up in 
which the top agar layer was replaced by methylcellulose. This allowed CFU-A colonies to 
be picked and analysed further for cell numbers. This could not be carried out for RMM or 
MMR as no more purified material was available, and these two had not shown any 
significant inhibitory activity. 5-10 colonies were picked from each plate containing the 
different chimaeras, pooled separately, single cell suspensions obtained in ice-cold PBS 
and the cells counted in a Scharfe System CASY 1 Cell Counter. Table 6.1 presents the 
results of the cell counts which indicate that the number of cells per colony is significantly 
lower in M IP-la- and RMR-inhibited colonies and slightly higher in RMR-inhibited than 
in MIP-la-inhibited colonies which corresponds well with the data presented in Fig. 6.9. 
The cell numbers per colony counted on the control plates were similar to numbers 
published previously, albeit a bit lower (2xl04 as compared to 4xl04 cells/colony) which 
may be due to the fact that the colonies were a bit smaller than the one in the previous 
report (Pragnell et al., 1988).
Furthermore, colonies were also picked from the methylcellulose assays for the analysis of 
the cell content in colonies in order to determine whether the different proteins affected the 
differentiation potential of CFU-A cells. Cells were cytospun and stained with GIEMSA 
which facilitates the morphological identification of different cell types. Inspection of the 
stained cells, obtained from colonies grown in the presence of the different chimaeras, 
under a light microscope established that the cell composition is the same in the colonies
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from each plate (control as well as in the presence of the different recombinant proteins). 
All slides contained mainly macrophages with a few blast-like cells (<5%) and about 1 
neutrophil per slide which compares to previously reported cell content analyses of CFU-A 
colonies (Pragnell et al., 1988). This suggests that M IP-la (and RMR) is a true inhibitor of 
proliferation (indicated by the lower cell counts per colony) and does not influence the 
differentiation potential of CFU-A cells.
6.7. Summary
Once it had been established that the identity of the M IP-la inhibitory receptor is 
unknown, attention was turned to M IP-la itself in an attempt to identify a region within 
the protein that confers this activity and that may even contain an identifiable inhibitory 
motif. This task was approached by constructing chimaeras that had three domains (the N 
terminus up to the CC motif, the main body, and the C terminal a  helix) exchanged 
between murine M IP-la and the highly related, yet non-inhibitory chemokine human 
RANTES. The aim was to take away from M IP-la the inhibitory activity and transfer it 
onto RANTES. The chimaeric cDNAs were generated by Overlap PCR, the chimaeric 
proteins produced using the Baculovirus System and purified in several chromatography 
steps. The functionality of the individual proteins was ascertained in calcium flux assays 
through CCR5, with only RMM showing markedly reduced activity. When the individual 
proteins were tested for stem cell inhibition in CFU-A assays, it was established that only 
the chimaera that contained the M IP-la main body (flanked by the RANTES C and N 
termini) displayed any inhibitory activity similar, yet not as potent, as wild type MIP-la. 
From that it was concluded that the main determinants for CFU-A cell inhibition reside 
within the main body of M IP-la, with possibly other residues in the N and C termini 
required for full activity. It is very unusual that the activity of a chemokine is 
predominantly determined by a region other than the N terminus and may suggest that the 
receptor for this activity is quite different from the other CC chemokine receptors that have 
been identified to date. Additional chimaeras that have smaller units within the M IP-la 
main body exchanged with the corresponding regions of RANTES have already been 
constructed at the DNA level and will be expressed and analysed for stem cell inhibitory 
activity in due course. It is hoped that this will narrow down the inhibitory region even 
further and lead to the generation of a peptide that has antagonistic or agonistic activities 
and is specific for the inhibitory receptor as this would be a valuable tool in the search for 
the identity of this receptor.
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Figure 6.10: Effect of RMM on CFU-A cell proliferation
A one-layer 24-well plate CFU-A assay was performed as described in the Methods 
section. The chemokines were added to the wells at the concentration given in brackets (in 
pg/ml in PBS).
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Proteins @ 100 ng/ml Number of Cells per Colony 
(xlO4)
control 2.055
bM IP-la 0.8025
RMR 1.0435
MRR 1.785
RRM 2.172
MRM 2.892
Table 6.1: Cell numbers in the chimaera-treated CFU-A colonies
A methylcellulose CFU-A assay was set up as described in the Methods section. At the end 
of the 11 day incubation period, 5-10 colonies were picked per chimaera, pooled in PBS 
and the number of cells determined using a cell counter.
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Chapter 7: DISCUSSION
7.1. Introduction
Since their first description as proinflammatory mediators, chemokines have been 
implicated in many other areas including regulation of leukocyte trafficking during normal 
immune surveillance, angiogenesis and vascularisation, and regulation of haemopoietic 
stem/progenitor cell proliferation, mobilisation and homing (Zlotnik et al., 1999). M IP-la 
is one such chemokine that has been shown to be involved in a number of different 
biological processes, including inflammatory responses, the regulation of haemopoietic 
stem and progenitor cells and the inhibition of keratinocyte proliferation.
Chemokines mediate their effects through members of the heptahelical G protein-coupled 
cell surface receptor family which are found on a wide range of different cell types. 
However, two other properties of chemokines can potentially influence their biological 
activities. The first one of these is their tendency to self-associate to form aggregates of 
varying sizes depending on their concentration and the ionic strength, pH and 
hydrophobicity of their environment (Clark-Lewis et al., 1995). Not all chemokines, 
however, seem to share this ability, with experimental evidence suggesting that HCC-2 
(Sticht et al., 1999), 1-309 (Keizer et al., 2000), SDF-1 (Crump et al., 1997) and Fractalkine 
(Mizoue et al., 1999) only exist as monomers. Others, such as IL-8 (Clore et al., 1990) and 
PF4 (St. Charles et al., 1989) cannot aggregate past the dimeric and tetrameric state, 
respectively, while M IP-la, MIP-lp and RANTES are able to form large and 
heterogeneous aggregates (Lodi et al., 1994; Patel et al., 1993; Skelton et al., 1995). 
Despite the fact that aggregation-incompetent chemokine mutants are still fully functional 
in bioassays in vitro and that the affinity for self-association is lower than the affinity for 
chemokine receptor binding, a number of functions have been suggested for chemokine 
aggregation, including increased resistance to proteolysis (Paolini et al., 1994), a 
mechanism for limiting the active amount of circulating chemokine in the blood (Skelton et 
al., 1995) and the activation of specific signalling pathways at high chemokine 
concentration (Czaplewski et al., 1999).
The other property of chemokines that has the potential to influence their biological 
activities in vivo is their ability to interact with glycosaminoglycans. The study of this 
interaction and the determination of its biological relevance are complicated by the
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diversity of glycosaminoglycans, both in their location as well as in their type and 
composition, and by the fact that different chemokines have very different affinities for 
these molecules. A further degree of complexity is introduced by the observation that the 
aggregation state of chemokines may influence their glycosaminoglycan-binding affinities. 
In the case of PF4, for example, the formation of the tetramer brings the individual binding 
sites on the monomers together in such a way that the overall glycosaminoglycan-binding 
area is increased which therefore results in a higher affinity of the tetramer for 
glycosaminoglycans than the individual monomers (Mikhailov et al., 1999; Stringer and 
Gallagher, 1997). Binding sites for heparin (a model glycosaminoglycan) have been 
identified in a number of chemokines and, as a general rule, seem to involve clusters of 
positive amino acids that interact with the negatively charged sulphate groups of 
glycosaminoglycans. As with the aggregation of chemokines, the relevance of chemokine- 
glycosaminoglycan interaction in vivo is not entirely clear. Mutants of M IP-la (Graham et 
al., 1996; Koopmann and Krangel, 1997), SDF-1 (Amara et al., 1999), MIP-ip (Koopmann 
et al., 1999) and MCP-1 (Chakravarty et al., 1998) that have lost their ability to interact 
with the glycosaminoglycans, are nevertheless still fully functional in bioassays in vitro. It 
has, however, been suggested that this interaction is relevant for a number of situations in 
vivo, including immobilisation of chemokines on vessel walls, their efficient packaging 
into secretory vesicles, enhancement of their anti-viral activity and sequestration of 
chemokines.
The aim of the work presented in this thesis was to characterise the relationship between 
the structure of murine M IP-la and its function as an inhibitor of the proliferation of 
transiently engrafting haemopoietic stem cells. In this context, the two properties of 
chemokines described above, aggregation and the interaction with heparin, were first of all 
considered. In chapter 3, potential mechanisms for the regulation of murine M IP-la 
aggregation, the possible influence of divalent cations and the effect of concentration of 
M IP-la on its aggregation, were investigated and a method for the isolation of different 
M IP-la aggregation states developed. In the following chapter, the control of the 
interaction of murine M IP-la with heparin was analysed and how this may be influenced 
by its aggregation state. Finally, the actual mechanism underlying MIP-la-mediated 
haemopoietic stem cell inhibtion was examined. It was confirmed that none of the known 
murine M IP-la receptors are involved in this particular function of M IP-la. Furthermore, 
a region within murine M IP-la was identified that confers stem cell inhibitory properties. 
Thus, the results presented in this thesis and discussed in the following sections have made
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a further contribution towards the understanding of the way in which murine M IP-la 
aggregation and proteoglycan binding is regulated. In addition, data was obtained on how 
M IP-la controls the proliferation of haemopoietic stem cells and that this control is 
mediated through a novel receptor.
7.2. The Aggregation of MIP-1a
A number of observations regarding the forces that control the aggregation of M IP-la had 
already been made. For example, it had been established that human M IP-la at 0.5 mg/ml 
exists predominantly as a range of large self-associated multimers that are held together by 
hydrophobic as well as electrostatic interactions (Patel et al., 1993). More specifically, it 
was shown that dimerisation and tetramerisation is driven through the interaction of 
hydrophobic residues, whereas the formation of larger aggregates (past the tetramer) is 
controlled by electrostatic forces. However, partial and complete disaggregation of M IP-la 
was also achieved by the neutralisation of specific negative charges. When the aspartate 
residue at position 26 of human M IP-la was changed to an alanine residue, a mutant was 
generated that existed in an equilibrium between monomers, dimers and tetramers, but 
could not aggregate past the tetrameric state (Hunter et al., 1995). In the crystal structure of 
the murine M IP-la tetramer, the Asp26 residue of one dimer is seen to form a salt bridge 
with the Arg45 residue of the other dimer, which, in addition to extensive hydrophobic 
interactions, helps to stabilise the tetramer. In another mutagenesis study (Graham et al., 
1994), the neutralisation of a glutamate residue at position 66 of murine M IP-la was also 
seen to result in a mutant that could not aggregate past the tetrameric state. This residue is, 
according to the crystal structure of the murine M IP-la tetramer, also in a position that 
allows it to form a salt bridge with Arg45/Arg47, and has therefore been implicated in the 
stabilisation of tetramer-tetramer interactions. The neutralisation of a further acidic residue 
in murine M IP-la (E66Q + D64N) resulted in a mutant that could not aggregate past the 
dimeric state (Graham et al., 1994). However, Asp64 is located on the external surface of
o
the a  helix where the distance to the nearest residue in the other dimer is about 10 A which 
is too far for a direct interaction. The fact that a mutation at this position nevertheless 
interferes with aggregation, suggests that the overall charge distribution is also critical for 
the aggregation process. When, in addition to Glu66 and Asp64, a third acidic residue in 
the a  helix is neutralised (E60Q), a complete disaggregation of murine M IP-la to 
monomers is achieved (Graham et al., 1994). Since this residue is seen to point away from 
the tetramer and is thus not involved in monomer-monomer or dimer-dimer interactions
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but may form a critical salt bridge with Arg45/Arg47 in tetramer-tetramer contacts, the 
dramatic effect this mutation nevertheless has on M IP-la aggregation again supports the 
assumption that changes in the overall charge may disturb the monomer-dimer-tetramer 
equilibrium found in the native protein.
In addition to these mutagenesis studies, other investigations have characterised additional 
factors that have the potential to influence M IP-la aggregation. It was shown that partial 
disaggregation was achieved in the presence of 1-2 M NaCl, while complete disaggregation 
occurs in the presence of 10 pM acetic acid (Graham et al., 1992). Serial dilutions of 
human M IP-la were also demonstrated to have a profound effect on aggregation, with a 
predominantly monomeric M IP-la solution found at concentrations below 0.1 jxg/ml 
(Graham et al., 1994).
The work presented in chapter 3 represents further investigations into the factors 
controlling murine M IP-la aggregation. It was first of all demonstrated that, analogous to 
the behaviour of human M IP-la, dilutions of the murine homologue also produced 
differentially aggregated protein (Fig. 3.2). At concentrations of 10 pg/ml or higher, murine 
M IP-la formed a range of oligomers, with most of the protein being present in higher 
order aggregates (tetramer and higher, data not shown). At 5 pg/ml it was mainly 
tetrameric (with some evidence of higher order aggregates), at 1 p,g/ml predominantly 
dimeric and at concentrations below 0.5 pg/ml M IP-la was completely disaggregated. As 
mentioned above, human M IP-la requires further dilution to below 0.1 p,g/ml for complete 
disaggregation which suggests that the forces that stabilise the human M IP-la oligomers 
are slightly stronger than for the murine counterpart. This may be explained by the fact that 
human M IP-la is more negatively charged than its murine homologue. Although the 
broadness and asymmetry of some of the peaks in Fig. 3.2 suggests that the preparations do 
not contain a completely homogeneous population of oligomers, the results nevertheless 
demonstrate that differentially aggregated M IP-la can be prepared in which the separate 
aggregation states are isolated.
Another potential method of regulating M IP-la aggregation emerged when the crystal 
structure of the murine M IP-la tetramer was solved. Two different tetrameric structures of 
murine M IP-la were detected, sometimes even within the same droplet. Both of these, 
however, were in association with calcium ions in almost identical positions (see Fig. 3.3). 
Because of the fact that 2/3 of the tetramer-tetramer contacts for one of the two types of
tetramers were mediated by these calcium ions, it was suggested that calcium may be 
involved in the aggregation of murine M IP-la, which received further support from the 
observation that the M IP-la tetramer could only crystallise when calcium was present. 
Despite there being evidence for the involvement of calcium in the self-association of other 
proteins (Ruano et al., 2000), this type of aggregation has so far not been described for 
chemokines. Ca2+ is a very ubiquitous intracellular mediator that is involved in many 
different processes, including neural signalling, muscle contraction, secretion and cell 
proliferation. In fact, chemokines are also known to induce intracellular calcium fluxes 
upon binding and activating their receptors. It may therefore not come as such a surprise 
that this universal messenger may be involved in the self-association of chemokines which 
would endow the cell with another means of regulating chemokine aggregation by varying 
the local Ca2+ concentration. This would also allow a fine tuning of chemokine 
aggregation. However, data presented in section 3.3. suggests that the presence of calcium 
ions is not required for the formation of higher order aggregates of murine M IP-la. Murine 
M IP-la was first completely disaggregated in 100 pM acetic acid in order to make the 
calcium ions accessible which were then chelated with 1 mM EDTA and 2 mM EGTA. 
This Ca2+-depleted preparation of murine M IP-la at ~13 jig/ml was then analysed for its 
aggregation state on a sizing column. Fig. 3.4 shows that even in the absence of calcium 
ions murine M IP-la is still capable of forming higher order aggregates well beyond the 
tetrameric state as would be expected at that concentration. It is unlikely that other ions 
present in the solution substituted for the removal of calcium and mediated the aggregation 
process in its absence for two reasons. First, during the crystallisation of the M IP-la 
tetramer it was noticed that it was not possible to replace the calcium ions with a number of 
other ions tested, thus suggesting that it was specifically calcium ions that were required 
for the crystallisation of the tetramer. Second, although EDTA and EGTA bind calcium 
ions with the highest affinity, they also complex other divalent cations, such as magnesium. 
It can therefore be assumed that the presence of EDTA and EGTA at these concentrations 
also resulted in a depletion of other divalent cations. The above results also demonstrate 
that the aggregation of M IP-la is a dynamic and reversible process since the complete 
disaggregation in the presence of acetic acid was reversed upon its removal, thus allowing 
the re-formation of oligomers.
Thus, the aggregation of murine M IP-la, like the aggregation of other chemokines, is 
controlled by the ionic strength and the pH of its environment and not by the presence of 
specific divalent cations. This may nevertheless represent a physiologically relevant control
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mechanism since salt concentrations similar to the salt concentrations found in the blood 
were shown to favour the formation of the MIP-ip dimer at 10 pM (Laurence et al., 1998) 
- a concentration at which some chemokines have been shown to be secreted from 
stimulated cells (Sotsios et al., 2000). The fact that the aggregation of M IP-la is 
concentration-dependent may also be of relevance in vivo. Although the concentration of 
free, circulating chemokines is likely to fall below the threshold for aggregation as do the 
concentrations required for the mediation of most of their biological effects, high local 
chemokine concentrations may nevertheless be achieved near sites of secretion. In addition, 
changes in the local environment, as described above, as well as immobilisation of 
chemokines on proteoglycans may create conditions under which chemokine aggregation 
can be achieved. Aggregation mutants of a number of chemokines have been generated 
(see Introduction) which generally display full activity in all bioassays. For example, all 
three aggregation mutants of murine M IP-la that were described above retain full stem cell 
inhibitory capacity in an in vitro assay (Graham et al., 1994). However, bioassays for 
chemokine function do not reflect the environment under which these functions are carried 
out in vivo. It may therefore be that aggregation is essential for certain processes for which 
there are currently no in vitro assays available. Indeed, it was only recently demonstrated 
that RANTES is able to trigger two different signalling pathways depending on its 
concentration. At nanomolar concentrations, chemotaxis is initiated via the activation of G 
protein-coupled receptors. At higher concentrations, micromolar and above, a different 
signalling pathway is activated which involves a Protein Tyrosine Kinase-mediated signal, 
leading to cell activation, and which requires RANTES aggregation, since an aggregation 
mutant which cannot aggregate past the dimeric state is unable to initiate the latter 
signalling pathway even at high concentrations (Appay et al., 1999; Bacon et al., 1995). 
Other aggregation-dependent activities may therefore still be discovered for other 
chemokines.
7.3. MIP-1 a - Heparin Interactions
As mentioned above, there is evidence to suggest that the presence of proteoglycans may 
enhance chemokine aggregation (Hoogewerf et al., 1997). Equally, there is evidence that 
shows that aggregation enhances proteoglycan binding. A first indication for this 
phenomenon came from studies on PF4 when it was shown that the individual heparin 
binding sites on each separate monomer are arranged in the tetramer in a way that increases 
the overall heparin binding surface which results in a higher affinity of the tetramer for
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heparin than each of the monomers alone (Mikhailov et al., 1999; Stringer and Gallagher, 
1997). Indeed, it is believed that PF4 is released from the cx-granules of platelets as a 
macromolecular complex in which the tetramer is bound to a proteoglycan carrier. Other 
studies have also since demonstrated the existence of positive cooperativity between the 
individual glycosaminoglycan binding sites in chemokine oligomers which results in an 
induction of chemokine oligomerisation, when bound to proteoglycans, and thus in an 
increase in the local chemokine concentration (Hoogewerf et al., 1997).
It was therefore decided to undertake similar studies on murine M IP-la in order to 
determine whether its affinity for self-association can be increased in the presence of 
proteoglycans. If that were the case, one could assume that M IP-la aggregation may occur 
more easily in vivo which would result in high local concentrations of immobilised 
chemokine.
The following basic residues in M IP-la have been implicated in heparin binding, Argl7, 
Lys44, Arg45 and Arg47, which are seen to form a cationic cluster on one side of the 
monomer (Graham et al., 1994; Koopmann and Krangel, 1997; and see Fig. 4.1). Upon 
dimerisation, these two clusters are slightly twisted away from each other, however, the 
three closely spaced basic residues, Lys44, Arg45 and Arg47, of both monomeric units are 
still found on top of the dimer and may therefore be able to interact with the same 
glycosaminoglycan chain. This may in fact be comparable to findings that were made with 
regards to the interaction of the IL-8 dimer with a single glycosaminoglycan chain 
(Spillmann et al., 1998). The heparin binding sites of IL-8 are located on the solvent- 
exposed side of the a  helices and are thus positioned at opposite ends on the top of the 
dimer. The authors, however, isolated a glycosaminoglycan chain that displayed high 
affinity binding to the IL-8 dimer and which was shown to contain two highly sulphated 
regions that were separated by a distance just long enough to bridge the gap between the 
heparin binding sites on top of the two helices of the IL-8 dimer. Fig. 4.1 also shows the 
arrangement of the individual heparin binding sites in the M IP-la tetramer where they are 
found to be organised in a circle on top of the oligomer. Again, it could be envisaged that a 
glycosaminoglycan chain is aligned on top of the tetramer in such a way that allows it to 
interact with more than one of the four heparin binding sites.
The interaction of the M IP-la monomer, dimer and tetramer with glycosaminoglycans was 
analysed using heparin affinity columns as sources for immobilised glycosaminoglycan 
chains since these allowed the measurement of the relative affinities of the different
oligomers as expressed by the concentration of NaCl or soluble heparin required to 
interrupt the protein - heparin interactions and elute the protein from the columns. As a first 
approach, the relative heparin binding affinities of the three murine M IP-la aggregation 
mutants (described in section 4.3.) PM1 (tetramer), PM2 (dimer) and PM3 (monomer) 
were determined as molarity of salt needed for their displacement. Fig. 4.2 shows that there 
is indeed a difference in their affinities. However, it came as a surprise to see the tetramer 
elute first (0.34 M NaCl), followed by the dimer (0.4 M NaCl) and the monomer (0.45 M 
NaCl), the latter of which had the highest affinity for heparin. This suggested that there was 
no positive cooperativity between the individual heparin binding sites in the oligomers and 
that, in fact, the opposite was observed. There are two alternative explanations for this 
observation. First, a progressive obstruction of the heparin binding site may occur upon 
aggregation which reduces the access of the sulphate groups of the glycosaminoglycan 
chains to the basic residues in M IP-la. Indeed, it was suggested that the dimerisation 
surface of murine M IP-la may slightly overlap with its heparin interaction site (MacLean, 
personal communication). The other possible explanation is that the progressive 
neutralisation of negative charges, the process by which these aggregation mutants were 
generated, results in an increasing affinity for heparin. The interaction of proteins with 
heparin is primarily of an electrostatic nature which could explain why a change in the 
overall charge of a protein may cause a change in its affinity for heparin. Indeed, it was 
shown in another study that chemokines in which negatively charged amino acids are 
interspersed between the positive heparin binding determinants exhibit more selective 
binding to heparin with a higher affinity for glycosaminoglycan chains in which the 
sulphate groups are spaced in a way that avoids a clash with the negative residues in the 
protein (Witt and Lander, 1994). The neutralisation of negative charges in the aggregation 
mutants may therefore result in higher affinities as repelling charges are removed.
In order to be able to distinguish between these two possibilities, differentially aggregated 
murine M IP-la was prepared by progressive dilution as described in the previous section, 
with 10 pg/ml containing a range of higher order aggregates, 5 pg/ml mainly tetramers, 1 
pg/ml predominantly dimers and 0.5 pg/ml monomers (see Fig. 3.2). However, when these 
were applied to the heparin column, no significant difference was observed between the 
individual elution profiles (Fig. 4.3) with the protein from all four preparations eluting on 
average at 0.36 M NaCl which is identical to the elution point of the tetrameric variant. 
This suggests that aggregation has no impact on murine M IP-la’s affinity for heparin and 
that the differences observed between the elution profiles of the aggregation mutants were
in fact due to their charge differences. As there may be a slight chance that the salt 
concentrations used for the elution of differentially aggregated M IP-la may lead to a 
partial disintegration of the complexes, the same preparations of differentially aggregated 
M IP-la were prepared, applied to the same column, but this time eluted with increasing 
concentrations of soluble heparin. The results, which are shown in Fig. 4.6, seem to 
support the previous findings that the aggregation state of M IP-la is irrelevant for its 
heparin binding affinity. However, it may still be possible that the samples become further 
diluted on the heparin column, resulting in a complete disaggregation, or that the 
interaction with heparin causes the complexes to fall apart, especially if there is indeed a 
partial occlusion of the heparin binding sites in the aggregates. The latter possibility may be 
less likely as that would imply that the forces holding the heparin - M IP-la complex 
together are stronger than the forces stabilising the oligomers. This is probably not the case 
since the interactions between the M IP-la molecules are more extensive than between 
M IP-la and heparin as reflected in the fact that a NaCl concentration of as little as 0.36 M 
is enough to disrupt M IP-la - heparin interactions, whereas 1-2 M NaCl are required to 
achieve at least a partial dissociation of M IP-la aggregates. However, in order to rule out 
these possibilities completely, covalently cross-linked and therefore stable M IP-la 
oligomers were also analysed for their binding to the heparin column and found to elute at 
exactly the same point (0.36 M NaCl) as the oligomers prepared by dilution, regardless of 
their aggregation state (Fig. 4.5). These stable oligomers were derived from a direct cross- 
linking of side chains from different monomeric units, as described in detail in section 4.5. 
Since there is no linker arm involved, this is a very local method for cross-linking and 
therefore expected to take place only where there is a true subunit interface. The specificity 
of this method seems to be confirmed in the fact that no trimers were observed. It is 
therefore likely that the cross-linked oligomers are a true representation of the native MIP- 
l a  oligomers and that the tertiary structure of M IP-la was not grossly perturbed as 
suggested by the fact that the cross-linked species bind to heparin with wild type affinity.
HiTrap heparin matrices such as the one employed in the experiments described above may 
occasionally act more like an ion-exchange matrix rather than a specific affinity matrix 
since the individual heparin chains are immobilised via multiple interactions with the 
agarose beads and therefore not completely free to interact with their ligands in a more 
physiological manner. For that reason, a different heparin matrix was obtained in which the 
glycosaminoglycan chains had been attached to the agarose beads by a process called 
reductive amination which immobilises the chains by their reducing ends, thus leaving the
remainder of the molecule free to interact with the ligands in a way that is more likely to 
reflect interactions that occur in vivo. The experiments described above were repeated 
using this new heparin affinity column. The salt elution of differentially aggregated murine 
M IP-la (Fig. 4.7), the salt elution of cross-linked murine M IP-la (Fig. 4.8) and the 
heparin elution of differentially aggregated M IP-la (Fig. 4.9) all demonstrate that there 
really is no difference in the affinities of the different murine M IP-la oligomers for 
heparin. The position and shape of the elution peaks of the differentially aggregated MIP- 
l a  were slightly altered on the heparin matrix prepared by reductive amination which 
indicates that M IP-la may interact somewhat differently with this matrix as compared to 
the HiTrap matrix. However, the results are consistent in that self-association does not 
affect murine M IP-la’s affinity for heparin, suggesting that there is no positive 
cooperativity between the individual binding sites which seem to be positioned in a way 
that only allows one site at a time to interact with a given glycosaminoglycan chain. 
Aggregation, on the other hand, also does not interfere with heparin binding as first 
suggested by the results obtained with the aggregation mutants (Fig. 4.2). The heparin 
binding site does not become partially buried upon oligomerisation since the covalently 
linked oligomers retain wild type affinity. It can therefore be assumed that the difference 
observed between the aggregation mutants can be exclusively attributed to their charge 
differences. In summary, the affinity of murine M IP-la for heparin is not determined by its 
aggregation state, but rather by its overall charge which may explain why, in comparison to 
other chemokines, murine M IP-la is a fairly weak heparin binder since it has a net 
negative charge, while most other chemokines have a net positive charge.
Despite the fact that the same results were obtained using two different heparin matrices, 
the possibility nevertheless remains that an effect of aggregation on heparin binding may 
have been observed with heparan sulphate chains that have a specific distribution and 
spacing of sulphate groups that mirrors the position of the heparin binding sites in the MIP- 
l a  oligomers more closely. Heparin chains are generally very highly sulphated, whereas 
heparan sulphate chains often have longer stretches of undersulphated disaccharide units 
between highly sulphated regions. The importance of undersulphated regions in bridging 
the space between individual heparin binding sites, especially when this intervening space 
contains negatively charged amino acids that would otherwise clash with sulphate groups 
of the glycosaminoglycan chain, has already been demonstrated (Spillmann et al., 1998; 
Witt and Lander, 1994). It may therefore be the case that in vivo, where there exists a wide 
range of different glycosaminoglycan chains with different patterns of sulphation, specific
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chains may be found that display increased affinities for the different M IP-la oligomers. 
However, as far as the binding to heparin is concerned, different aggregation states of MIP- 
l a  have no selective advantages over other aggregation states as all the oligomers tested 
showed identical binding to heparin.
It may still be the case that binding of M IP-la to heparin induces oligomerisation and that 
the affinities measured above may in fact represent the affinity of M IP-la oligomers that 
form while bound to the heparin matrix. Such an oligomerisation-inducing effect of 
heparin has previously been demonstrated where immobilised heparin was shown to induce 
M IP-la dimerisation and, in a separate experiment, the apparent molecular weight of MIP- 
la , as determined by gel filtration chromatography, was seen to increase from 19.9 kD 
(dimer) to 52 kD in the presence of soluble heparin (Hoogewerf et al., 1997). However, if 
immobilised heparin indeed induces MEP-la dimerisation, it would not explain the 
indistinguishable affinity of the stable tetramer (see Fig. 4.5 and 4.8), again arguing that the 
aggregation state does not influence M IP-la’s heparin binding affinity. The M IP-la 
concentration used in the study by Hoogewerf et a l was also up to 50 times higher than the 
highest concentration employed in this thesis. At concentrations as high as that, M IP-la 
oligomers are expected to form and, if the soluble heparin chains employed by Hoogewerf 
et a l were long enough, each glycosaminoglycan chain may have been able to bind to more 
than one M IP-la molecule. However, in the work presented in this thesis, M IP-la‘s 
heparin binding affinity was tested at concentrations of as low as 10 ng/ml, when M IP-la 
is completely disaggregated, and still found to be the same as for the M IP-la oligomers 
(data not shown). It was therefore concluded that the affinity of murine M IP-la for heparin 
does not change upon oligomerisation of this chemokine.
7.4. Molecular Mechanism of MIP-1a-mediated 
Haemopoietic Stem Cell Inhibition
M IP-la’s activity as a haemopoietic stem cell inhibitor was first demonstrated in 1990, 
when it was shown to inhibit the proliferation of transiently engrafting stem cells in the 
CFU-A assay, an in vitro assay that detects a cell that has properties indistinguishable from 
day 12 CFU-S cells (Graham et al., 1990). This property of M IP-la has since been 
confirmed in vivo, and, in addition, a stimulatory effect on the proliferation and the 
mobilisation of more mature progenitor cells described. However, the molecular
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mechanism underlying MDMa-mediated stem cell inhibition is still largely unknown. It 
has been illustrated that aggregation is not required for the direct inhibition of CFU-A cells, 
since aggregation-incompetent M IP-la mutants are fully active as stem cell inhibitors. A 
further MBP-la mutant in which the heparin binding site had been destroyed also retained 
full stem cell inhibitory capacity, suggesting that M IP-la does not need to be immobilised 
on proteoglycans in order to affect the proliferation of CFU-A cells.
A number of different chemokines have now been shown to be involved in the regulation 
of haemopoietic stem cells and, more specifically, in the inhibition of their proliferation. 
However, data presented in this thesis demonstrates that none of the chemokines tested 
have any effect on the proliferation of CFU-A cells (Fig. 5.1). Not even chemokines that 
are very closely related to M IP-la, such as MIP-lp, RANTES and DCCK-1, or 
chemokines that have been shown to inhibit the proliferation of other haemopoietic stem 
cells, such as MPIF-1 and MPIF-2 (Patel et al., 1997), had any noticeable effect on the 
formation of CFU-A colonies. Among the chemokines tested for CFU-A cell inhibition 
were ligands for all of the currently known CC chemokine receptors (Table 5.1). 
Furthermore, included also were other ligands for each one of the four murine M IP-la 
receptors, CCR1, CCR3, CCR5 and D6. Since none of these ligands (neither for the MIP- 
l a  receptors, nor for any of the other known CC chemokine receptors) showed any 
significant activity as a CFU-A cell inhibitor, it is unlikely that any of the known CC 
chemokine receptors are involved in CFU-A cell inhibition. It therefore seems that this 
effect is mediated by a novel, as yet uncharacterised receptor, which is expressed on CFU- 
A cells and likely to be specific for M IP-la.
Further support for the assumption that none of the known M IP-la receptors are involved 
in MIP-la-mediated stem cell inhibition was obtained from the analysis of the inhibitory 
potential of a number of human M IP-la variants (see also section 5.3.). The two human 
M IP-la isoforms, LD78a and LD78P, which have recently been characterised (Menten et 
al., 1999; Nibbs et al., 1999), are almost identical in sequence apart from single amino acid 
substitutions at positions 2, 39 and 47. In addition, sequence analysis predicts two 
alternative signal sequence cleavage sites for LD78a (Nibbs et al., 1999) producing the 
full-length protein and a -4 variant, in which the first four amino acids are missing. 
However, so far only the -4 variant has been isolated from natural sources (Menten et al., 
1999). For LD78P, on the other hand, the full length as well as a -4 variant have been 
detected in vivo (Menten et al., 1999), however, studies from our laboratory suggest that
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only the full length LD78|3 protein is produced in cells. Receptor binding studies have 
highlighted differences in which these four proteins bind to murine CCR1, CCR5 and D6 
which can be attributed to the two different amino acids found at position 2 in the two full 
length proteins, which are absent in the two -4 variants. LD78a has a serine residue at that 
position, thus it has been alternatively named M IP-laS and will be referred to as such from 
now on, while LD78|3 has a proline in that position and is thus now referred to as MIP- 
laP . M IP-laS is a slightly better ligand than M IP-laP for CCR1, while MIP-laP has a 
much higher affinity for CCR5 and D6 than M IP-laS (Nibbs et al., 1999). The binding 
affinities for the two -4 variants are indistinguishable from each other, but are high as far as 
binding to CCR1 is concerned, whereas their affinity for CCR5 and D6 is very poor. 
Because of the differences with which these four human M IP-la variants bind to these 
three murine receptors, they were ideally suited for the investigation of the possible identity 
of the inhibitory receptor. If indeed murine CCR1, CCR5 or D6 were involved in this 
process, then it could be expected that the differences in the receptor affinities of the four 
variants will be reflected in their potencies as haemopoietic stem cell inhibitors, as 
measured in the CFU-A assay. However, results presented in Fig. 5.2 clearly indicate that 
all four human M IP-la isoforms are potent inhibitors of CFU-A cells with no significant 
difference observed between them. This again points to a novel receptor as being the 
mediator of M IP-la’s inhibitory signal - a receptor, which binds to all four human M IP-la 
variants with indistinguishable affinities and which does not require the first four amino 
acids for full activation.
However, the most unequivocal way of determining whether any one of the four murine 
M IP-la receptors is involved in stem cell inhibition is by testing bone marrow from mice, 
in which the genes for each individual M IP-la receptor are deleted, in CFU-A assays for 
inhibition. If their CFU-A cell proliferation is still inhibited in the presence of M IP-la, it 
would then rule out the participation of the knocked-out receptors in stem cell inhibition. 
Bone marrow was therefore obtained from CCRl'/_, CCR3'/_, CCR5'7" and D6"/_ mice and 
their stem cells analysed for their sensitivity to M IP-la. None of these null mice displayed 
any defects that might be explained by a lack of haemopoietic stem cell control 
(Broxmeyer et al., 1999; Gao et al., 1997; Gerard et al., 1997; Huffnagle et al., 1999; Zhou 
et al., 1998; A. Humbles, unpublished results; D. Cook, unpublished results). The CCR1_/' 
mice exhibited a phenotype that suggested that this receptor mediates M IP-la’s stimulation 
of more mature progenitors. However, MIP-la-mediated stem cell inhibition appeared to 
be normal (Broxmeyer et al., 1999). Indeed, Fig. 5.3 shows that CFU-A cells from all four
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knock-out mice are inhibited by M IP-la, again demonstrating that none of these receptors 
are required for stem cell inhibition. It may appear from Fig. 5.3 c) that CFU-A cells from 
CCR3 7 mice are slightly refractory to the effects of M IP-la as a concentration of 200 
ng/ml, 2 fold higher than required for the cells from the other knock-out mice, is necessary 
for full inhibition. The CFU-A colonies formed by these cells are also on average a lot 
larger than the colonies formed by CFU-A cells from the other null mice. In fact, it is the 
unusually large size of these colonies that interferes with proper assay scoring, since 
uninhibited CFU-A colonies are identified on the basis of having a diameter of larger than 
2 mm. Therefore, despite the fact that the colonies formed by CCR37' cells showed the 
typical signs of inhibition at 100 ng/ml (denser/more darkly stained and very well defined 
colony edges), their diameter nevertheless remained above 2 mm. It is unknown whether 
and how the absence of CCR3 can result in this altered colony morphology. It is not even 
clear whether it is a cell migratory or a cell proliferation effect, however evidence points to 
the former possibility since these colonies are paler and more diffuse looking which 
suggests that they contain the same number of cells spread out over a larger surface. It is 
unlikely that this effect is mouse strain specific, as the cells from the CCR17' mice, which 
are of the same strain, do not form such large colonies. However, since the CCR37' 
colonies inhibited with 200 ng/ml were indistinguishable from the other inhibited colonies, 
it was assumed that MIP-la-mediated stem cell inhibition was not impaired by the absence 
of CCR3.
One might still be able to argue that M IP-la, in the absence of one of its receptors, may 
revert to the use of one of its other receptors for stem cell inhibition. In order to be able to 
rule out this possibility, the chemokine analogue AOP-RANTES which can bind to CCR1, 
CCR3, CCR5 and D6 (Eisner et al., 2000 and data not shown) was included in the CFU-A 
assays at a concentration 5-10 fold higher than M IP-la and thus competed with M IP-la 
for binding to these receptors (Eisner et al., 2000; Townson et al., 2000). Fig. 5.4 shows 
that AOP-RANTES on its own does not have any effect on stem cell proliferation. 
Furthermore, it shows that its presence does not abrogate or even impair M IP-la’s ability 
to inhibit CFU-A cell proliferation, even when the CFU-A assays were carried out using 
bone marrow from the four receptor knock out mice. As AOP-RANTES at these 
concentrations will displace M IP-la from its known receptors (Eisner et al., 2000; 
Townson et al., 2000), one must assume, the M IP-la conveys its inhibitory signal via 
another, as yet uncharacterised receptor.
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As all of the data presented above make a very strong case for the existence of a novel 
inhibitory receptor and thus ruled out the involvement of any of the known M IP-la 
receptors in stem cell inhibition, attention was then turned to M IP-la itself and attempts 
made at identifying an inhibitory motif within the structure of this chemokine which can 
then be of assistance in the search for the inhibitory receptor.
The best way of proving that a particular region of M IP-la is involved in stem cell 
inhibition is by separating it from the rest of the molecule and by testing whether it can 
effect inhibition in isolation. However, since the conformation of an effector domain is 
likely to be as crucial for activity as its primary sequence, it is necessary to present the 
detached domain in a framework that will conserve the domain’s native secondary 
structure, but that will not in itself participate in the reaction. Such an inert framework is 
found in the chemokine RANTES which has never been demonstrated to possess any 
activity on haemopoietic stem cells and which, as shown in Fig. 5.1, does not inhibit CFU- 
A cells. However, despite this functional difference between M IP-la and RANTES, their 
structures are very highly homologous (Fig. 6.1), thus making it possible to exchange 
domains between them in a way that will preserve the secondary structure of the exchanged 
domain and that will not alter the overall tertiary structure of the protein. A rational basis 
for the design of these chimaeric molecules was provided by the availability of the NMR 
structure of human RANTES (Skelton et al., 1995) and the crystal structure of murine 
M IP-la (J MacLean, unpublished results). Initially, it was decided to divide the 
chemokines into three major domains; (1) the flexible amino terminus up to the CC motif, 
(2) the main body of the chemokine between the second and the fourth cysteine residue 
which includes the loop, that leads into the first |3 strand, and the triple-stranded p sheet, 
and (3) the C terminal a  helix. These domains were swapped singly or doubly in all 
possible combinations between M IP-la and RANTES by a PCR-based method, and the 
chimaeric proteins expressed in the baculovirus system and purified from the cell culture 
medium. All of the recombinant proteins were functional, as determined by their ability to 
induce a calcium flux through CCR5 (Fig. 6.8) with the exception of RMM (M IP-la + N 
terminus of RANTES) which was only partially functional. When all of the recombinant 
proteins were tested in the CFU-A assay for stem cell inhibition, only the plates that 
contained wild type M IP-la and RMR (M IP-la body + RANTES N/C terminus) showed 
clear signs of inhibition (Fig. 6.9 and 6.10), as reflected in the reduced number of CFU-A 
colonies found on the plates, in the morphology of the inhibited colonies which in both 
cases were smaller and denser, and in the reduced number of cells per colony (Table 6.1).
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Despite the fact that MRR, RRM and MRM induced a robust calcium flux in CCR5- 
transfected cells, they showed no activity in the CFU-A assay, thus indicating that the MIP- 
l a  N and C terminus are not sufficient for stem cell inhibition and that the main 
determinants for stem cell inhibition reside within the main body of the chemokine. The 
fact that RMR is not quite as potent as wild type M IP-la in CFU-A cell inhibition suggests 
that further residues either in the amino or the carboxy terminus of M IP-la may 
nevertheless be required for full activity, or that the structure of the M IP-la main body 
becomes slightly altered when inserted between the RANTES N and C termini. It was 
surprising in that context that the other two chimaeric proteins that contained the main 
body of M IP-la, MMR and RMM, did not inhibit the proliferation of CFU-A cells. This 
suggests that the conformation of the main body of M IP-la is better maintained when the 
adjacent N and C terminus both originate from RANTES. This is supported by the poor 
performance of RMM in the calcium flux assays. Experiments are currently underway that 
will further subdissect the M IP-la main body in an attempt to narrow down the inhibitory 
region even more.
What do these results suggest about the way in which M IP-la interacts with its inhibitory 
receptor and how does this compare to what is already known about the interaction of 
chemokines with their receptors? Although it has been suggested that chemokines may 
exert their inhibitory effects by displacing growth factors required for the proliferation of 
stem cells from proteoglycans on which they are presented to the growth promoting 
receptors on the stem cells, it is more likely that such a specific effect as seen with M IP-la 
is mediated through a specific receptor. It is also unlikely that this is a receptor other than a 
member of the family of G protein-coupled receptors since no chemokine has ever been 
shown to be able to interact with other types of protein receptors. Most activated 
chemokine receptors couple to the G«i type of G protein subunits which is inhibited by 
Pertussis Toxin, thus making this a commonly employed test for the involvement of this 
type of G protein. This approach was also applied to this case in order to establish whether 
G«i subunits are part of the signalling pathway that leads to MIP-la-mediated stem cell 
inhibition. Pertussis Toxin was added to the CFU-A assay plates at concentrations of 1, 10, 
100 and 1000 ng/ml, as commonly used (data not shown). However, even in the absence of 
M IP-la, Pertussis Toxin has an inhibitory effect on the formation of CFU-A colonies 
which makes it unsuitable for this approach.
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The current dogma of how chemokines interact with their receptors (see Introduction) 
states that this is a 2-step process in which the first step involves the initial docking of the 
chemokine, possibly via its N loop (the region between the cysteine motif and the first p 
strand), to the receptor. This step is determined by how specific the ligand is for this 
particular receptor and is also the main determinant for receptor-ligand affinities. This is 
followed by the activation of the receptor by the flexible N terminus of chemokines. The 
crucial role that the N terminus of chemokines plays in receptor activation has been 
confirmed by a great number of mutagenesis studies. In a subgroup of CXC chemokines, a 
three amino acid motif - ELR - which directly precedes the CXC motif has been shown to 
be essential for receptor activation, while in most CC chemokines the extreme N terminal 
residues are the most important ones for receptor interactions, as reflected in the 
differences in the binding of the four human M IP-la variants to CCR1, CCR5 and D6 
(Nibbs et al., 1999). It was therefore surprising to see that an integrity of the N terminus of 
M IP-la is not required for the binding to and activation of the inhibitory receptor, as all 
four human M IP-la variants which had shown such marked differences in binding to 
CCR1, CCR5 and D6 displayed the same potencies as stem cell inhibitors. This also 
suggests that the inhibitory receptor found on CFU-A cells is quite different from the other 
known M IP-la receptors which receives further support from the observation that AOP- 
RANTES, which can interact with all four known M IP-la receptors, does not seem to be 
able to bind to the inhibitory receptor. The assumption that the N terminus may not be of 
such major importance for the interaction with the inhibitory receptor also receives further 
support from the studies with the chimaeric mutants which suggest that the region between 
the second and the fourth cysteine residue contains the main determinants for inhibition. It 
can, however, not be ruled out that there are also crucial residues in the N terminus which 
are conserved between M IP-la and RANTES. One could thus imagine the possibility that 
the presence of the M IP-la main body in RMR allowed this protein to dock to the 
inhibitory receptor (something that RANTES cannot do because it lacks the docking site) 
and that, once it was tethered to the receptor, residues that are conserved between the 
RANTES and the M IP-la N termini may result in almost full activation. A possible role 
for the M IP-la N terminus is also suggested by the fact that DCCK-1, a CC chemokine 
whose N terminal region is very different from M IP-la’s sequence while the rest of the 
molecule shows a high degree of homology, is nevertheless nonfunctional as a stem cell 
inhibitor.
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When one compares the tertiary structure of M IP-la to those of MIP-ip and RANTES, 
they are found to be most divergent in the N terminal region as well as in the loop 
connecting strand 1 and strand 2 of the |3 sheet. On comparison of the primary sequence of 
human RANTES and murine M IP-la, the greatest number of nonconservative changes is 
found just in front of the CC motif, between cysteines 2 and 3 and around the a  helix. As 
most of the evidence listed above, including the data from the chimaera studies, point to 
the main body of M IP-la as the site for the main determinants for inhibition, future 
mutagenesis studies will focus on that region, especially the stretch between cysteines 2 
and 3 which contains a lot of nonconservative changes between M IP-la and RANTES.
7.5. Conclusions and Aspects for Further Investigations
The aim of this thesis was to undertake extensive structural studies on the murine 
chemokine M IP-la that may shed some light on the mechanism by which this protein 
inhibits the proliferation of transiently engrafting haemopoietic stem cells. Attention was 
first turned to the two well known properties of chemokines, their ability to self-associate 
and to interact with proteoglycans. In addition to what was already known about the factors 
controlling murine M IP-la aggregation, it was shown that this process is in large part 
concentration-dependent, however, the concentrations required for its aggregation lie 
beyond the concentrations required for receptor activation, thus making it unlikely to be 
important for the direct inhibition of stem cells. It has previously been demonstrated that 
aggregation-incompetent murine M IP-la mutants are potent stem cell inhibitors, thus 
lending further support to the assumption that M IP-la interacts with its receptor as a 
monomer. Nevertheless, it remains possible that aggregation is important for other, as yet 
undescribed, activities of M IP-la and that it is of relevance for the production and 
secretion of M IP-la.
It was further demonstrated that the aggregation process was not influenced by the presence 
of calcium ions, nor did there seem to be a connection between the aggregation state of 
M IP-la and its affinity for heparin. It is still possible that M IP-la, at high local 
concentrations, interacts with proteoglycans as an oligomer, but as far as the binding to 
heparin is concerned, aggregation was not of any advantage. Despite the fact that heparin is 
often used in the study of chemokine - proteoglycan interactions, it does not accommodate 
for the diversity of proteglycans, especially in the sulphation patterns of the 
glycosaminoglycan moieties. It has been demonstrated that specific sulphation patterns of
180
heparan sulphate chains in the stem cell niche can have differential effects on haemopoietic 
stem cells (Drzeniek et al., 1999; Gupta et al., 1998), and chemokines were shown to have 
different affinities for different heparin/heparan sulphate chains depending on the 
frequency and distribution of the sulphate groups along the chain (Witt and Lander, 1994). 
It may therefore be possible that there are specific proteoglycans present in the bone 
marrow microenvironment that display differential binding of M IP-la oligomers which 
may play a role in the immobilisation and sequestration of this chemokine. Since a mutant 
of M IP-la that has lost its ability to interact with heparin is nevertheless a potent stem cell 
inhibitor as demonstrated in the in vitro CFU-A assay, it is unlikely that the interaction 
with proteoglycans, in a process of ligand presentation, is directly required for the 
interaction of M IP-la with its inhibitory receptor. For the same reason, it is unlikely that 
M IP-la exerts its suppressive effect by displacing growth factors, that are required for 
CFU-A cell proliferation, from proteoglycans. It was therefore assumed that stem cell 
inhibition by M IP-la is mediated via a specific, probably G protein-coupled, receptor.
It was further shown in this thesis that the inhibitory receptor is not one of the four known 
murine M IP-la receptors, but a novel, as yet unidentified, receptor. The analysis of a 
number of murine M IP-la chimaeras and human M IP-la variants established that the 
main body of M IP-la contains the major determinants for interacting with the inhibitory 
receptor and suppressing the proliferation of CFU-A cells and that the extreme N terminus 
plays a rather negligible role. This distinguishes this receptor from the other known MIP- 
l a  receptors and therefore makes it an interesting target for future studies. The 
identification of the inhibitory receptor is also of particular interest in the context of 
leukaemia, as stem cells from patients suffering from Chronic Myeloid Leukaemia are 
resistant to MIP-la-mediated inhibition, suggesting a defect in the signalling pathway 
following the binding of M IP-la to these cells (Chasty et al., 1995; Eaves et al., 1993; 
Holyoake et al., 1993). For that same reason, it is also important to identify the downstream 
signals following the activation of the inhibitory receptor by MIP-la. As it is currently 
impossible to obtain a pure population of MIP-la-sensitive haemopoietic stem cells for 
direct analysis, other, more indirect ways of investigation have to be employed. These 
include a continuation of the chimaera approach that may eventually lead to the 
identification of an inhibitory motif and to the derivation of an inhibitory peptide that spans 
the identified domain. Furthermore, it is possible to obtain bone marrow from mice in 
which the genes for individual components of signalling pathways have been deleted and 
which can then be tested in CFU-A assays for the integrity of the signalling pathway that
leads to inhibition. Protocols for the enrichment for MIP-la-sensitive stem cells by 
fluorescence-activated cell sorting also exist, which may make it possible to obtain a 
population of cells that is sufficiently pure to allow their mRNA to be used for the 
construction of an expression library that can then be screened for the expression of 
receptors that bind to either the full length M IP-la protein or, if available, an inhibitory 
peptide.
Although the phenotype of the M IP-la knock-out mice suggests that M IP-la is not one of 
the key players in stem cell inhibition and that back-up systems exist that can compensate 
for its absence, it is nevertheless important to continue the research in this particular field 
for several reasons. The dissection of the mechanism by which M IP-la inhibits 
haemopoietic stem cells will no doubt provide valuable insights into the way transiently 
engrafting stem cells, the more active members of the stem cell compartment, are 
controlled. Furthermore, as mentioned above, these findings may have a therapeutic value 
as they may shed light on the possible defects underlying stem cell proliferative disorders, 
such as leukaemia.
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